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ABSTRACT 
Lung cancer and chronic obstructive pulmonary disease (COPD) are both leading 
causes of death in the world, and these two disease are closely linked in the clinical 
setting and at the genetic level. Previous studies have indicated that COPD confers a 
higher risk for development of lung cancer, and also affects prognosis once lung cancer 
has occurred. The present thesis further explored the influences of timing of COPD 
diagnosis, severity of airflow limitation, radiological emphysema, and genetic variants 
on lung cancer outcomes. Over 1,000 patients who were diagnosed with non-small cell 
lung cancer at Mayo Clinic were included. Near two-thirds of patients with COPD were 
underdiagnosed at the time of lung cancer diagnosis. In comparison to the previously 
recognized COPD, an incidentally diagnosed COPD was a major factor that increased 
risks of postoperative complications (incidental COPD versus non-COPD: 28.1% versus 
16.5%, p<0.01) and impaired lung cancer survival (HR, 1.23; 95%CI, 1.05-1.45). Patients 
with moderate (HR, 1.22; 95%CI, 1.04-1.44) to severe airflow obstruction (HR, 1.75; 
1.38-2.23) had a significantly poorer long-term outcome, while similar survival was 
found between patients with mild COPD and with normal lung function (p=0.97). The 
severity of regional emphysema was associated with overall survival in early stage lung 
cancer (p<0.01), which was independent of tumor location, and it was predictive of 
quality of life related to dyspnea after lung cancer treatment (p<0.05). Radiological 
emphysema was also correlated with postoperative lung function recovery (FEV1% and 
DLCO%, both p<0.05) when tumor resection was performed in the emphysematous 
region. Meta-analysis indicated that the negative impact of COPD was more 
pronounced in patients with non-small cell lung cancer (pooled HR, 1.23; 95%CI, 1.16-
1.30), at an early-stage (pooled HR, 1.35; 95%CI, 1.12-1.63), and who received surgical 
treatment (pooled HR, 1.31; 95%CI, 1.13-1.51). The effects of single nucleotide 
polymorphisms on lung cancer survival differed by COPD status; SNP rs74798757 was 
significantly associated with survival from lung cancer with COPD, whereas SNP 
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rs10218481, CASP7 rs17090907, GPC5 rs1409600 and rs163933, and TAAR8 rs8192627 
were independent factors for survival in lung cancer patients who were COPD-free. 
These results indicate that COPD status may play a significant role in the association 
between genetic variants and lung cancer outcomes. Further validation from 
independent cohorts and functional characterization for these associations are 
necessary, which in future may benefit the COPD-lung cancer population.   
 iii 
ACKNOWLEDGEMENTS 
Prof. Gening Jiang, my supervisor has my deepest and sincerest gratitude for his 
constant support, advice and help. He gave me the invaluable opportunity to finish my 
Ph.D. study in USA (Mayo Clinic) and UK (the University of Sheffield) where I had 
privilege of learning from my co-supervisors (Prof. Ping Yang and Prof. Angela Cox) and 
working together with many colleagues. I would express my sincere thanks for all the 
continuous care, encouragement, and great freedom that he offered me. 
Specific thanks also goes to Ms. Yongmei Yu and my fellow colleagues for sharing their 
working experience and scientific knowledge with me, and all the support they gave 
to me. 
To Dr. Wenxin He, Dr. Ming Liu, Dr. Nan Song, Dr. Yang Yang, Dr. Xiaoxiong Xu, Dr. Jie 
Yang, Dr. Siming Jiang, Dr. Yuling Yang, Dr. Yong Yang, Dr. Zhiyi Liu, Dr. Chao Jiang, Dr. 
Linsong Chen, Dr. Weiwei Xu, Dr. Hongdou Ding, Dr. Xinnan Xu, Dr. Qiuyuan Li, Dr. Kaiqi 
Jin, Dr. Yingran Shen, Dr. Jinghan Shi, Dr. Jian Can, Dr. Xinsheng Zhu, Dr, Dongliang Bian, 
Dr. Kaixuan Zhang, Dr. Feng Zhou, Dr. Yunfei Zhang, and Dr. Yanhua Guo. 
I am grateful to my co-supervisor Prof. Ping Yang during my study at Mayo Clinic. Most 
of the present work was carried out under the supervision of Prof. Ping Yang. I deeply 
express my sincere thanks to Prof. Ping Yang for her suggestions during my Ph.D. study, 
valuable criticism to manuscripts, and kind treat during our group discussion at 
weekends.  
Sincere thanks also goes to my friend-colleagues for their practical knowledge and 
technical assistance throughout my study at Mayo Clinic.  
To Ms. Shawn Stoddard, Ms. Amy Bennett, Ms. Ruchi Gupta, Mr. Jason Wampfler, Ms. 
Pamela Neville, Ms. Connie Edwards, Ms. Carol J Greenlee, Ms. Glenda Mueller, Dr. 
Mingrui Zhang, Dr. Kunlatida Maneenil, Dr. Qiang Lu, Dr. Qian Guo, Dr. Liming Zhao, Dr. 
 iv 
Yi Liu, Dr. Jie Na, and Mr. Tim Skogen.  
I would like to extend my sincere thanks to my co-supervisor Prof. Angela Cox for her 
scientific vision and patient guidance during my writing process of literature review, 
and for her continued support and enthusiasm during my research in Sheffield. I 
appreciate her time and effort to help me solve all the problems before I came to 
Sheffield.  
Sincere thanks also goes to my friend-colleagues for their technical assistance and 
encouragement through the time I have spent in Sheffield.  
To. Dr. Shobha Silva, Dr. Rebecca Bastock, Dr. Fiona Taylor, Dr. Clair Fellows, Ms. Helen 
Cramp, Mr. Daniel Connley, Mr. Ian Brock, Ms. Ms. Amy Shaw, and Dr. Martina Dal. 
Moreover, I owe a significant debt of gratitude for the following people for their help, 
advice and encouragement.  
To Dr. Peng Zhang, Dr. Jingyun Shi, Dr. Yiming Zhou, Dr. Haifeng Wang, Dr. Dong Xie, Dr. 
Alan Sihoe, Dr. Minwei Bao, Dr. Wei Huang, Dr. Xiaogang Liu, Dr. Xuefei Hu, Dr. Yanfeng 
Zhao, Dr. Xiao Song, Dr. Junjie Zhu, Ms. Jin Zhou, Ms. Hui Li, and Ms. Jia Zhai. 
Additionally, my sincere gratitude goes to the staff at the following departments, and 
many others who cannot be individually acknowledged in such a short space.  
Department of Thoracic Surgery, Shanghai Pulmonary Hospital Tongji University 
Department of Health Science Research, Mayo Clinic, Rochester, MN 
Department of Oncology and Metabolism, Medical School, the University of Sheffield 
This study could never have been achieved without all these people. 
Finally, I dedicate this thesis to my family, in particular to my mother, my twin brother, 
and my deceased father and grandma, for their unconditional love and unwavering 
support. 
 v 
Publications 
From this project  
Dai J, Yang P, Cox A, Jiang G. Lung cancer and chronic obstructive pulmonary disease: 
From a clinical perspective. Oncotarget 2017;8(11):18513-18524. 
Dai J, Liu M, Swensen SJ, Stoddard SM, Wampfler JA, Limper AH, Jiang G, Yang P. 
Regional Emphysema Score Predicting Overall Survival, Quality of Life and Pulmonary 
Function Recovery in Early-stage Lung Cancer Patients. J Thorac Oncol 2017;12:824-
832. 
Dai J, Liu M, Jiang G, Yang P. The Impact of Chronic Obstructive Pulmonary Disease on 
Lung Cancer Survival: A Meta-analysis. Arch Cancer Res 2016;4:1. 
 
Others  
Dai J, Zhu X, Bian D, Fei K, Jiang G, Zhang P. Surgery for predominant lesion in 
nonlocalized bronchiectasis. J Thorac Cardiovasc Surg 2017;153:979-985.  
Dai J, Jiang G. Lymphadenectomy in Pulmonary Metastasectomy: For Diagnostic 
Purpose or Therapeutic Effect? Ann Thorac Surg 2017;103:688.  
Dai J, Xie D, Wang H, He W, Zhou Y, Hernandez-Arenas LA, Jiang G. Predictors of survival 
in lung torsion: A systematic review and pooled analysis. J Thorac Cardiovasc Surg 
2016;152:737-745. 
Dai J, Shi J, Soodeen-Lalloo AK, Zhang P, Yang Y, Wu C, Jiang S, Jia X, Fei K, Jiang G. Air 
bronchogram: A potential indicator of epidermal growth factor receptor mutation in 
pulmonary subsolid nodules. Lung Cancer 2016;98:22-28. 
Dai J, Song N, Yang Y, Jiang G. Is it valuable and safe to perform reoperation for 
recurrent thymoma? Interact Cardiovasc Thorac Surg 2015;21:526-531.
 I 
Table of Content 
 
CHAPTER 1. INTRODUCTION .................................................................................. 1 
1.1 Lung Cancer ...................................................................................................... 2 
1.1.1 Epidemiology......................................................................................... 3 
1.1.2 Risk factors ............................................................................................ 6 
1.1.3 Prognosis ............................................................................................. 12 
1.2 Chronic Obstructive Pulmonary Disease (COPD) ........................................... 18 
1.2.1 Epidemiology....................................................................................... 19 
1.2.2 Severity and phenotypes .................................................................... 22 
1.2.3 Comorbid diseases .............................................................................. 30 
CHAPTER 2. ASSOCIATION BETWEEN LUNG CANCER AND COPD ............................ 41 
2.1 Clinical Association between Lung Cancer and COPD ................................... 42 
2.1.1 COPD and lung cancer risk .................................................................. 42 
2.1.2 Lung cancer prevention in COPD ........................................................ 47 
2.1.3 Lung cancer screening in COPD........................................................... 48 
2.1.4 Clinical features of COPD-associated lung cancer ............................... 53 
2.1.5 Treatment for lung cancer coexisting with COPD ............................... 54 
2.1.6 Role of COPD in lung cancer prognosis ............................................... 58 
2.1.7 Cancer prevention strategy and future efforts ................................... 60 
2.2 Genetic Association between Lung Cancer and COPD .................................. 61 
2.2.1 Genome-wide association studies on COPD and lung cancer ............ 64 
2.2.2 Candidate gene approach as to linking COPD and lung cancer .......... 67 
2.2.3 Clinical implications and future work ................................................. 71 
 II 
CHAPTER 3. TIMING OF DIAGNOSIS AND SEVERITY OF COPD IN LUNG CANCER ..... 73 
3.1 Methods ......................................................................................................... 75 
3.1.1 Patients and data collection ................................................................ 75 
3.1.2 Statistical analysis ............................................................................... 76 
3.2 Results ............................................................................................................ 76 
3.2.1 Presenting symptoms and comorbid diseases .................................... 78 
3.2.2 Perioperative outcomes ...................................................................... 79 
3.2.3 Health-related quality of life ............................................................... 80 
3.2.4 Long-term overall survival................................................................... 81 
3.2.5 Risk factors for lung cancer with incidental COPD .............................. 82 
3.3 Discussion ....................................................................................................... 84 
3.4 Chapter Summary .......................................................................................... 88 
CHAPTER 4. ROLE OF REGIONAL EMPHYSEMA IN EARLY STAGE LUNG CANCER 
OUTCOMES .......................................................................................................... 89 
4.1 Methods ......................................................................................................... 90 
4.1.1 Subject inclusion ................................................................................. 90 
4.1.2 Patient evaluation ............................................................................... 90 
4.1.3 Computed tomography scan ............................................................... 91 
4.1.4 Emphysema evaluation ....................................................................... 92 
4.1.5 Statistical analysis ............................................................................... 93 
4.2 Results ............................................................................................................ 93 
4.2.1 Baseline clinical features ..................................................................... 93 
4.2.2 Changes in pulmonary function .......................................................... 96 
4.2.3 Post-treatment quality of life .............................................................. 97 
4.2.4 Overall survival .................................................................................... 99 
 III 
4.3 Discussion ..................................................................................................... 101 
4.4 Chapter Summary ........................................................................................ 105 
CHAPTER 5. IMPACT OF COMORBID COPD ON OVERALL SURVIVAL IN LUNG CANCER 
PATIENTS ........................................................................................................... 106 
5.1 Methods ....................................................................................................... 108 
5.1.1 Literature search strategy ................................................................. 108 
5.1.2 Data extraction .................................................................................. 109 
5.1.3 Statistical analysis ............................................................................. 109 
5.2 Results .......................................................................................................... 111 
5.2.1 General Impact in all patients ........................................................... 113 
5.2.2 Stratified analysis based on ethnic populations ............................... 114 
5.2.3 Stratified analysis according to cancer types .................................... 115 
5.2.4 Stratified analysis according to cancer stages .................................. 116 
5.2.5 Stratified analysis according to treatment modalities ...................... 116 
5.3 Discussion ..................................................................................................... 117 
5.4 Chapter Summary ........................................................................................ 121 
CHAPTER 6. GENETIC VARIATIONS AND SURVIVAL IN LUNG CANCER SUBGROUPING 
BY COPD ............................................................................................................ 122 
6.1 Methods ....................................................................................................... 124 
6.1.1 Patient cohort ................................................................................... 124 
6.1.2 SNP selection and genotyping .......................................................... 124 
6.1.3 Statistical analysis ............................................................................. 125 
6.2 Results .......................................................................................................... 126 
6.2.1 Patient clinical features ..................................................................... 126 
6.2.2 Baseline survival model .................................................................... 128 
 IV 
6.2.3 Associations of individual SNPs with survival ................................... 128 
6.2.4 Cumulative risk assessment .............................................................. 130 
6.3 Discussion ..................................................................................................... 132 
6.4 Chapter Summary ........................................................................................ 136 
CHAPTER 7. CONCLUSIONS AND FUTURE WORK ................................................. 137 
7.1 Summary of main findings ........................................................................... 138 
7.2 Suggestions for future work ......................................................................... 141 
BIBLIOGRAPHY ................................................................................................... 143 
APPENDICES....................................................................................................... 186 
Appendix A: Patient enrollment, data collection, and follow-up strategies ...... 187 
Appendix B: Selected single nucleotide polymorphisms and survival models .. 189 
 
  
 V 
List of Tables 
Table 1.1 Proposed clinical T descriptor of part-solid nodules by the IASCL 
Table 1.2 Possible components in tumor grading system 
Table 1.3 Composite scores for assessing COPD severity 
Table 1.4 Clinical characteristics of COPD, asthma, and COPD-asthma overlap 
phenotype 
Table 1.5 Assessment of comorbid diseases in patients with COPD 
Table 1.6 Multi-dimensional prognostic tool for comorbidities accompanying 
COPD 
Table 1.7 Checklist for screening COPD-associated comorbidities 
Table 2.1 Lung cancer risk according to airflow limitation and emphysema 
Table 2.2 COPD-LUCSS and COPD-LUCSS-DLCO scoring system 
Table 2.3 Chromosomal loci and candidate/nearest genes associated with COPD 
and lung cancer identified by genome-wide association studies 
Table 3.1 The Lung Cancer Symptom Scale (patient scale) 
Table 3.2 Patient demographics and clinical characteristics 
Table 3.3 Presenting symptoms and comorbid diseases 
Table 3.4 Type of surgical procedure and postoperative complications 
Table 3.5 Multivariate Cox proportional hazard model for overall survival 
Table 3.6 Logistic regression analysis to predict incidentally-diagnosed COPD in 
lung cancer patients 
Table 4.1 Patient demographics and clinical characteristics by tumor location and 
regional emphysema score 
Table 4.2 Postoperative complications in surgically treated patients 
Table 4.3 Univariate and multivariate analysis for overall survival in 3 
comparative groups 
 VI 
Table 4.4 Multivariate analysis for overall survival in 3 comparative groups 
Table 5.1 General characteristics of included studies. 
Table 6.1 Patient demographic and clinical characteristics 
Table 6.2 SNPs associated with lung cancer survival 
Table 6.3 Multivariate Cox analysis of significant SNPs in LC only cohort 
Table 6.4 Genotypes score-based prediction model for survival in LC only cohort 
  
 VII 
List of Figures  
Figure 1.1 Ten leading cancer types for cancer incidence and mortality. 
Figure 1.2 The worldwide incidence of lung cancer in 2012 among both sexes. 
Figure 1.3 Global level of PM2.5 air pollution. 
Figure 1.4 Relationship between pre-existing respiratory diseases and lung cancer. 
Figure 1.5 World map of the probability of death due to chronic obstructive 
pulmonary disease. 
Figure 1.6 GLOD 2013 and 2017 classifications. 
Figure 1.7 Proposed pharmacological treatment of COPD according to clinical 
phenotypes. 
Figure 1.8 Comorbidities of COPD and their prevalence. 
Figure 1.9 Comorbidome solar system. 
Figure 2.1 Clinical epidemiologic association between COPD and lung cancer in six 
areas. 
Figure 2.2 Putative mechanisms linking chronic obstructive pulmonary disease 
and lung cancer. 
Figure 2.3 Repetitive cycles of cell injury and turnover in the context of chronic 
inflammation 
Figure 2.4 Process of epithelial-mesenchymal transition 
Figure 2.5 Genome-wide association study 
Figure 2.6 Chromosomal loci and associated genes related to COPD and lung 
cancer from GWA studies 
Figure 3.1 Comparison of postoperative quality of life among non-COPD, 
incidental COPD and previous COPD. 
Figure 3.2 Kaplan-Meier curves for overall survival. 
Figure 4.1 Study population. 
 VIII 
Figure 4.2 Postoperative pulmonary function changes within 2 years.  
Figure 4.3 Quality of life within 2 years after treatment. 
Figure 4.4 Kaplan-Meier curves for overall survival between different regional 
emphysema scores in three groups 
Figure 5.1 Literature selection procedures to identify relevant studies reporting 
the impact of COPD on OS in patients with lung cancer. 
Figure 5.2 Data extraction from Kaplan-Meier survival curve using Engauge 
Digitize. 
Figure 5.3 Correction of Hazard ratios in two studies using RevMan Calculator. 
Figure 5.4 Forest plots of HR for the impact of COPD on survival of lung cancer 
Figure 5.5 Forest plots of HR for the impact of COPD on survival of lung cancer in 
different ethnic groups. 
Figure 5.6 Forest plots of HR for the impact of COPD on survival of lung cancer in 
different histopathologic types. 
Figure 5.7 Forest plots of HR for the impact of COPD on survival of lung cancer in 
different cancer stages. 
Figure 5.8 Forest plots of HR for the impact of COPD on survival of lung cancer in 
surgically treated lung cancer. 
Figure 5.9 Funnel plots of meta-analysis. 
Figure 6.1 Kaplan-Meier estimates of overall survival grouped by the genetic risk 
score in the lung cancer only cohort. 
Figure 6.2 Expression quantitative trait loci analysis for association of the 
rs17090907 genotypes with expression level of CASP7 gene in normal 
lung tissue. 
  
 IX 
List of Abbreviations  
6MWD    6-min walk distance 
AATD   α-1 antitrypsin deficiency 
BMI    body mass index 
CCI    Charlson comorbidity index 
CI    confidence interval 
COPD   chronic obstructive pulmonary disease 
CT    computed tomography  
DLCO   diffusion capacity of lung for carbon monoxide 
EGFR   epidermal growth factor receptor 
EMT   Epithelial-mesenchymal transition 
FEV1   forced expiratory volume in one second 
FDR    false discovery rate 
FVC    forced vital capacity 
GOLD   Global Initiative for Chronic Obstructive Lung Disease 
GWA   genome-wide association 
HDI    human development index 
HR    hazard ratio 
HWE   Hardy-Weinberg equilibrium  
IASLC    International Association for the Study of Lung Cancer 
ICS    inhaled corticosteroids 
ILCCO   International Lung Cancer Consortium 
ILD    interstitial lung disease 
LDCT   low-dose computed tomography 
LVRS   lung volume reduction surgery 
MAF   minor allele frequency 
MDT   multidisciplinary treatment 
 X 
MMP   matrix metalloproteinase 
nAChR    neuronal nicotinic acetylcholine receptors 
NLST   National Lung Screening Trial 
NSCLC   non-small cell lung cancer 
OR    odds ratio 
OS    overall survival 
PFT    pulmonary function test 
PPC    postoperative pulmonary complication 
QOL   quality of life 
RES    regional emphysema score 
RR    relative risk 
RV    residual volume 
SBRT   stereotactic body radiotherapy 
SCC    squamous cell carcinoma 
SCLC   small cell lung cancer 
SHS    secondhand tobacco smoke 
SNP    single nucleotide polymorphism 
TLC    total lung capacity 
USPSTF   United States Preventive Services Task Force 
VO2peak   peak oxygen uptake 
  
 1 
CHAPTER 1. INTRODUCTION 
 
CHAPTER ONE 
INTRODUCTION 
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1.1 Lung Cancer 
Lung cancer is one of the most devastating diseases and it imposes a major disease 
burden on the world. According to cancer statistics research in United States, lung 
cancer ranks second among all newly diagnosed cancer, after prostate cancer (21% of 
all cancers) in males and breast cancer (29% of all cancers) in female, respectively1. 
However, lung cancer is the greatest cause of cancer-related death, which accounts for 
one-quarter of all cancer deaths globally; it kills almost twice as many women as breast 
cancer and more than three times as many men as prostate cancer1. A report from 
World Health Organization has shown that lung cancer remains the most common 
cancer and the leading cause of cancer death in China and across the world (Figure 
1.1).  
 
Figure 1.1: Ten leading cancer types for cancer incidence and mortality. 2012 International 
Agency for Research on Cancer. Available from URL: http://globocan.iarc.fr/Pages/online.aspx 
(Accessed March 9, 2017). 
In addition, lung cancer is the most ‘expensive’ cancer; it constitutes 15% of overall 
cancer costs worldwide2. The lost productivity due to lung cancer mortality (27% of 
total cost) is more than the next four costliest cancers (colorectal cancer, 9%; breast 
cancer, 8%; pancreas cancer, 5%; and leukemia, 4%) combined3.  
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Lung cancer incidence has steadily increased from 2002 to 20124,5, and is predicted 
to continue to increase in the near future1,6. Nevertheless, with an increasing 
awareness of the health hazards of smoking and enforcement of tobacco control 
policies, alongside the implementation of low-dose computed tomography (LDCT) in 
lung cancer screening, there have been substantial changes in the pattern of incidence 
of lung cancer across the world over the past decades.  
 
1.1.1 Epidemiology 
1.1.1.1 Gender 
Lung cancer has traditionally stood out as a predominantly male disease7; 
however, it has been increasingly recognized that women appear to have a greater 
susceptibility to tobacco carcinogens, but have a lower rate of fatal outcomes of lung 
cancer compared to men8. Biological explanations for gender differences in lung 
cancer include reproductive and hormonal factors and difference in the sex 
chromosomes between female and male9,10. Several epidemiologic studies have 
indicated that there has been a significant downward trend among men and a 
dramatic increase in the incidence of lung cancer in women during the past 50 
years4,11,12, contributing to incidence rates for males and females gradually converging 
over time5. This is primarily because of the high prevalence of exposure to secondhand 
smoke and biomass fuels among women13,14. It is also anticipated that gender equality 
in lung cancer incidence rates will be attained in the coming future15. The recognition 
of the temporal changes in gender distribution may have potentially valuable 
implications in clinical trial design as many genetic mutations targeted for new drug 
development are highly related to gender, such as epidermal growth factor receptor16. 
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1.1.1.2 Histologic type 
 Lung cancer is typically divided into two major histologic types: small cell lung 
cancer and non-small cell lung cancer (NSCLC), and adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma constitute the three main NSCLC subtypes17. In 
parallel with the gender-specific changes in incidence pattern, histologic type 
distribution has also shifted over time. Until early 1980, squamous cell carcinoma was 
most prevalent in men, and the most common type of lung cancer reported in United 
States, Europe, and Asian countries18-20. Now, in almost every epidemiologic study, 
adenocarcinoma has overtaken squamous cell carcinoma as the most common form 
of lung cancer in both men and smoking population5,21, and has remained the 
dominant pathologic type diagnosed among females22. Modifications to cigarette 
composition and smoking behavior are believed to account for the histological shift 
towards adenocarcinoma18, because smoke from lower yield cigarettes (i.e., low tar, 
low nicotine, or filtered) tends to be inhaled more deeply, resulting in a higher 
concentration of carcinogens in the peripheral lungs where adenocarcinomas s usually 
occur23.  
The US age-adjusted incidence rate of small cell carcinoma rose though the mid-
1980s and peaked in the early 1990s, reaching 11 cases per 100,000 person-years12. 
Meanwhile, the proportion of women increased, from 28% of all small cell carcinomas 
in 1973 to 50% in 200224. Since then, there has been a roughly parallel decrease in the 
incidence rates of small cell lung cancer among both males (9.8 per 100,000 person-
years) and females (7.9 per 100,000 person-years)25. By contrast, the proportion of 
small cell lung cancer (among all lung cancer histologic types) has steadily increased in 
Chinese males (from 13.8% to 15.0%) but stabilized among Chinese women 
(approximately 10.2%) from 2000 to 201226,27. 
Large cell carcinoma is an ambiguous tumor entity that lacks any specific features 
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of small cell carcinoma, adenocarcinoma, and squamous cell carcinoma28. It is the least 
frequent subtype of lung cancer (less than 10%), and is considered to be a diagnosis 
of exclusion29. Data from the Surveillance, Epidemiology, and End Results (SEER) 
database indicates that the incidence rate of large cell carcinoma has declined 
drastically since the late 1980s, with only 1 case per 100,000 person-years in 201012. 
However, this trend data is most likely due to the change in diagnostic criteria and 
improvement in immunohistochemistry and molecular analysis. 
  
1.1.1.3 Geographic region 
Lung cancer incidence varies across continents, and is generally more common in 
the developed world (Figure 1.2)30. In males, the highest lung cancer incidence rates 
are reported in the United States and Eastern Europe, while in women, the highest 
rates are found in North America and parts of Europe (including United Kingdom)31. By 
socioeconomic grouping (based on the Human Development Index (HDI), a composite 
measure of population health, knowledge, and living standards) the incidence rate is 
highest in the countries with a very high HDI (e.g., United States, United Kingdom, 
Sweden, and Spain), followed by countries with a medium HDI (e.g., India and South 
Africa), then those with a high HDI (e.g., Russia and Iran), and is lowest in those with a 
low HDI (e.g., Cameroon and Kenya)5.  
Although the incidence rate of lung cancer currently remains high worldwide, the 
global burden of lung cancer has shifted towards less developed countries4,32. A 
dramatic rise in the incidence of lung cancer in China is particularly noticeable6. In fact, 
international variations and trends in lung cancer rates largely reflect the changes in 
the tobacco epidemic because smoking accounts for more than 80% of lung cancers in 
men and 50% of lung cancers in women33. In contrast to several western countries 
where comprehensive national tobacco control measures have been developed and 
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implemented34, the consumption of cigarettes is still growing steadily in China35, 
resulting in an upward trend in lung cancer incidence. Estimates indicate that by 2030, 
70% of tobacco-related deaths will occur in developing countries36. 
 
Figure 1.2: The worldwide incidence of lung cancer in 2012 among both sexes. International 
Agency for Research on Cancer. Available from URL: http://globocan.iarc.fr/Pages/online.aspx 
(Accessed March 10, 2017). 
 
1.1.2 Risk factors 
The development of lung cancer can be conceptualized as the joint consequence 
of the interaction between exposure to etiologic agents and individual intrinsic 
susceptibility37. Lung cancer has an important heritable component38. Although 
individual genetic variations are not modifiable, they can serve as potential targets to 
define the high-risk population and improve primary prevention for lung cancer39 
(which will be discussed in the next chapter). However, there are still large knowledge 
gaps in the perception of lung cancer amongst the general population40; the majority 
consider lung cancer to be tobacco-induced while a minor proportion regard it as an 
environment-associated disease40. The following section focuses mainly on tobacco 
smoking and environmental risk factors (occupational exposure and air pollution), and 
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previous lung disease is also considered, given that its role in lung cancer development 
has been increasingly recognized.  
 
1.1.2.1 Tobacco smoking exposure 
Tobacco smoking is by far the most important and evident etiologic factor for all 
major histological types of lung cancer41,42. The carcinogenic effect of tobacco on the 
lung was described for the first time in early 1950s43. It has been estimated that around 
80% and 50% of lung cancer cases in men and women are caused by smoking, 
respectively44. A recent meta-analysis quantified the relationship of smoking with lung 
cancer risk, clearly demonstrating an elevated risk of lung cancer among current 
smokers (relative risk [RR], 8.43; 95%CI, 7.63-9.31) and ex-smokers (RR, 4.30; 95%CI, 
3.93-4.71)45. Moreover, a dose-response relationship has been observed where the 
risk of cancer developing increases as the amount and duration of smoking increase, 
and with earlier starting age41,45. As discussed above, the low-yield cigarettes have 
caused a shift in the site of disease as well as in the histology of lung cancer, but there 
is a lack of information about their impact on overall lung cancer risk compared to 
higher tar cigarettes. The favorable effect of tobacco cessation is enormous34,46; 
however, the residual risk for lung cancer may persist even in those who have quitted 
for as long as 15 years, as indicated by both hospital- and community-based studies47,48.  
 In addition to voluntary tobacco smoking, exposure to secondhand smoke (i.e., 
passive smoking) is another smoking-related cause of lung cancer, which increases risk 
of lung cancer by 31% (95%CI, 17-45%) when compared to those never exposed49. 
Moreover, this association holds true among both ever smokers and never smokers, 
and regardless of cancer histological type and source of exposure (residential or 
workplace)41,50,51. A linear relationship is also noted between lung cancer risk and both 
the duration of exposure and the quantity of cigarettes smoked by smoking partner52. 
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It has been reported that approximately 40% of children, 35% of women, and 33% of 
men are regularly exposed to secondhand smoke53. In fact, secondhand smoke has 
become an important issue across all countries and caused almost 603,000 deaths 
worldwide in 2004 (including 21,400 lung cancers attributable to secondhand tobacco 
exposure)53.  
 
1.1.2.2 Occupational exposures 
Occupational exposures play an important role in lung cancer etiology, and the 
respiratory system is the most vulnerable site of occupationally-acquired malignancy41. 
It has been estimated that around 10% of lung cancers result from occupational 
agents54. The International Agency for Research on Cancer (IARC) has documented 12 
common occupational lung carcinogens, of which evidence for asbestos, silica, radon, 
heavy metals and polycyclic aromatic hydrocarbons is the most well-established. 
The risk of lung cancer is observed to increase with increased exposure to asbestos, 
with an RR for lung cancer of 3.49 (95%CI, 1.69-7.17) after controlling for age and 
smoking status33. Moreover, a 37-year cohort study on 577 workers exposed to 
asbestos in China showed a significantly greater risk of lung cancer death in the 
asbestos workers when compared with the control workers (age and smoking-adjusted 
HR, 3.31; 95%CI, 1.60-6.87)55. Concurrent cigarette smoking and asbestos can act 
synergistically to greatly increase lung cancer risk41. Silica is considered to be one of 
the most serious occupational hazards to workers' health, and leads to silicosis. It has 
been reported that more than 33 million workers are exposed to crystalline silica dust 
in China. The association of silica exposure with lung cancer risk was recently 
confirmed by a meta-analysis, where the carcinogenic role of silica was more 
pronounced at higher levels of exposure and in the presence of silicosis (pooled 
standardized incidence ratio, 2.49; 95%CI, 1.87-3.33)56. Radon has come to attention 
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in recent years because it is recognized as a ubiquitous indoor air pollutant37. For 
occupational radon exposure, such as underground miners of uranium, an increased 
risk of lung cancer has been well documented57. Like asbestos, smoking synergistically 
modifies the carcinogenic effect of radon58.  
Exposures to heavy metals are commonly seen in nickel miners, workers in 
cadmium-based battery manufacture, and chromate production workers, and studies 
on these heavy metals (cadmium, nickel, and chromium) have shown an increased risk 
of lung cancer59. A recent health assessment report from China revealed that, in 
heavily industrialized urban environments, chromium, cadmium and cobalt also posed 
lifetime lung cancer risks to local residents60. Polycyclic aromatic hydrocarbons (PAH) 
are a complex group of chemicals that derive from the incomplete combustion of 
organic materials. An excess risk of respiratory tract cancer (mainly lung cancer) has 
been reported in PAH-related occupations by a recent meta-analysis and systematic 
review61,62, including iron and steel foundries (pooled RR, 1.31; 95%CI, 1.08-1.59), coal 
gasification (pooled RR, 2.39; 95% CI 1.36-4.21), and aluminum production (pooled RR, 
1.29; 95% CI 1.12-1.49).  
 
1.1.2.3 Air pollution 
Outdoor air pollution is a complex mixture containing a number of hazardous 
compounds, many of which come from vehicle exhaust and industrial burning of 
waste44, and has been associated with increases in both lung cancer incidence and 
mortality63,64. It is estimated that 8% of global lung cancer deaths can be attributed to 
exposure to fine particulate matter (PM) alone65. PM2.5, defined as particles 2.5μm or 
less in diameter, has caught much attention due to its ability to penetrate deep into 
the respiratory tract (Figure 1.3)63. A recent systematic review by the International 
Agency for Research on Cancer (IARC) that combined 14 studies indicated a positive 
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association for PM2.5 with lung cancer risk (meta-RR, 1.09; 95%CI, 1.04-1.14), with a 
greater meta-estimate of 1.40 (95%CI, 1.07-1.83) if only adenocarcinoma of the lung 
is considered66. The RR of lung cancer promoted by air pollution seems generally small, 
but the attributable risk (RR multiplied by the number of exposed people) is 
significant63. Therefore, effective policies to control the sources of air pollution should 
be implemented, to reconcile the need for industrial development with concern for 
public health. 
 
Figure 1.3: Global level of PM2.5 air pollution. (a) mean annual exposure (micrograms per cubic 
meter); (b) population exposed to levels exceeding WHO guideline value (% of total). Available 
from URL: http://www.worldbank.org/ (Accessed March 21, 2017). 
Indoor air pollution is a major risk factor for lung cancer in never smokers, 
particularly in women and children as they spend most of their time indoors67. Indoor 
pollutants may originate from biomass fuels burning in poorly ventilated homes in 
rural households, and also may result from building materials and wall coverings in 
urban cities59,67. Globally, around 2.4 billion people rely on biomass fuels for heating 
and/or cooking, and a recent meta-analysis of 13 case-control studies further 
supported a causal relationship between biomass burning and lung cancer risk (overall 
OR, 1.17; 95%CI, 1.01-1.37)68. Indoor exposure to radon is significantly associated with 
lung cancer41. In fact, the current concern about lung cancer risk from radon mainly 
comes from residential and/or indoor rather than occupational exposure, and lung 
cancer risk increases in areas of higher level of radon concentration58. Apart from the 
recognized indoor pollutants in developed countries, exposure to fumes from high-
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temperature cooking is considered to be an important cause of lung cancer in Chinese 
women, which is independent of passive smoking44,69.  
 
1.1.2.4 Pre-existing lung disease 
 Many respiratory diseases have been demonstrated to confer an increased risk for 
lung cancer (Figure 1.4)70-72. A recent multicenter observational study revealed that 
about 28.2% of patients with newly diagnosed lung cancer had latent tuberculosis 
infection73. Another nationwide cohort study demonstrated that patients with 
pulmonary tuberculosis had a standardized incidence ratio (compared to the expected 
cancer incidence) of 3.55 (95%CI, 3.24-3.89) for lung cancer74, and the excess lung 
cancer risk appeared to be concentrated mainly within the first 3 years after the 
diagnosis of tuberculosis75. Evidence for the relationship between pulmonary 
tuberculosis and lung cancer was further strengthened by the two recent meta-
analyses71,72. An increased lung cancer risk was also implicated in patients with 
bronchiectasis76, but the connection is not well studied. Contrary results indicated that 
pre-existing bronchiectasis was associated with a lower risk of lung cancer in the same 
lobe and when accompanying chronic obstructive pulmonary disease77,78. Interstitial 
lung disease (ILD), represented by idiopathic pulmonary fibrosis (IPF) and connective 
tissue disease-related ILD, is associated with lung cancer. Several studies have reported 
a high prevalence of lung cancer in patients with ILD, ranging from 5.5% to 20.4%79,80. 
Ozawa and colleagues studied 103 IPF patients without lung cancer at the time of their 
initial diagnosis, and found the cumulative incidence of lung cancer was 15.4% at 5 
years, and the median duration was 120.0 months from IPF diagnosis to the 
development of lung cancer79. A high lung cancer incidence was detected in heavy 
smokers hospitalized to due to community-acquired pneumonia, with 1-year 
cumulative incidence of lung cancer being 8.14%81. Additionally, in contrast to 
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bronchiectasis, lung cancer tended to be located in the same lobe as the prior 
pneumonia81. This finding was supported by a pooled analysis from the International 
Lung Cancer Consortium, which showed a history of pneumonia conferred a 1.57-fold 
increased risk of lung cancer (95%CI, 1.22-2.01)72. The relationship between asthma 
and lung cancer is still controversial; some studies suggested an increased risk of lung 
cancer in patients with asthma82 but others indicated an inverse association64,83. A 
recent study investigated the joint effect of co-existing pulmonary diseases on lung 
cancer risk, and demonstrated that co-occurrence of chronic bronchitis and 
emphysema had a stronger positive association with lung cancer than chronic 
bronchitis alone64. The association between chronic obstructive pulmonary disease 
(COPD) and lung cancer risk will be discussed in detail in the next chapter.  
 
Figure 1.4: Relationship between pre-existing respiratory diseases and lung 
cancer. COPD: chronic obstructive pulmonary disease. 
 
1.1.3 Prognosis 
1.1.3.1 Tumor-related factors 
(i) Tumor size  
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Tumor size plays a significant part in lung cancer prognosis. Recently, TNM staging 
system was updated to 8th edition based on prognostic data from a multinational study 
cohort of the International Association for the Study of Lung Cancer (IASLC)84. The 
major changes in this updating are in T category, where T1 classification was 
subclassified into T1a (≤1 cm), T1b (>1 to ≤2 cm), and T1c (>2 to ≤3 cm); T2 was 
subclassified into T2a (>3 to ≤4 cm) and T2b (>4 to ≤5 cm), emphasizing the prominent 
role of size in defining the T category85. In clinical practice, tumor size can be 
determined by maximum diameter either on the resected specimen (pathological T 
stage), or based on the computed tomography scan (clinical T stage), both of which 
have important prognostic implications. The respective 5-year survivals in node-
negative patients were 92%, 86%, 81%, 74%, 65% for pathologically staged T1a-T2b, 
and 92%, 83%, 76%, 67%, 60% for clinically staged T1a-T2b85. In addition, the 
prognostic significance of tumor size remains in node-positive and/or locally invasive 
disease86.  
With respect to clinical tumor size, it remains a topic of open discussion as to 
whether whole tumor size or solid component size provides more prognostic 
information. Historically, whole tumor size has been regarded as the benchmark for 
tumor aggressiveness and prognosis87. However, recent studies have shown that size 
of consolidation on CT has a better discriminative ability than whole tumor size in 
terms of both overall and disease-free survival in early-stage lung cancer88,89. Sakakura 
and colleagues examined the correlation of pathological invasive size with different 
radiological parameters, and demonstrated that pathological invasive size correlated 
well with consolidation dimension, and moderately well with whole tumor 
dimension90; invasive size roughly approximated to tumor dimension in the 
mediastinal window plus 3mm90. However, Hattori and colleagues held an opposite 
view since their study showed that neither maximum tumor size nor solid component 
size was prognostic in part-solid lung cancer91. Along with the debate on tumor 
diameter, another indicator of tumor size, volumetric measurement, has also been 
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increasingly validated due to advances in radiologic technology92,93. To better address 
and unify the assessment of tumor size, the IASCL proposed the revised clinical staging 
algorithm for T category in part-solid nodules (Table 1.1)94.  
Table 1.1: Proposed clinical T descriptor of part-solid nodules by the IASCL. 
CT image 
 
     
total tumor size (cm) ≤0.5 0.6-3.0 ≤3.0 0.6-3.0 1.1-3.0 2.1-3.0 
solid part (cm) 0 0 ≤0.5 0.6-1.0 1.1-2.0 2.1-3.0 
clinical stage  cTis cT1mi cT1a cT1b cT1c 
AIS is classified as Tis; MIA is classified as T1mi. 
 
(ii) Histological type 
 More than 80% of all lung cancers are NSCLC, among which adenocarcinoma is 
predominant and its incidence is rising steadily17. In an effort to better prognosticate 
lung adenocarcinoma beyond the use of the T component of the TNM staging 
classification, therefore, a new coding system was released by a multidisciplinary 
group (IASLC/ATS/ERS) in 201195. In this new classification, adenocarcinoma is divided 
into three major groups based on the extension of tumor invasion: preinvasive lesions 
(atypical adenomatous hyperplasia and adenocarcinoma in situ [AIS]), minimally 
invasive adenocarcinoma (MIA), and invasive adenocarcinoma. The latter group is 
further subdivided on the basis of the morphologic pattern of tumor cells: lepidic, 
acinar, papillary, micropapillary, and solid predominant adenocarcinoma95. These 
classifications showed a good inter-observer agreement96 and correlated well with 
patient survival and disease recurrence, and these associations were independent of 
treatment modalities and TNM stage97,98. Therefore, the World Health Organization 
adopted this system in 201517.  
 As for squamous cell carcinoma (SCC), only a little progress has been made at the 
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histopathologcal level. The total number of SCC variants is cut down to 4 groups in the 
2015 WHO classification17: keratinizing SCC, nonkeratinizing SCC, basaloid SCC, and 
preinvasive lesion (squamous cell carcinoma in situ). Nonkeratinizing SCC is a newly 
established subtype; however, this histologic subtyping seems of little clinically 
prognostic significance99. There is an ongoing need for additional studies to evaluate 
the clinical relevance of histopathologcal subtypes in SCC.  
 
(iii) Grade and differentiation 
Currently, there is no established histologic grading system for most lung cancers17. 
Usually, histologic grade is determined by the percentage of tumor differentiation and 
other features, such as specific growth patterns, cytological atypia, and mitotic rates 
(Table 1.2)100. Sun and colleagues, based on 5018 hospital- and 712 population-based 
cases, demonstrated that histologic grade was significantly associated with survival100. 
In addition, patients with less-differentiated carcinoma had a higher risk of recurrence 
than those with well differentiated carcinoma after resection, with a respective HR of 
1.41, 1.71, and 1.83 for moderately-, poorly-, and undifferentiated carcinoma100. These 
findings were further confirmed by the study of von der Thusen and colleagues, in 
which the histological grade was defined by nuclear diameter and mitotic count101.  
Table 1.2: Possible components in tumor grading system 
components implications 
nuclear atypia survival, risk of recurrence 
nuclear diameter survival 
mitotic index (count and rate) survival  
tumor budding overall survival, risk of recurrence 
architectural pattern survival 
For stage I adenocarcinoma, mitotic index has been shown to be an independent 
predictor for survival, with mean survival time of 8.9 years for tumors with up to 10 
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mitoses per 10 high-power fields compared to 5.2 years for tumors with more than 10 
mitoses per 10 high-power fields102. In addition, tumor budding, defined as small 
tumor nests composed of less than five tumor cells, has been demonstrated to have 
prognostic significance in both adenocarcinoma and SCC103,104. 
 
1.1.3.2 Non-tumor related factors 
(i) Age and sex 
 Patient’s demographic characteristics play a significant role in lung cancer 
prognosis. It has been well acknowledged that chronological age is a negative predictor 
of various outcomes105,106. Undoubtedly, increasing age is associated with more 
comorbidities and higher risks of competing events, such as death from non-cancer 
diseases107. Eguchi and colleagues enrolled 2,186 patients with pathologic stage I 
NSCLC and found that both lung cancer-specific cumulative incidence of death and 
noncancer-specific incidence of death increased with patients getting older105. 
Postoperative complications are also more commonly seen in elderly patients 
receiving surgery for lung cancer108. In addition, older age is an independent predictor 
of poor quality of life106. Since the aging of the population is invreasing, more efforts 
should be dedicated to effective disease management in the elderly population, to 
improve their life expectancies as well as quality of life109. 
The association of gender with lung cancer survival has been widely reported, in 
which female sex has a consistently more favorable prognosis. A number of studies 
have demonstrated that women had better outcomes in terms of postoperative 
morbidities, 30-day mortality, long-term overall survival, and quality of life110-112. The 
mechanistic explanation underlying these observations has not been clearly 
elucidated yet, although premenopausal women were found to have a survival 
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advantage over postmenopausal women113.  
 
(ii) Body mass index 
 Being underweight has traditionally been regarded as a risk factor for major lung 
resection114. More currently, body mass index (BMI) has also been shown to correlate 
with patient survival115,116. Gupta and colleagues pooled 14 studies of lung cancer and 
observed, compared to patients with normal BMI (18.5–24.9 kg/m2), a significantly 
lower lung cancer-related mortality in overweight (BMI 25.0–29.9 kg/m2) and obese 
(BMI ≥30 kg/m2) patients, with a respective HR of 0.76 (95%CI, 0.68-0.85) and 0.68 
(95%CI, 0.57-0.81)115. Dahlberg and colleagues pointed out a time dependence of 
obesity on survival; superior outcomes in obese patients were only noted in the early 
courses of cancer treatment (HR, 0.86; 95%CI, 0.75-0.99), after which (16 months from 
the date of treatment) they experienced increased hazard (HR, 1.54; 95%CI, 1.22-
1.94)116.  
 Dynamic change in body weight is also predictive. Early weight loss (>5% weight 
loss after baseline) has been identified as an indicator of worse survival (HR, 1.9; 95%CI, 
1.10-3.19)117, independent of traditional markers of prognosis. In contrast, patients 
with advanced lung cancer who had >5% weight gain during chemotherapy had 
significantly improved overall survival (HR, 0.54; 95%CI, 0.47-0.62)118. Besides 
implications for survival, weight loss is recognized as a negative prognostic factor of 
response to chemotherapy and quality of life119.  
 
(iii) Pulmonary comorbid disease 
A growing number of studies have indicated that respiratory diseases do not only 
increase the risk of lung cancer development, but might also affect prognosis once 
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lung cancer has occurred. A recent population-based study revealed that pulmonary 
tuberculosis was an independent poor prognostic factor for lung cancer survival (HR, 
2.36; 95%CI, 1.1-4.9)120. Similarly, Zhou and colleagues found that the presence of an 
old pulmonary tuberculosis lesion posed a 1.72-fold increased risk of mortality (95%CI, 
1.12-2.64) in patients with squamous cell carcinoma121. However, on the contrary, 
concomitant active tuberculosis was reported to have the opposite effect, which 
prolonged survival in patients with advanced stage (III-IV) NSCLC122. There have been 
limited data on asthma in lung cancer. Brown and colleagues indicated that asthma 
increased risk of lung cancer death in non-smokers (RR, 3.54; 95%CI, 1.93-6.42)123, 
whereas Vesterinen and colleagues described no survival difference in asthmatic and 
non-asthmatic lung cancer patients124. The presence of ILD significantly increased 
operative risk in patients receiving lung cancer resection, including postoperative 
acute respiratory distress syndrome and mortality125. Additionally, patients with lung 
cancer concomitant with ILD showed a higher risk of death, which is more likely due 
to cancer recurrence rather than the progression of ILD126. The impact of COPD and/or 
emphysema will be discussed in the next chapter. Interestingly, the contribution of 
coexisting pulmonary disease to lung cancer survival appeared to be gender-
related127,128. The negative impact of tuberculosis, asthma, and/or COPD on lung 
cancer mortality was only observed among male patients in two recent studies from 
Taiwan127,128.   
 
1.2 Chronic Obstructive Pulmonary Disease (COPD) 
COPD is a progressive debilitating disease with an overall global prevalence of 10.1% 
in adults over the age of 40129. Alarmingly, it is now the third leading cause of death 
worldwide (around 5.6% of global death, Figure 1.5), after ischemic heart disease and 
stroke130, and it substantially increases the burden on health care systems131,132. The 
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definition of COPD is still problematic, and the most acceptable one, as proposed in 
the updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline 
(2017), is ‘a common, preventable and treatable disease that is characterized by 
persistent respiratory symptoms and airflow limitation that is due to airway and/or 
alveolar abnormalities usually caused by significant exposure to noxious particles or 
gases’133. Progressive dyspnea, chronic cough, and sputum production are the most 
frequent symptoms134, while the diagnosis requires confirmatory spirometry 
demonstrating the presence of persistent airflow limitation: a ratio of post-
bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity 
(FVC) of less than 0.7134.  
 
Figure 1.5: World map of the probability of death due to chronic obstructive pulmonary disease 
in all ages, by country. Institute for Health Metrics and Evaluation (IHME). Available from URL: 
http://vizhub.healthdata.org/gbd-compare/ (Accessed March 5, 2017). 
 
1.2.1 Epidemiology 
The prevalence of COPD is highly variable135, ranging from 4.3% to 24.8%, which 
is possibly due to differences between geographic regions and methods for 
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establishing COPD diagnosis129,132,136. The rate is higher in South Africa (24.8%) but 
relatively lower in Asian countries, such as China (8.2%) and Japan (4.3%)137,138. In 
addition, several studies detected COPD based on pre-bronchodilator 
measurement139,140; it has been estimated that disease prevalence after use of a 
bronchodilator would be 27-52% lower than that without bronchodilation141,142.  
The U.S. National Health and Nutrition Examination survey showed that the 
overall age-adjusted prevalence of COPD was stable from 1988 through 2010, reaching 
about 14% of adults aged ≥20 years with an evidence of airflow obstruction (FEV1/FVC 
<0.7)143. Additionally, the prevalence estimate is much higher in older age groups144. 
Males were historically considered to be more susceptible to development of COPD, 
attributed to the gender-specific patterns of tobacco and occupational exposures145,146. 
Nevertheless, a significant shift in gender prevalence towards higher rates in females 
has been noted in several recent epidemiological investigations147,148. As to 
socioeconomic status, COPD is more prevalent among those who are in poverty and 
have no educational qualifications149,150.  
The accurate estimate of COPD prevalence, as alluded to earlier, depends largely 
on a correct diagnosis of COPD. However, COPD is commonly misdiagnosed in the 
primary care setting, which consists of both underdiagnosis (not diagnosing COPD in 
patients with evident airflow limitation), and over-diagnosis (diagnosing COPD in 
someone who does not have it).  
 
1.2.1.1 Underdiagnosis of COPD 
Although individuals with COPD can suffer from relentless respiratory symptoms, 
many individuals may not recognize their symptoms as being due to a disease, because 
shortness of breath or exertional dyspnea may be attributable to aging, while cough 
 21 
and sputum production may be considered a consequence of smoking151. Moreover, 
even if these patients are able to visit their primary care doctors during the onset of 
the signs of COPD, doctors often fail to recognize the significance of symptoms as 
well152,153. Hence, a high rate of underdiagnosis would be anticipated. It has been 
estimated that 60-85% of patients, mainly with mild to moderate disease, have not 
been diagnosed in the general population154,155. Patients with undiagnosed COPD miss 
valuable opportunities to retard disease progression through optimal management, 
placing them at substantial risk of poorer health status156,157, which in turn contributes 
to a great extent to the health care burden131. Predictors for an undiagnosed COPD 
include male sex, younger age, lower education level, and being of racial/ethnic 
minority155,156. A COPD-like respiratory exacerbation event may act as a trigger for 
physician to consider the diagnosis of COPD.  
 
1.2.1.2 Over-diagnosis of COPD 
Over-diagnosis is also frequent, with a reported rate ranging from 25.8% to 42.5% 
across different countries158,159. A recent population-based longitudinal cohort study 
has shown that over-diagnosed but not undiagnosed COPD seems to place significant 
burden on the health care system160. It is because over-diagnosis of COPD will 
inevitably lead to over-treatment, which may be detrimental to the patient due to the 
side effects associated with medications161. Pre-bronchodilator spirometry use, 
improper spirometry technique, and incorrect interpretation of the results appeared 
to contribute to over-diagnosis in clinical practice162,163, and training in spirometry 
holds the promise of improving the accuracy of identification of COPD162. From a 
patient’s perspective, overweight and obese subjects are prone to be given a 
misdiagnosis of COPD164,165. Therefore, health-care professions should be aware that 
respiratory health (symptom and function) is linked to an individual’s weight, and thus 
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an alternative diagnosis for respiratory symptoms ought to be entertained and 
treatment should be adjusted accordingly166.  
 
1.2.2 Severity and phenotypes 
Historically, the classification of COPD was based solely on FEV1. Nowadays, the 
use of spirometry results alone has been realized insufficient to characterize COPD, as 
COPD is a complex syndrome with numerous pulmonary and extra-pulmonary 
components167. In 2013, the GOLD recommendations proposed two additional 
parameters for the assessment of COPD, i.e. symptoms and exacerbations134. 
Symptom evaluation is based on either the Modified British Medical Research Council 
(mMRC) questionnaire168 or the COPD Assessment Test (CAT)169, where mMRC 
assesses merely the impact of dyspnea whereas CAT provides a border health status 
assessment (covering both respiratory and systemic symptoms). The cut-off points are 
2 and 10 for mMRC and CAT, respectively, with a higher score indicating a high level of 
symptoms. An exacerbation is defined as a worsening of the patient’s respiratory 
symptoms that is beyond normal day-to-day variations and leads to a change in 
medication134, with a history of ≥2 exacerbations in the preceding year indicating high 
risk. Thus, patients are classified as A, B, C, D depending on the combination of these 
three parameters (Figure 1.6). However, subsequent analyses have revealed that the 
GOLD quadrant classification does not seem to perform any better than spirometric 
grades (FEV1 alone) in predicting mortality and other serious health outcomes170-172. 
In addition, physicians are often confused about the classification of risk dimension 
because patients may present different degrees of airflow limitation and exacerbation 
history. Therefore, the GOLD 2017 guideline has tried to revise the ABCD classification, 
separating spirometric grades from the ABCD grouping (Figure 1.6). Further 
classification systems are also needed to address this issue.  
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Figure 1.6: GLOD 2013 and 2017 classifications. If there is a discrepancy between the risk 
category as assessed by spirometric classification and that derived from exacerbation history, 
the assessment pointing to the highest risk should be used. 
 
1.2.2.1 Severity  
 COPD severity refers to the extent of functional loss of the target organ(s) that 
eventually impacts on prognosis173, which has traditionally been determined by the 
degree of airflow limitation measured by FEV1134. In recent years, however, it is 
increasingly recognized that FEV1 by itself does not adequately describe disease 
severity, and that its role in predicting disease progression is also limited in some 
circumstances such as during hospitalization174. Therefore, a comprehensive 
assessment using a multicomponent index is largely being advocated to refine 
prognostication. The best well known indices are BODE, ADO, and DOSE (Table 1.3), 
among which the BODE index serves as the benchmark that lays the groundwork for 
further risk stratification projects. 
 (i) BODE. The BODE index integrates four variables due to their strong 
associations with 1 year mortality in COPD patients175. The index has been regarded as 
one of the most effective multidimensional grading systems as it captures various 
domains of COPD: degree of pulmonary impairment (FEV1), patient’s perception of 
symptoms (the mMRC dyspnea scale), as well as systemic consequences of COPD (6-
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min walk distance [6MWD] and BMI)175. The total score of the BODE index ranges from 
0 to 10 points, with higher scores indicating a greater risk of death. In terms of 
predictive ability, the BODE index has been demonstrated to perform better than FEV1 
alone at predicting the risk of death from all causes and from respiratory causes among 
patients with COPD175. Moreover, the BODE index also provides valuable prognostic 
information with regard to quality of life, exacerbation and hospitalization, and 
patient’s willingness to participate in a rehabilitation programme176-179.  
Table 1.3 Composite scores for assessing COPD severity 
variable 
points 
0 1 2 3 
BODE175     
  FEV1 (% of predicted) ≥65 50-64 36-49 ≤35 
  distance walked in 6 min (m) ≥350 250-349 150-249 ≤149 
  mMRC dyspnea scale  0-1 2 3 4 
  body mass index (kg/m2) >21 ≤21   
mBODE180     
  peak oxygen uptake* (ml/min/kg) >25 20-25 15-20 <15 
  or (% of predicted) >70 60-69 40-59 <40 
eBODE
¶ and BODEx
§ indices181 
  frequency of severe exacerbations 0 1-2 ≥3  
ADO182     
  FEV1 (% of predicted) ≥65 36-64 ≤35  
  mMRC dyspnea scale 0-1 2 3 4 
  age
※
 (years) 40-49 50-59 60-69 70-79 
DOSE183     
  mMRC dyspnea scale 0-1 2 3 4 
FEV1 (% of predicted) ≥50 30-49 <30  
smoking status nonsmoker smoker   
  exacerbations per year  0-1 2-3 >3  
*peak oxygen uptake replacing distance walked in 6 min in BODE index; 
¶
adding frequency of 
severe exacerbations into BODE index; 
§
frequency of severe exacerbations replacing distance 
walked in 6 min in BODE index; 
※
score 4, age 80-89; score 5, age ≥90.  
(ii) mBODE, eBODE, and BODEx. These indices are derived from BODE index. The 
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mBODE index replaced the 6MWD with peak oxygen uptake (VO2peak) as a 
measurement of exercise capacity, for the reason that VO2peak is considered an 
objective test, and it can reflect the physiologic response during effort, while 6MWD 
depends mostly on individual motivation180. Similarly, eBODE and BODEx take into 
consideration the frequency of severe exacerbations requiring hospital management 
in one year181. All the three modified indices show a comparable predictive ability as 
the conventional BODE index in terms of all-cause mortality181,184.  
(iii) ADO and DOSE. Both indices are introduced to lend support the prognostic 
assessment of COPD patients in different clinical settings. The ADO index is used to 
estimate 3-year risk of mortality in patients with more severe COPD, and it showed 
improved predictive value compared to the BODE index182. DOSE further progresses 
the prognostic tool from mortality to health-related outcomes. It is a stronger 
predictor of future hospital admission and is also related to the number of 
exacerbations in the subsequent year183.  
These multicomponent grading systems have been shown to better reflect COPD 
severity and predict patient’s outcomes than FEV1 alone; however, whether such 
prognostic information can aid clinicians in the choice of therapy, and improve patient 
prognosis, is not yet clear. Therefore, further studies are desirable to validate the 
clinical utility of these prognostic indices in terms of resources allocation and 
treatment assignment. 
 
1.2.2.2 Phenotypes  
At the individual level, phenotype is derived from genotype and refers to the 
observable structural and functional characteristics of an organism185. Nowadays, the 
concept of phenotype is embedded in the clinical setting, and COPD phenotype is used 
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to depict ‘a single or combination of disease attributes that describe differences 
between individuals with COPD as they relate to clinically meaningful outcomes such 
as symptoms, exacerbations, response to therapy, rate of disease progression, or 
death’186. Therefore, the goal of phenotyping, from the clinical point of view, is to 
characterize the homogeneous features of clinical presentation and disease 
progression that are shared within a distinct group of individuals, and then provide 
them with the best health care in order to achieve better clinical results187. Therefore, 
in contrast to the severity, a clinical phenotype captures a wider range of disease 
characteristics and has both prognostic and therapeutic implications. 
Although there is still little agreement as to the total number of COPD phenotypes, 
several phenotypes are generally agreed upon. One of the most well-identified 
phenotypes is α-1 antitrypsin deficiency (AATD), which is an inherited genetic disorder 
determined by the α1AT gene on chromosome 14q32.1188. The exact prevalence of 
AATD in patients with COPD is unknown because it is frequently under-recognized by 
clinicians189, with an estimated delay between first symptom and initial diagnosis of 
7.2 to 8.3 years190. The AATD phenotype is characterized by an early onset of 
emphysema with a basal predominance and positive response to intravenous 
augmentation therapy (i.e., the infusion of purified pooled human plasma α-1 
antitrypsin)191.  
The second validated phenotype is emphysema-hyperinflation phenotype. 
Pulmonary emphysema is defined, in pathological terms, as the abnormal permanent 
enlargement of the airspaces distal to the terminal bronchioles192. The destruction of 
bronchiolar walls contributes to the difficulty in alveolar emptying, originating air 
trapping and hyperinflation. This phenotype is featured by upper lobe emphysema, 
significant dyspnea, and intolerance to exercise151,193,194, and is seen more frequently 
in patients of older age, male sex, and lower BMI195,196. Compared to other phenotypes, 
the emphysema-hyperinflation phenotype appears to respond best to lung volume 
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reduction surgery, with a significant improvement in survival and functional 
outcomes197,198. The presence of hyperinflation has also been regarded as a reliable 
predictor of the response to bronchodilators199. On the other hand, anti-inflammatory 
treatment seems not to be indicated in this phenotype during periods of stability, 
because it failed to demonstrate any benefit on pulmonary function and exacerbation 
rates200,201. 
The third common phenotype is chronic bronchitis phenotype. It is classically 
defined as habitual cough and sputum production for 3 months in a year for a period 
of 2 consecutive years202. Appropriately 11.5-24.5% patients with COPD are found to 
have a chronic bronchitis phenotype203,204, and patients are more likely to be younger, 
male gender, Caucasian race, and current smokers204,205. Radiological increased airway 
wall thickness is an indication of chronic bronchitis. This phenotype is also reportedly 
associated with multiple clinical consequences, including greater symptom burden 
(dyspnea and sputum), higher risk of exacerbations and worse quality of life202,205,206. 
Therefore, treatment aimed at increasing mucus clearance and reducing exacerbations 
may be crucial in these patients207. 
The COPD-asthma overlap syndrome has been increasingly recognized as a 
particular phenotype due to its distinct manifestations and treatment in the clinical 
setting208. The estimated prevalence ranges from 23% to 38% of COPD patients, being 
31.5% when using the bronchodilator test as a reference154,187. The accepted definition 
for this mixed phenotype is an airflow obstruction that is not completely reversible, 
along with signs of increased obstruction reversibility (Table 1.4)208. Personal history 
of asthma and/or atopy, less intense smoking exposure, sputum and/or peripheral 
eosinophilia, high concentration of exhaled nitric oxide, positive prick test, and 
reversibility in the bronchodilator test suggest a diagnosis of COPD-asthma overlap 
syndrome187,209. In addition, patients with overlap phenotype seem to have more 
concomitant wheezing compared to those with COPD only210. With respect to 
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differential treatment, the COPD-asthma overlap phenotype demonstrates a good 
response to inhaled corticosteroids at the level of lung function and symptom relief, 
while the benefit of anti-inflammatory treatment is only marginal in patients with 
COPD alone who do not present the aforementioned characteristics211,212. 
Table 1.4: Clinical characteristics of COPD, asthma, and COPD-asthma overlap phenotype 
 healthy asthma mixed phenotype COPD 
symptoms  absence presence presence presence 
FEV1/FVC ≥70% ≥70% <70% <70% 
FEV1% predicted >80% >80% <80% <80% 
airway hyper-responsiveness# >12 ml <12 ml <12 ml >12 ml 
#provocation dose of hypertonic saline that induces a 15% fall in FEV1. FEV1: forced expiratory 
volume in one second; FVC: forced vital capacity; COPD: chronic obstructive pulmonary disease. 
 The frequent exacerbator phenotype, defined as 2 or more exacerbations per year 
with at least 4 to 6 weeks interval between these exacerbations213,214, which causes an 
enormous burden on the health care systems187, has gained significant attention in 
recent years. Exacerbator patients have without doubt poor lung function and quality 
of life215,216, and patients who do not completely recover from an exacerbation may 
have an average of 8ml/year more deterioration in FEV1215. Although patient gender, 
smoking history, COPD duration and severity are predictive of frequent 
exacerbations217, history of previous exacerbations has been demonstrated to be the 
single risk determinant across all GOLD stages213,218. The treatment of choice includes 
long-acting bronchodilators and anti-inflammatory agents, both of which have been 
shown to reduce the frequency of exacerbations219,220. The use of antibiotics is also 
suggested during stable phases, particularly for patients with purulent sputum, 
without showing a significant increase in bacterial resistances221,222.  
 Other possible phenotypes have been proposed, but are not fully validated against 
clinical outcomes and best treatment assignments. A phenotype of fast lung function 
decline has been described, with an annual decline in FEV1 by around 40ml to 60ml, 
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which seems strongly associated with current smoking223,224. However, the diagnosis 
can only be made after close monitoring of lung function for at least 3 years, and no 
modifiable treatment has been identified for this type of patient; thus, it is of little 
clinical significance. A COPD-bronchiectasis clinical phenotype has also been 
suggested225, since radiologic bronchiectatic change has been shown to exert a 
negative impact on overall prognosis of COPD, including airway obstruction, 
exacerbations, and all-cause mortality226,227. Still, it is debatable whether it is a 
comorbid association or clinically relevant phenotype. In addition to the 
aforementioned, phenotypes of mild airway obstruction but disproportionately severe 
dyspnea228, severe pulmonary hypertension disproportionate to the underlying 
COPD229, non-exacerbator230, and a phenotype with persistent inflammation231 have 
been reported. It should be noted that any phenotype may have different underlying 
mechanisms and that any one individual may manifest multiple phenotypes.  
 Accordingly, pharmacologic therapy should be tailored to specific phenotype 
during the multidimensional assessment of COPD. A phenotype-based therapeutic 
approach was proposed by Miravitlles and colleagues232 based on the currently 
available evidence (Figure 1.7), in order to maximize the scope of therapy while 
limiting unnecessary use of drugs. Comprehensive intervention is the cornerstone of 
the management of COPD, and bronchodilators are the basis of treatment of COPD 
irrespective of the clinical phenotype. Inhaled corticosteroids are indicated in all 
phenotypes except for non-exacerbator. Patients with chronic bronchitis phenotype 
are the only candidates to receive phosphodiesterase-4 inhibitors. These indications 
offer a pragmatic and achievable approach to the management of the complexity 
implicit to this disease. However, further investigation is still warranted to justify the 
phenotyping. From a clinical perspective, validation from independent cohorts should 
be conducted to test the reliability and discriminative ability and then to refine the 
phenotypic group for each of the outcomes of interest. From a research standpoint, 
mechanistic studies are needed to understand the biologic and physiologic basis for 
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the shared clinical features within any distinct phenotype. 
 
Figure 1.7: Proposed pharmacological treatment of COPD according to clinical phenotypes. 
COPD: chronic obstructive pulmonary disease; PDE4: phosphodiesterase-4.  
Note: the order of the bars does not represent the order of preference for treatment. 
 
1.2.3 Comorbid diseases 
Though smoking and aging may lead to comorbidities, it is increasingly recognized 
that patients with COPD also have a high burden of concurrent diseases which may be 
independent of the two known major risk factors. Data from epidemiological studies 
have shown that COPD is frequently associated with comorbidities, with an average 
number of 3.7 comorbid diseases compared with 1.8 in healthy controls233. It is 
estimated that 84 to 97.7% of individuals with COPD have at least one comorbid 
condition234-237, 68.8 to 83.6% have at least two238,239, and 46.5 to 72.9% have three or 
more234,237-239, with the most serious and prevalent being cardiovascular diseases, lung 
cancer, metabolic disorders, and cognitive and psychological impairment167,240. It is still 
uncertain whether the frequency of comorbidities increases with COPD 
progression241,242, however. Several concomitant diseases have been reportedly 
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associated with an early or late COPD; for example, diabetes, hypertension, and 
dyslipidemia are frequently described in advanced COPD243-245 while lung cancer and 
chronic kidney disease are more commonly seen in mild to moderate COPD246-248. 
Figure 1.8 displays the major comorbidities in COPD and their prevalence244,249,250.  
 
Figure 1.8: Comorbidities of COPD and their prevalence. COPD: chronic obstructive pulmonary 
disease. 
The association of comorbidities with specific COPD phenotypes has also been 
sporadically reported251, where patients with emphysema phenotype had a greater 
prevalence of pulmonary heart disease and cachexia252; patients with chronic 
bronchitis phenotype had a higher risk of obesity, diabetes, and gastroesophageal 
reflux disease (GERD)205,252,253; and patients with asthma/COPD overlap phenotype 
were more likely to have arthritis, stroke, and other respiratory diagnoses (pulmonary 
tuberculosis, bronchiectasis, and sleep apnea)254. Patients with frequent exacerbator 
phenotype are reported to be susceptible to psychiatric disorders, namely anxiety and 
depression255. The comorbid GERD seems to be specifically associated with chronic 
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bronchitis phenotype in COPD205, and this phenotype of patients showed a higher 
concentration of cardiovascular risk factors195.  
Beyond establishing the prevalence and characteristics of comorbidities in COPD, 
there have been a great number of studies that have attempted to understand the 
general contribution of comorbidities to COPD outcomes. Accumulating evidence has 
indicated a nearly ubiquitous negative impact of comorbidities in the COPD population, 
which increases healthcare utilization, reduces health-related quality of life, and 
complicates the management of COPD250,256,257. Almagro and colleagues studied 
hospitalized patients with a COPD exacerbation, and found that comorbidity was 
related to the length of stay and hospital readmission for both COPD and other causes, 
independent of age, sex and severity of airflow obstruction258. In addition, the excess 
healthcare expenditure in COPD was associated with overall comorbidity burden259,260 
as well as some specific comorbidities, such as hypertension, congestive heart failure, 
mild liver disease, diabetes and anemia261-263.  
The relationship between the increasing number of comorbidities and the 
deterioration in quality of life has been well demonstrated in 4 large epidemiologic 
studies239,264-266 and 1 recent systemic review267. Meanwhile, several studies have 
found that some prevalent comorbidities were individually associated with a 
significant decline in health status, including heart failure, arthritis, urinary 
incontinence/prostatic disease, diabetes, osteoporosis, anemia, and psychiatric 
disorders (depression and anxiety)239,268-270. Furthermore, the presence of 
comorbidities also poses a challenge for the effective management of COPD. For 
example, heart failure and abnormal obesity may obscure the diagnosis of COPD by 
preventing accurate assessment of airflow limitation271. Pharmacological treatment 
also becomes more complex, as some agents that are viewed as the cornerstone of 
the treatment for comorbidities might have some risks in COPD patients (e.g. β-
blockers for congestive heart failure might affect COPD with asthmatic component), 
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and vice versa (e.g. systemic steroids for COPD exacerbations might worsen coexistent 
diabetes, hypertension, and/or osteoporosis)272. 
 Therefore, defining the nature of the association between COPD and other chronic 
conditions is of prime importance to improve the health status of COPD patients 
through the timely detection, accurate assessment and optimal care of comorbidities.  
 
1.2.3.1 Assessment of comorbidities in COPD 
 There are a number of approaches to assessing comorbidities in COPD patients, 
including Charlson Comorbidity Index (CCI), COmorbidity TEst (COTE), and 
COMorbidities in Chronic Obstructive Lung Disease (COMCOLD) index, which are 
designed for the description of comorbidity burden in COPD specifically (Table 1.5). 
Other studies have attempted to incorporate comorbidities into a multi-dimensional 
assessment tool for COPD, such as Comorbidity, airway Obstruction, Dyspnea, and 
previous Exacerbation (CODEX) index, Dyspnea, Eosinopenia, Consolidation, Acidemia 
and atrial Fibrillation (DECAF) score, and Comorbidome (Table 1.6). The selection of 
index depends largely upon the outcome of interest.  
(i) Charlson comorbidity index (CCI). This is a general index and probably the most 
extensively used tool for assessing the impact of comorbid diseases on overall 
survival273. CCI was proposed for the first time in 1987, and encompasses 19 chronic 
diseases which were assigned point scores corresponding to their risks of mortality273. 
Although CCI was not developed using COPD patients (it was based upon 685 patients 
with primary carcinoma of the breast), it could also provide some clinical and 
prognostic information in regard to healthcare utilization and mortality after discharge. 
in patients hospitalized for an acute exacerbation of COPD258,261,274. Patients having a 
CCI score of 3 or more were at 2.2-fold increased risk of death as compared to those 
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with a lower burden of comorbidities274.  
Table 1.5: Assessment of comorbid diseases in patients with COPD 
scales the spectrum of comorbidities predictive value 
CCI273 metastatic solid tumor, acquired immune deficiency syndrome 
(6 points); moderate or severe liver disease (3 points); 
hemiplegia, moderate or severe renal disease, diabetes with 
end organ damage, any tumor, leukemia, lymphoma (2 
points); myocardial infarction, congestive heart failure, 
peripheral vascular disease, cerebrovascular disease, 
dementia, chronic pulmonary disease, connective tissue 
disease, ulcer disease, mild liver disease, diabetes (1 point) 
all-cause 
mortality274; 
healthcare 
utilization and 
medication 
costs261 
COTE275 lung, esophageal, pancreatic, and breast# cancer, anxiety# (6 
points); all other cancer, liver cirrhosis, atrial 
fibrillation/flutter, diabetes with neuropathy, pulmonary 
fibrosis (2 points); congestive heart failure, gastric/duodenal 
ulcers, coronary artery disease (1 point) 
COPD specific 
mortality275 
COMCOLD
269 
depression (6 points); anxiety (4 points); peripheral artery 
disease (3 points); cerebrovascular disease (defined 
cerebrovascular accident or transient ischemic attack, 3 
points); symptomatic heart disease (defined as coronary heart 
disease and/or heart failure, 3 points) 
health status269 
#valid on the female population only. CCI: Charlson comorbidity index; COTE: COPD specific 
comorbidity test; COMCOLD: Comorbidities in chronic obstructive lung disease. 
 (ii) COPD specific comorbidity test (COTE). The COTE index, the first COPD-specific 
index that predicts the mortality risk associated with comorbidities accompanying 
COPD, was proposed by Divo and colleagues in 2012275. The index was constructed 
based on 12 easily identifiable comorbidities that exhibited significant association with 
mortality, and each comorbidity was given a point score in proportion to their hazard 
ratios275. Patients with a higher COTE index had an increased risk of death from both 
causes related to COPD (HR, 1.13; 95%CI, 1.08-1.18) and causes other than COPD (HR, 
1.18; 95%CI, 1.15-1.21)275, and a COTE score greater than or equal to 4 points 
increased by 2.2-fold the risk of death275. With respective to prognostication, the 
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behaviour of the COTE index to predict mortality was similar to that of the Charlson 
index but with the advantage of being simpler to construct256,276. Additionally, adding 
the COTE to the BODE index could significantly improve outcome prediction277.  
Table 1.6: Multi-dimensional prognostic tool for comorbidities accompanying COPD 
index description prognostic ability 
CODEX278 comorbidity (Charlson index): 0-4 [0], 5-7 [1], ≥8 [2]; 
obstruction (FEV1%): ≥65 [0], 50-64 [1], 36-49 [2], ≤35 [3]; 
dyspnea (mMRC scale): 0-1 [0], 2 [1], 3 [2], 4 [3]; 
exacerbation (hospitalization): 0 [0], 1-2 [1], ≥3 [2]. 
mortality and hospital 
readmission in the 
short (3m) and 
medium term (12m) 
after discharge 
DECAF279 dyspnea (eMRCD): eMRCD 5a [1], eMRCD 5b [2]; 
eosinopenia: <0.05×109/L [1]; 
consolidation (chest radiography): presence [1]; 
acidemia: pH<7.3 [1]; 
atrial fibrillation (ECG): presence [1]. 
in-hospital mortality in 
patients hospitalized 
for acute 
exacerbations of COPD 
comorbi
dome280 
age, number of hospital admissions in the previous year, 
dyspnea (mMRC), functional status (Katz index), chronic 
home oxygen therapy, and comorbidities (ischemic heart 
disease, heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, chronic kidney 
disease, depression, and atrial fibrillation).  
mortality at 3 months 
in hospitalized COPD 
patients 
The number in brackets represents the assigned point score.  
CODEX: Comorbidity, airway obstruction, dyspnea, and previous exacerbation; DECAF: Dyspnea, 
eosinopenia, consolidation, acidemia and atrial fibrillation. 
 (iii) Comorbidities in chronic obstructive lung disease (COMCOLD). The COMCOLD 
index was developed in 2014 to evaluate the collective impact of comorbidities on 
patient-reported health status269, as measured by the Feeling Thermometer – a 
modified visual analogue scale ranging from 0 (dead) to 100 (perfect health)281,282. 
After adjusting for FEV1% predicted, 5 prevalent comorbidities (with prevalence >5%) 
were identified to contribute to the poor health status in patients with COPD, and then 
point scores were assigned to each comorbidity, with higher score indicating worse 
health outcome. Therefore, the COMCOLD index complements the existing 
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comorbidity indices that predict death, which can help clinicians to identify patients 
who may suffer from a decreased health status, and therefore to prioritize treatment 
opinions269.  
 (iv) Comorbidity, airway obstruction, dyspnea, and previous exacerbation (CODEX). 
The CODEX index was proposed by Almagro and colleagues in 2014, with the principal 
aim to predict mortality and hospital readmission for 3 to 12 months after discharge 
in patients hospitalized for COPD exacerbations278. It is based on 4 parameters, 
comorbidity, obstruction, dyspnea, and previous severe exacerbations, in which 
comorbidity was measured using the age-adjusted CCI283, whereas the remaining 3 
variables were evaluated as described for BODEX thresholds181. The original Charlson 
index was stratified in tertiles (0-4, 5-7, and ≥8) in the CODEX index, and a 
corresponding score point (0, 1, and 2) was allocated. When compared with other 
existing indices, the CODEX index had a significant better predictive capacity in terms 
of death and/or re-hospitalization at 3 months and 1 year after discharge than BODEX 
(BMI, airflow obstruction, dyspnea, and previous severe exacerbations)181, DOES 
(dyspnea, airflow obstruction, smoking status, and exacerbation frequency)183, and 
ADO (age, dyspnea, and airflow obstruction) instruments182.  
 (v) Dyspnea, eosinopenia, consolidation, acidemia and atrial fibrillation (DECAF). 
The DECAF score is the first index that incorporates both clinical and laboratory 
information, to predict in-hospital mortality in patients hospitalized with an 
exacerbation of COPD279. For pragmatic reasons, the 5 strongest predictors of 
mortality were selected to form the index, and point scores for each predictor were 
assigned according to the regression coefficient. The DECAF index showed excellent 
discrimination with an area under the receiver operator characteristic curve of 0.86, 
and performed significantly better for the prediction of in-hospital mortality than 
other prediction tools279,284, including the Acute Physiology and Chronic Health 
Evaluation II prognostic index285, the COPD and Asthma Physiology Score286, and the 
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BAP-65287, which have all been proposed as useful predictive instruments in acute 
exacerbations of COPD. The superior performance of DECAF is of prime importance for 
patients deemed at low risk (score 0-1), who may be considered suitable for home 
treatment284.  
 (vi) Comorbidome. The COPD comorbidome is a graphic expression of the 
relationship between comorbidities and COPD that resembles the solar system, where 
the area of the circle relates to the prevalence of the diseases, and the proximity to 
the center (mortality) expresses the strength of the association between the diseases 
and risk of death (Figure 1.9)288.  
 
Figure 1.9 Comorbidome solar system. Each ‘planet’ represents one comorbid disease. The area 
of the circle relates to the prevalence of the disease, while the proximity to the ‘sun’ expresses 
the strength of the association between the disease and risk of death. Bubble colors represent 
organ systems. 
It was initially created by Divo and colleagues275 based on the BODE cohort, which 
enrolled clinically stable COPD outpatients with relatively few comorbidities175. In 
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order to verify and expand its applicability, Almagro and colleagues subsequently 
replicated the comorbidome in patients who were hospitalized for COPD exacerbation 
for the assessment of mortality at 3 months after discharge280. Comorbid conditions 
were collected via the Charlson index, with other relevant chronic diseases identified 
using a specific questionnaire. Additionally, data on dyspnea, functional status, and 
previous hospitalizations for COPD or other causes were analyzed. Finally, a new 
comorbidome was developed encompassing different parameters from that 
previously published by Divo and colleagues275, reflecting the distinct pattern and 
influence of comorbidities in different COPD patient population.  
These multi-dimensional indices could help unravel the overall burden of COPD-
related comorbidities, assist in the assessment and prognosis of various outcomes in 
COPD, and advance our understanding of the systemic manifestations and extra 
pulmonary effect of COPD.  
 
1.2.3.2 Current challenges and future efforts 
As aforementioned, comorbidities have a considerably detrimental impact on the 
overall prognosis in patients with COPD. The negative impact is exacerbated because 
some comorbidities, such as depression and osteoporosis, are still substantially 
underdiagnosed and/or undertreated in the majority of COPD patients250,289. A 
screening strategy for comorbidities has not been established so far. In this regard, for 
instance, Negewo and colleagues recommended timely diagnosis of all COPD-
associated comorbidities during the assessment of pulmonary condition256. Smith and 
colleagues argued that screening protocols should be limited to comorbidities that are 
prevalent, have effective therapeutic options, and alter prognosis significantly249, and 
they proposed a checklist to assist the clinicians in screening for comorbidities in the 
outpatient setting (Table 1.7). The checklist is grouped by organ systems, including 
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cardiovascular system, pulmonary pathology, mental health, metabolic disease, 
chronic kidney disease, and gastroenterology249.  
Table 1.7: Checklist for screening COPD-associated comorbidities. 
Cardiovascular system Pulmonary pathology Metabolic disease 
□ hypertension □ pulmonary hypertension □ hyperlipidemia 
□ atrial fibrillation □ lung cancer □ diabetes 
□ ischemic heart disease □ pulmonary fibrosis □ osteoporosis 
□ heart failure □ pulmonary embolism □ obesity 
Mental health Gastroenterology Urology 
□ anxiety □ GERD □ chronic kidney disease 
□ depression □ peptic ulcer disease  
GERD: gastroesophageal reflux disease. Data from Smith MC, et al. Int J Chron Obstruct Pulmon 
Dis. 2014;9:871-888. 
 In addition to screening, current management strategies largely fail to provide 
clear recommendations to address these complex comorbid diseases in the presence 
of COPD, although the importance of integrating comorbidities in the assessment and 
treatment of COPD is gradually being recognized290. Agusti and colleagues proposed 
the ‘COPD control panel’ as a disease management model291. The control panel 
considers three domains of the disease: severity (FEV1, inspiratory to total lung 
capacity ratio [IC/TLC], arterial oxygen pressure [PaO2], 6-min walk distance [6MWD], 
and number of comorbidities), activity (smoking, FEV1 decline, frequency of 
exacerbations, weight, and inflammatory biomarkers), and impact (mMRC, CAT, and 
daily activity), to guide clinician to assess and manage patients with COPD more 
comprehensively291. Vishnivetsky and colleagues subsequently pointed out that the 
‘COPD control panel’ should place more emphasis on comorbidities292 since 
comorbidities are the second most prevalent sign of COPD after non-reversible 
obstruction in real-life COPD patients236. Similarly, the chronic care model289 and 
inflammometry, multidimensional assessment, and case management approach293 
have been recently proposed, providing some practical interventions as to integrated 
care for COPD patients. Nevertheless, it has to be admitted that these suggestions are 
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largely based on expert opinion. Therefore, there is still an ongoing need to explore 
more efficient screening strategies and optimal tailored interventions in the 
management of comorbid patients with COPD in large-scale studies, which could help 
to maximize efficacy, limit cost, and ultimately improve patient clinical outcomes. 
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2.1 Clinical Association between Lung Cancer and COPD 
COPD and lung cancer have attracted substantial attention over the past few 
decades due to the potential links between these two diseases and their combined 
mortality burden on healthcare system worldwide294,295. Recent systematic research 
from the Global Burden of Disease Study shows that both COPD and lung cancer are 
among the top ten causes of years of life lost in 2013294, and they are projected to rank 
fourth and sixth cause of death in the next decades, respectively295. COPD is generally 
defined as chronic minimally reversible airflow obstruction on the basis of spirometry 
(post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity 
[FVC] less than 70%134), but it has now been recognized as a heterogeneous group of 
diseases, encompassing two well-characterized phenotypes: chronic bronchitis and 
emphysema134.  
Although many previous studies have investigated the role of COPD in the 
development and prognosis of lung cancer, their conflicting results have not been 
clearly understood, and some burgeoning areas of research, such as the incorporation 
of COPD into lung cancer screening criteria, still remain as a forum of open discussion 
(Figure 2.1). 
 
2.1.1 COPD and lung cancer risk 
Numerous studies have demonstrated the presence of COPD per se to be an 
independent risk factor for lung cancer296. Evidence on the first epidemiologic 
association between lung cancer and COPD can be traced back to the 1980’s when 
Skillrud and Tockman revealed a four-fold increase in lung cancer incidence in patients 
with COPD247,297. Since then, this association has been extensively observed in 
population-based studies298,299, lung cancer screening trials300-302, and case-control 
 43 
studies296,303-305. However, with the widespread use of computed tomography (CT), the 
research on the etiologic association has been gradually changing from spirometry-
defined COPD to CT-diagnosed emphysema306. This has led to controversy about 
whether airflow obstruction on spirometry, or emphysema on CT scan, is the more 
important manifestation of COPD linked to an increased risk of lung cancer. Several 
studies298-300,303,304,307-309 have investigated the interaction between airflow 
obstruction and emphysema relative to lung cancer risk, but their results are still 
contradictory (Table 2.1). Reasons for these disparities may be threefold.  
 
Figure 2.1: Clinical epidemiologic association between COPD and lung cancer in six areas. The 
color codes refer to the current evidence showing the magnitude of association, where green 
indicates the association is clearly defined, amber is a debatable issue, and red is poorly 
understood. COPD: chronic obstructive pulmonary disease. 
(i) Different study populations. Patient demographic characteristics might have a 
residual effect on the risk of lung cancer even after adjustment. Several studies 
revealed that the magnitude of COPD lung cancer association was influenced by 
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smoking habit298,301,305. A large cohort study showed that the odds ratio (OR) for lung 
cancer prevalence in never smokers with emphysema was six-fold greater than those 
without emphysema, while the corresponding OR was only two-fold in smokers301. In 
addition, the relationship was modified by sex, with near two-fold amplified risk in 
women299,310. Furthermore, patient previous respiratory disease other than COPD (e.g., 
pneumonia) could alter the risk of lung cancer64; these factors have not been 
commonly considered in previous analysis on the association between COPD and lung 
cancer. 
(ii) Distinct methods to determine emphysema. The presence of emphysema can 
be detected automatically (densitometry) or visually (direct interpretation by 
radiologist). Automated analysis can provide reproducible and blinded assessments 
across studies, and can virtually eliminate subjectivity in the estimation of 
emphysema303,311. In contrast, visual assessment provides the capability of accurately 
detecting clinically meaningful emphysema and avoiding incorrect interpretation by 
computer software312,313. In the context of lung cancer risk, a recent meta-analysis 
revealed that the COPD lung cancer association was only significant for visually 
determined emphysema314. 
(iii) Variable definitions of airflow obstruction. A ratio of FEV1 and FVC of less than 
0.7 was generally used to define airflow obstruction304; however, other indices, such 
as FEV1/FVC under the lower limit of normal criteria, and reduction of FEV1% predicted, 
were also considered indicative of airway obstruction and applied in the 
research310,315,316. The use of inconsistent parameters for labelling airflow obstruction 
may give rise to conflicting results. 
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Table 2.1: Lung cancer risk according to airflow limitation and emphysema 
study 
case 
vs. 
control 
sex, 
female 
smoking 
status 
Evaluation of emphysema, 
associated lung cancer risk, 
OR (95%CI) 
Measurement of airflow 
limitation, associated lung 
cancer risk, OR (95%CI) 
Schwartz 
et al.307 
(2016, 
n=1093) 
341 
vs. 
752 
54.3% never: 
2.8% 
ever: 
97.2% 
emphysema on qCT-950HU: 
2.66 (1.80, 3.95)¶ 
emphysema by radiologist 
read: 1.80 (1.35, 2.41)¶ 
self-reported emphysema: 
1.87 (1.25, 2.79)¶ 
spirometry FEV1/FVC<0.7: 
1.98 (1.50, 2.61)¶ 
self-reported COPD: 1.43 
(1.05, 1.94)¶ 
Wang et 
al.308 
(2012, 
n=2201) 
1069 
vs. 
1132 
31.7% never: 
47.7% 
ever: 
52.3% 
self-reported emphysema: 
1.92 (1.31, 2.81)§ 
self-reported emphysema: 
1.55 (1.03, 2.32)¶ 
spirometry FEV1/FVC<0.7: 
1.54 (1.21, 1.96)§ 
spirometry FEV1/FVC<0.7: 
1.29 (1.00, 1.68)¶ 
Maldana
do et 
al.303  
(2010, 
n=441) 
64 
vs. 
377 
61.6% current: 
58.0% 
former: 
42.0% 
percent emphysema 
volume on qCT-900HU: 1.04 
(0.82, 1.33)¶ 
spirometry FEV1/FVC 
continuous: 1.29 (1.02, 
1.62)¶ 
spirometry FEV1% 
continuous: 1.15 (1.00, 
1.32)¶ 
Schwartz 
et al.299 
(2009, 
n=1126) 
562 
vs. 
564 
100% never: 
49.2% 
smoker: 
50.8% 
self-reported emphysema: 
3.21 (1.60, 6.45)¶ 
self-reported COPD#: 1.67 
(1.15, 2.41)¶ 
Koshiol 
et al.298 
(2009, 
n=4042) 
1934 
vs. 
2108 
22.4% never: 
20.1% 
former: 
43.0% 
current: 
36.9% 
self-reported emphysema: 
3.8 (2.8, 5.1)¶ 
self-reported emphysema: 
1.9 (1.4, 2.7)‡ 
self-reported COPD#: 4.1 
(3.4, 4.9)¶ 
self-reported COPD#: 2.5 
(2.0, 3.1)‡ 
Wilson 
et al.300 
(2008, 
n=3638) 
99 
vs. 
3539 
48.6% current: 
60.2% 
ex-
smoker: 
39.8% 
emphysema by radiologist 
read: 4.39 (2.76, 6.99)§ 
emphysema by radiologist 
read: 3.56 (2.21, 5.73)¶ 
emphysema by radiologist 
read: 3.14 (1.91, 5.15)‡ 
spirometry FEV1/FVC<0.7: 
2.89 (1.89, 4.43)§ 
spirometry FEV1/FVC<0.7: 
2.09 (1.33, 3.27)¶ 
spirometry FEV1/FVC<0.7: 
1.41 (0.87, 2.29)‡ 
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Table 2.1: Lung cancer risk according to airflow limitation and emphysema 
study 
case 
vs. 
control 
sex, 
female 
smoking 
status 
Evaluation of emphysema, 
associated lung cancer risk, 
OR (95%CI) 
Measurement of airflow 
limitation, associated lung 
cancer risk, OR (95%CI) 
de 
Torres et 
al.304 
(2007, 
n=1166) 
23 
vs. 
1143 
26% former: 
100% 
emphysema by radiologist 
read: 3.33 (1.41, 7.85)§  
emphysema by radiologist 
read: 3.13 (1.32, 7.44)¶ 
emphysema by radiologist 
read: 2.51 (1.01, 6.23)‡ 
spirometry FEV1/FVC<0.7: 
4.83 (2.05, 11.41)§ 
spirometry FEV1/FVC<0.7: 
2.89 (1.14, 7.27)¶ 
spirometry FEV1/FVC<0.7: 
2.10 (0.79, 5.58)‡ 
Kishi et 
al.309 
(2002, 
n=120) 
24 
vs. 
96 
58.3% former: 
45% 
current: 
55% 
percent emphysema 
volume on qCT-900HU: 1.1 
(0.6, 1.9)¶ 
spirometry FEV1/FVC 
continuous: 1.4 (1.0, 2.2)¶ 
spirometry FEV1% 
continuous: 1.2 (1.0, 1.5)¶ 
OR: odds ratio; CI: confidence interval; FEV1: post-bronchodilator forced expiratory volume in 1 
second; FVC: forced vital capacity; COPD: chronic obstructive pulmonary disease. 
§unadjusted analysis; ¶adjusted for patient demographics; ‡adjusted for patient demographics, and 
emphysema or airflow limitation, as appropriate. 
# including reports of emphysema, COPD, and/or chronic bronchitis. 
Apart from the three aforementioned factors, timing of COPD diagnosis298,305, 
degree of airflow obstruction246,303 and severity of emphysema300,312 have also been 
reported to exert a remarkable effect on the significance and/or the magnitude of the 
impact of COPD on lung cancer risk. Although no solid evidence is available at present 
to clearly distinguish roles of airflow obstruction and emphysema in lung cancer 
development, it is certain that the highest lung cancer risk occurs when airflow 
obstruction and emphysema coexist304,307. A prospective cohort from the lung cancer 
screening study demonstrated two- and eleven-times higher incidence density of lung 
cancer among individuals with both diseases as compared to those with either one of 
them and those with neither one304. Therefore, both airflow obstruction and 
emphysema should be regarded as risk factors for lung cancer, and as such, could help 
identify individuals who may need active interventions to preempt tumorigenesis and 
target population who may benefit most from cancer screening. 
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2.1.2 Lung cancer prevention in COPD  
2.1.2.1 Minimizing tobacco exposure  
Since lung cancer is one of the most common causes of death among COPD 
patients317, the task to preempt lung cancer in COPD is critical. Cigarette smoking is 
the main element that these two diseases share in common, and it conferred an 
additional lung cancer risk in patients with preexisting COPD318. So the first priority of 
lung cancer preventive measures is smoking cessation. A population-based cohort 
study with 31-year follow-up demonstrated that participants who quit smoking 
reduced their lung cancer risk by 50%46. The Lung Health Study, which enrolled 5,887 
smokers with asymptomatic airflow obstruction (FEV1/FVC ≤70%), further confirmed 
that lung cancer mortality could be improved most by smoking cessation319, with rates 
of 6.04 per 1,000 person-year in those who quit smoking and 11.09 per 1,000 person-
year in continuing smokers (p<0.001). 
Secondhand tobacco smoke (SHS) exposure is another important risk factor for 
lung cancer49. Henschke and colleagues revealed that emphysema increased the risk 
of lung cancer in never smokers while the SHS exposure was an independent indicator 
of emphysema301. In addition, Kim and colleagues pooled data from 18 case-control 
studies in the International Lung Cancer Consortium (ILCCO)49, and found that SHS 
exposure was associated with an increased risk of lung cancer among both ever 
smokers and never smokers, and that risk of lung cancer increased with increasing 
years of SHS exposure. Therefore, SHS exposure should be avoided in COPD patients 
at the same time. 
 
2.1.2.2 Pharmacologic chemoprevention  
Inhaled corticosteroids (ICS), which are commonly prescribed to COPD patients, 
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are now showing a potential cancer prevention effect320. A nested case-control study 
of patients with COPD demonstrated that regular use of ICS was significantly 
associated with a decreased lung cancer risk321. Moreover, Parimon and colleagues 
observed a dose-response relationship where higher doses of ICS (≥1,200 ug/d) 
conferred a risk reduction of lung cancer of 61% in COPD patients322. 
Statins could attenuate the inflammation in COPD323,324 and have potential 
anticancer effects325,326; however, two recent meta-analyses indicated no significant 
association between statin use and the risk of lung cancer327,328. For patients with 
COPD who are already at an increased risk of developing lung cancer, Liu and 
colleagues found that COPD patients who used statins exhibited a 63% reduced lung 
cancer risk329. Although the data on chemopreventive agents (i.e., ICS and statin) at 
present are not as definitive as smoking cessation, it is axiomatic that the above-
mentioned measures could help not only reduce the incidence of lung cancer but also 
mitigate the progression of COPD. 
 
2.1.3 Lung cancer screening in COPD 
Low-dose CT (LDCT) is recommended for lung cancer screening by the United 
States Preventive Services Task Force (USPSTF)330, which contributed to earlier 
detection of lung cancer and a significant reduction in mortality331,332. However, a 
recent report showed an increasing number of patients with newly diagnosed lung 
cancer falling outside the population suggested by USPSTF eligibility criteria for 
screening47, implicating the need for a more sensitive screening strategy. Since 
patients with COPD, regardless of airflow obstruction or emphysema, are at higher risk 
for developing lung cancer296,302, several studies have targeted this population as a 
candidate for lung cancer screening302,315,333. Lowry and colleagues compared the 
health benefits of different screening programs, and the results showed that a 
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program using lower pack-year thresholds (≥1 pack-year) for individuals with COPD 
could yield higher life expectancy gains than USPSTF using smoking history alone315. 
Meanwhile, the detection rate and diagnostic precision could be improved by adding 
CT-detected emphysema as a complementary entry criterion to the National Lung 
Screening Trial (NLST)302. With respect to survival advantage, results from the Danish 
Lung Cancer Screening Trial indicated a favorable effect of screening on lung cancer 
mortality in COPD patients334. In order to increase the implementation of lung cancer 
screening among COPD patients, however, several aspects should be considered. 
 
2.1.3.1 Underdiagnosis and overdiagnosis of COPD  
It has been demonstrated that COPD is remarkably under-diagnosed worldwide, 
with an estimated rate of underdiagnosis of 71.2%-81.4%155,156. Overdiagnosis of 
COPD also poses a clinical challenge; 30.4%-40% of patients with a prior COPD 
diagnosis were found to have normal lung function on spirometry335,336. As a result, 
recommendation for lung cancer screening in self-reported COPD would only benefit 
a limited population, leaving four-fifths of cases unrecognized and one-third over-
treated. Evidence on airflow obstruction and/or emphysema are therefore the ideal 
surrogates in the context of lung cancer screening. Young and colleagues337 argued for 
a widespread use of spirometry screening for airflow obstruction in asymptomatic 
smokers, in an attempt to appropriately evaluate the prevalence of COPD and detect 
individuals at an increased risk for lung cancer early. Some identified determinants of 
under-diagnosed COPD include male sex, lower level of education, being of ethnic 
minority, and lower comorbidity burden155,156,160, while younger age, being overweight, 
and higher levels of comorbidities are risk factors for COPD overdiagnosis160,164,338. 
Therefore, individuals with these characteristics should be offered spirometry for a 
correct diagnosis of COPD, which in turn will allow for further risk stratification in lung 
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cancer screening339. Since the presence of emphysema is primarily diagnosed by CT 
and most individuals do not have a CT scan beforehand, the value of emphysema in 
selecting candidates for the baseline lung cancer screening is thus limited. However, 
the identification of emphysema during baseline screening would be conducive to 
determining individuals who may need close follow-up304. 
 
2.1.3.2 Further risk assessment  
As COPD is identified as a driving factor in lung cancer, a refined risk stratification 
among patients with preexisting COPD can further improve the cost-effectiveness of 
CT screening and avoid unnecessary radiation exposure340. De-Torres and colleagues 
explored risk factors associated with lung cancer development in a cohort of 
outpatients with COPD, and identified four independent predictors: baseline age, body 
mass index (BMI), predicted percentage of diffusion capacity for carbon monoxide 
(DLCO%), and GOLD stages246.  
Subsequently, the COPD-specific score (COPD-LUCSS) was developed to predict 
lung cancer risk for patients with COPD318. COPD-LUCSS is determined by four 
parameters: age >60, BMI <25kg/m2, pack-years >60, and presence of radiological 
emphysema, with a total range from 0 to 10 points (Table 2.2). In comparison to those 
with low-risk (scores 0-6), patients in high-risk category (scores 7-10) had a 3.5-fold 
greater risk of developing lung cancer. As COPD could be a driving factor in lung cancer, 
these results further indicated a risk stratification among COPD patients. Therefore, 
screening strategy based on COPD-LUCSS system allows for further reduction in cost 
and screening-related harms. 
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Table 2.2: COPD-LUCSS and COPD-LUCSS-DLCO scoring system 
COPD-LUCSSa   COPD-LUCSS-DLCOb  
components Score  components Score 
body mass index <25 1  body mass index <25 1.5 
pack-year history >60 2  pack-year history >60 1 
age >60 year 3  age >60 year 2.5 
radiologic emphysema  4  DLCO <60% 3 
total 10  total 8 
categories    categories  
low risk 0-6  low risk 0-3 
high risk  7-10  high risk  3.5-8 
a predictive score for lung cancer risk for patients with COPD; b identification of COPD patients 
at high risk of lung cancer mortality. COPD: chronic obstructive pulmonary disease; DLCO: 
diffusion capacity of lung for carbon monoxide 
 
2.1.3.3 Over-diagnosis of pulmonary nodules 
Over-diagnosis refers to excess lung cancer detected by screening that would not 
affect the patient during their lifetime if left untreated341, which may incur additional 
cost, patient anxiety, and potential morbidities related to subsequent diagnostic 
procedures342. It is estimated that over-diagnosis accounted for as much as 18.5% of 
all lung cancers detected by LDCT343. Seeing that COPD is associated with more 
aggressive forms of lung cancer344,345, over-diagnosis in this high-risk population may 
be less likely. De-Torres and colleagues found that screening in COPD patients resulted 
in a higher detection rate of early-stage lung cancer, without showing a significant 
“histology shift” towards over-diagnosis333,346. Young and colleagues examined the 
effect of COPD on over-diagnosis and demonstrated that LDCT screening in COPD 
patients yielded a doubling of lung cancer incidence without apparent over-diagnosis, 
whereas in non-COPD patients, the stage shift was counterbalanced by the excess 
diagnosis of bronchioloalveolar carcinoma347. The available data suggest that lung 
cancer screening in individuals with COPD may contribute to a high rate of diagnosis 
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of lung cancer at curable stage while minimizing over-diagnosis347,348. 
 
2.1.3.4 Competing causes of mortality/morbidity  
The USPSTF recommended that screening should not be offered to people who 
have substantial comorbid conditions with limited life expectancy330. Sin and 
colleagues reviewed the underlying causes of death in COPD patients and reported 
that the main cause of death for mild-to-moderate COPD was lung cancer, while for 
more advanced COPD, respiratory failure was the predominant cause317. As regards 
benefit from screening, De-Torres and colleagues explored the impact of screening on 
lung cancer mortality in patients with mild-to-moderate COPD333, and the results 
showed that the mortality incidence densities from lung cancer were significantly 
lower in the screening group (0.08/100 person-years) than in the control group 
(unscreened COPD, 2.48/100 person-years), justifying active screening in patients with 
milder COPD. However, screening patients with more severe COPD may reduce cost-
effectiveness because the benefits could be surpassed by other competing causes of 
death inherent to COPD175. In preliminary data from a post-hoc analysis of the NLST, it 
has been shown that the lung cancer specific mortality reduction in screening 
participants with COPD was approximately one half that of those without COPD (15% 
vs 28% respectively), suggesting the benefits of CT screening in COPD may be diluted 
by competing causes of death349,350. Therefore, the trade-off between the potential 
benefits and harms should be considered by participants and their health providers 
together, when considering lung cancer screening in patients with more severe 
COPD340. 
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2.1.4 Clinical features of COPD-associated lung cancer 
It has been demonstrated that squamous cell carcinoma is more commonly seen 
in the setting of COPD246. Research on emphysema also indicated its association with 
squamous cell type (OR, 2.6; 95%CI, 1.4-4.8), even after adjustment for COPD 
diagnosis and smoking history351. A shared predisposing factor -tobacco smoking- may 
account for this observation344. 
Lung cancer arising in COPD was more likely to be centrally located352. Similarly, 
emphysema severity was indicative of tumor location in COPD-associated lung cancer, 
as lower emphysema grade had a tendency towards central location of lung cancer 
while higher grade towards peripheral location352. When the extent of emphysema 
was quantified regionally, a strong association was found for cancer being located in 
the area with the highest degree of emphysema, with a corresponding OR of 1.342 
(95%CI, 1.112-1.620)353. Apart from the cancer site, the emphysema severity of the 
region where tumor occurred was correlated to tumor size354. 
In histopathologic analysis, Schiavon and colleagues described that COPD-
associated adenocarcinoma tended to manifest less invasive characteristics, such as 
increased lepidic component and lower cell proliferation, as compared to COPD-free 
adenocarcinoma355. However, Murakami and colleagues commented that cancer 
arising in emphysematous lung possessed a more aggressive nature356, because the 
matrix metalloproteinase (MMP), which was widely up-regulated in emphysematous 
lungs, was associated with the occurrence of lymphovascular invasion and 
postoperative recurrence345,356. Moreover, in post-hoc analyses of two CT screening 
studies, it has been shown that smokers with impaired lung function had shorter 
volume doubling times of pulmonary nodules (more aggressiveness) and less 
prevalence of indolent lung cancers, suggesting COPD is a clinical marker of aggressive 
lung cancer357-359. 
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With regard to molecular features, several studies found that both EGFR 
mutations and ALK rearrangements were less prevalent in COPD-associated lung 
cancer360,361, and the presence of EGFR mutations was inversely correlated with the 
severity of airflow limitation361. In contrast, KRAS mutations were independent of 
COPD status362,363. It is worth mentioning, however, that the traits of driver genes 
alternations in lung cancer with COPD could be partly due to their associations with 
patient clinical characteristics362. 
 
2.1.5 Treatment for lung cancer coexisting with COPD 
Major lung resection is the best option for cure in lung cancer patients; however, 
it has been reported that about one-third of patients with comorbid COPD may be 
ineligible for surgery for lung cancer that would otherwise be technically operable, due 
to poor physical condition360. Furthermore, the frequencies of all postoperative 
pulmonary complications (PPCs), including pneumonia (10.1%-16.2% in COPD patients 
following lung cancer surgery)364-366, atelectasis (3.5%-15.4%)365,367, empyema (2.2%-
8.3%)366, and persistent air leak (12%-16.2%)364,368, and prolonged mechanical 
ventilation (4%-16.7%)366-368 were often higher in COPD patients369. Therefore, an 
accurate risk assessment in patients with lung cancer coexisting with COPD is critically 
important, in order to optimize treatment for these patients. 
 
2.1.5.1 Identifying risk factors for PPCs  
There are only a small number of studies to date that have investigated risk factors 
for PPCs in COPD patients undergoing lung cancer surgery. Kim and colleagues, in their 
prospective study, reported that the incidence of PPCs was higher in patients with 
COPD but not different between COPD grades (FEV1% ≥70% vs. FEV1% <70%) or 
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symptom burden (less symptoms vs. more symptoms)365. Multivariate analysis 
revealed that BMI (OR=0.8), DLCO% (OR=0.97), and operation time (OR=1.01) were 
significant predictors of PPCs in COPD patients undergoing cancer surgery. In 
cardiopulmonary exercise testing, peak oxygen uptake (VO2peak) is an important 
parameter in the assessment of surgical risk370. Rodrigues and colleagues found that 
the cutoff value of 61% for VO2peak% (ml/kg/min) was a significant discriminator 
between COPD patients with and without complications following tumor resection371. 
With regard to surgical approach, Jeon and colleagues performed a propensity score-
matched analysis and demonstrated that video-assisted thoracoscopic surgery in lung 
cancer patients with comorbid COPD could reduce PPCs compared with 
thoracotomy372. Thus, such identified risk factors are supposedly taken into 
consideration in preoperative risk assessment. 
 
2.1.5.2 Effective perioperative management 
Patient functional status must be optimized during the preoperative workup. 
Medical management for COPD, smoking abstinence, and pulmonary rehabilitation 
are three major effective strategies to improve postoperative outcomes370,373. 
Pharmacologic therapy for COPD, such as bronchodilators and ICS, can help reduce 
symptoms, prevent exacerbations, and thus increase perioperative safety365,374. The 
use of ICS was thought to pose an increased risk of pneumonia375, but a recent study 
has demonstrated no relationship between the perioperative ICS administration and 
the incidences of PPCs in COPD patients receiving pulmonary resection for lung cancer, 
justifying the use of ICS during the perioperative period376. 
It is clear that smoking cessation should be advocated preoperatively which helps 
to not only reduce PPCs but improve quality of life (QOL) and long-term survival370,377. 
However, the timing of tobacco cessation is still controversial. Although a general trend 
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was observed for decreasing PPCs with an increase in the length of cessation prior to 
surgery378, some studies, were not as supportive, showing a higher risk for PPCs in 
patients who had quit smoking in the immediate preoperative period379,380. 
Hypothetical explanations for this increased risk may relate to the effect of nicotine 
withdrawal and increased sputum volume caused by the reduction in irritant-induced 
coughing, before the recovery of ciliary function381. Therefore, smoking cessation 
should be encouraged with sufficient duration (2-4 weeks) before surgery373. 
Pulmonary rehabilitation programs are widely applied in the nonpharmacologic 
management of moderate-to-severe COPD, which yields an improvement in exercise 
capacity134. The effect of preoperative pulmonary rehabilitation has now been 
demonstrated in patients with COPD undergoing lung cancer resection382-384. Stefanelli 
and colleagues randomly divided 40 patients with concomitant lung cancer and COPD 
into two groups382; VO2peak displayed a remarkable improvement in the group receiving 
3-week intensive pulmonary rehabilitation (from 14.9±2.4 to 17.8±2.1 ml/kg/min, 
p<0.001), while no change was found in the control group. Similarly, Divisi and 
colleagues targeted 27 patients with compromised lung function and observed a 
significant increase in FEV1 (from mean FEV1 of 1.14L to 1.65L) after a 4-week 
preoperative pulmonary rehabilitation385. Moreover, pulmonary rehabilitation is 
shown to decrease postoperative complications as well as length of hospital stay384. 
Despite the small sample size included in previous studies384-386, the documented 
benefits underscore the importance of pulmonary rehabilitation for patients with 
advanced COPD prior to lung cancer surgery, to help to reduce the function limitations 
of inoperability. 
 
2.1.5.3 Predictors of lung volume reduction effect  
Patients with lung cancer and COPD receiving cancer resection may have a 
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minimal loss, or improvement, in postoperative pulmonary function, which is referred 
to as the “lung volume reduction effect”387,388. Various methods have been reported 
to determine potential candidates who are more likely to have the functional benefit. 
Korst and colleagues defined the COPD index, a scoring system combining 
preoperative FEV1% predicted and FEV1/FVC389, and found that COPD index <1.0 was 
a good indicator of an improvement of pulmonary function following lobectomy. 
Sekine and colleagues documented a greater actual postoperative FEV1 than predicted 
in COPD patients with lobectomy of lower portion390. Furthermore, quantitative 
analysis of radiologic emphysema could characterize the respiratory dynamics 
underlying the volume reduction effect391. Alternatively, a concomitant surgery of 
tumor resection and lung volume reduction surgery (LVRS) is feasible in patients who 
satisfy the criteria for both LVRS and cancer surgery392. This combination offers the 
best opportunity to cure lung cancer, treat COPD/emphysema, and thus yield a survival 
advantage during one surgical procedure393. The intraoperative strategies, such as 
lobectomy combined with contralateral LVRS, are highly dependent on the site of 
tumor, heterogeneous distribution of emphysema, patient’s attitude, as well as 
surgeon’s experience. 
 
2.1.5.4 Non-surgical treatment 
Patients who are unfit for surgery due to poor lung function and/or COPD-related 
systemic comorbidities (such as ischemic cardiac disease) could benefit from 
stereotactic body radiotherapy (SBRT), which has been shown as a safe and effective 
alternative treatment for early-stage lung cancer394. A recent study by Pamla and 
colleagues reported a 3-year actual local control rate of 89% in stage I non-small cell 
lung cancer (NSCLC) patients with concomitant COPD (GOLD class III/IV) after SBRT395, 
and a subsequent systematic review demonstrated comparable outcomes between 
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SBRT and surgery in this patient population395. The toxicity following SBRT was 
tolerable, and even milder in patients with COPD than those with normal lung 
function396. Data on the effectiveness of chemotherapy in COPD-associated lung 
cancer remain limited, although COPD has been reported to increase the risk of 
chemotherapy-induced febrile neutropenia397. 
 
2.1.5.5 Multidisciplinary treatment (MDT) 
MDT can improve adherence to evidence-based guidelines and timeliness of care 
for lung cancer patients398. In addition, in the setting of advanced NSCLC, MDT has 
been reportedly associated with a better survival rate399. Since lung cancer and COPD 
often coexist, pulmonologists could provide prompt diagnosis for lung cancer and 
effective management of pulmonary comorbidities400. Data from the Surveillance, 
Epidemiology and End Results (SEER) database showed that the involvement of 
pulmonologists in the care of patients with early-stage NSCLC and COPD could increase 
surgical resection rate (OR, 1.26; 95%CI, 1.11-1.45) and reduce mortality risk (HR, 0.80; 
95%CI, 0.75-0.85)401. Thus, MDT should be incorporated into the treatment of lung 
cancer concomitant with COPD. 
 
2.1.6 Role of COPD in lung cancer prognosis 
The prognostic significance of COPD in lung cancer remains equivocal. Most 
studies found that COPD exerted an unfavorable effect on lung cancer 
prognosis366,402,403, while others did not404,405. Two recent meta-analyses indicated 
COPD as an adverse prognostic predictor, but the results suffered from a high level of 
heterogeneity between studies406,407. The heterogeneity of effect size is possibly 
subject to cancer stage, treatment modality and status of COPD per se407. Zhai and 
 59 
colleagues found that coexisting COPD was associated with worse survival (HR, 1.41; 
95%CI, 1.13-1.75) in patients with early-stage NSCLC undergoing surgical resection402. 
However, this association was insignificant (HR, 1.20; 95%CI, 0.83-1.50) in the study by 
Izquierdo and colleagues404, who targeted patients with advanced lung cancer (stage 
IIIB/IV) treated with chemotherapy. In terms of COPD grade, there was a more 
apparent decrease in survival for patients with severe COPD, but not for those with 
mild-to-moderate COPD, as compared to non-COPD patients following lung cancer 
resection366,408. In addition, quantitative analysis of emphysema on CT demonstrated 
a direct association with lung cancer mortality (HR, 1.21; 95%CI, 1.06-1.38)313. 
Recently, a prognostic model was designed to identify patients with COPD at high 
risk of lung cancer death409. In this model (COPD-LUCSS-DLCO), a corresponding score 
was assigned to each indicator: patient’s age (2.5 points), BMI (1.5 points), pack-year 
of smoking (1 point), and DCLO% (3 points); participants were then classified into low 
risk (scores 0-3) and high risk group (scores 3.5-8), where the latter conferred a 2.4-
fold (95%CI, 2.0-2.7) increased risk of death when compared to the low-risk category 
(Table 2.2)409. In addition, research from the linked SEER-Medicare Database 
demonstrated the addition of comorbid COPD to a comprehensive model could 
improve prognostication over similar models using cancer information alone410. 
With regard to health-related quality of life, Pompili and colleagues performed a 
propensity score-matched analysis among patients undergoing lobectomy for lung 
cancer, and found that patients with COPD experienced a comparable postoperative 
quality of life to matched patients without COPD411. Pompeo and colleagues studied 
patients who underwent tailored combined surgery for both stage I NSCLC and severe 
emphysema, and demonstrated a significant improvement in general health domain 
based on short-form 36 item questionnaire after surgery, associated with 
improvements in dyspnea index and exercise capacity412. 
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2.1.7 Cancer prevention strategy and future efforts 
Lung cancer prevention strategies should be emphasized and encouraged 
throughout the entire disease process. Primary prevention is aimed at limiting the 
incidence of lung cancer. COPD, characterized as either airflow obstruction or 
emphysema, is an important predisposing factor for lung cancer development. Thus, a 
primary aim is to control the additional exposures (such as smoking and SHS exposure) 
which contribute to COPD, lung cancer, and the progression from COPD to lung cancer. 
The use of chemopreventive agents such as ICS and statin remain relatively 
rudimentary in COPD patients, and should be tested in prospective, controlled trials. 
Secondary prevention refers to the early detection of lung cancer at a pre-clinical 
phase, and lung cancer screening represents the most important component of this 
approach. The current available evidence shows that lung cancer screening in COPD 
patients confers a high detection rate of cancer at early stage (stage shift), and reduces 
lung cancer mortality. Nevertheless, some screening-related issues (e.g., 
underdiagnosis of COPD and potential benefit offset) ought to be recognized and 
discussed in the future. With respect to clinical features, lung cancer in COPD is quite 
distinct from that in non-COPD, highlighting the demand for a designated screening 
criteria as well as a tailored treatment algorithm in this patient population. Tertiary 
prevention points to the execution of treatment and rehabilitation with the principal 
aim of alleviating disability and improving the outcomes of illness. Surgery for lung 
cancer in COPD may have a lung volume reduction effect. Precise risk assessment, 
optimal preoperative management (smoking cessation, medical treatment for COPD, 
and pulmonary rehabilitation), and MDT care are critically important before surgery. 
Meanwhile, the recognition of the effect of COPD on lung cancer prognosis enables 
refined prognostication and thus allows for personalised clinical decision-making. 
Increasing understanding of the relationship between COPD and lung cancer will allow 
the development of better cancer preventive strategies and ultimately will improve 
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the outcomes of this patient population. 
 
2.2 Genetic Association between Lung Cancer and COPD 
As already discussed in section 2.1, COPD and lung cancer are inextricably linked 
in many clinical aspects; however, the exact mechanisms connecting COPD and lung 
cancer remain obscure. Tobacco exposure is a common risk factor for both lung cancer 
and COPD, but these two diseases have been demonstrated to be linked by more than 
smoking alone; only 15-20% of smokers develop lung cancer and/or clinically 
significant COPD, while 10-15% of individuals with either of these disease turn out to 
be never smokers299,413. Therefore, additional intrinsic factors might be responsible for 
the association between COPD and lung cancer. 
Several hypotheses are being proposed, such as chronic inflammation and 
associated pro-inflammatory mediators, oxidative and noxious stress, and epithelial to 
mesenchymal transition (Figure 2.2)167,414,415.  
 
Figure 2.2: Putative mechanisms linking chronic obstructive pulmonary disease and lung cancer.  
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Generally, pulmonary chronic inflammation resulting from smoking and COPD 
plays a central role in the development of lung cancer, which results in repeated 
epithelial cell injury and high cell turnover, subsequently leading to accumulation of 
DNA replication errors and initiation of carcinogenesis (Figure 2.3)416. Meanwhile, 
several pro-inflammatory cytokines (e.g., IL-1β, IL-6), and, in particular, activation of 
nuclear factor kappa B (NF-κB) and signal transducer and activator of transcription 3 
(STAT3) have also been implicated in the progression from COPD to lung cancer by 
means of inhibiting apoptosis, inducing proliferation, and, finally, accelerating cancer 
development417,418.  
 
Figure 2.3: Repetitive cycles of cell injury and turnover in the context of chronic inflammation. 
Additionally, oxidative stress is considered as a causative agent of both diseases344; 
an imbalance between oxidants and antioxidants can drive free radical damage of DNA 
(point mutations, single and/or double stand breaks, and DNA cross-linking), which if 
incorrectly repaired, contributes to the earliest stage of tumorigenesis344. 
Epithelial-mesenchymal transition (EMT) represents a process whereby cells with 
an epithelial phenotype transform into cells with a mesenchymal phenotype, in which 
transformed cells are endowed with the ability to invade, resist apoptosis and 
disseminate415. The process is commonly promoted by transforming growth factor-β 
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(TGF-β) and matrix metalloproteinase (MMP) that underlie COPD, contributing to 
malignant transformation of the respiratory epithelium (Figure 2.4)419.  
 
Figure 2.4: Process of epithelial-mesenchymal transition (EMT). (1) tight-junction dissociation 
and loss of microvilli; (2) loss of cell polarity; (3) cytoskeleton reorganization and migration; (4) 
invasion.  
Collectively, chronic inflammation in COPD may increase the probability of 
aberrant mutations in airway and/or alveolar epithelium that promotes tumor 
initiation and progression. Meanwhile, the abnormal inflammatory response 
alongside pro-inflammation mediators may lead to excessive oxidative stress, which in 
return activates proliferative and inflammatory pathways and favors carcinogenesis 
through DNA damages420. In these circumstances, bronchial epithelial cell integrity and 
function are disrupted by matrix remodeling and growth factor release (TGF-β and 
MMP), and together trigger EMT421, accelerating tumor growth and angiogenesis. 
In addition, epigenetic modifications play a part in the mechanistic links422. 
Tobacco smoking induces a myriad of DNA methylation (for example genes such as 
CCDC37, MAP1B)423 and histone acetylation (HDAC2)344, as well as changes in 
microRNA expression (let‑7c)424. Some of these patterns have been demonstrated to 
predispose an individual to both COPD and cancer. Importantly, from a clinical 
standpoint, the reversible nature of epigenetic modulations provides a promising 
chemopreventive target for lung cancer and COPD together.  
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Although the basis of the link between COPD and lung cancer has not been clearly 
elucidated at the biological level, genetic association studies are now attempting to 
clarify this important relationship. Genetic association analysis is based on a case-
control study to compare the difference in allele frequencies between groups of 
affected and unaffected individuals at the population level425, aiming to detect 
association between one or more genetic polymorphisms and disease risk426. 
Historically, it includes two major types of investigation to determine the contribution 
of genes to disease susceptibility: the genome-wide association approach and the 
candidate gene approach.  
 
2.2.1 Genome-wide association studies on COPD and lung 
cancer 
The term genome-wide association (GWA) study refers to a case-control 
association study using high-throughput genotyping techniques to assess hundreds of 
thousands of single nucleotide polymorphisms (SNPs) that span the whole genome, 
and to relate them to clinical conditions and measurable traits (Figure 2.5)427. The GWA 
study design is based on the common disease common variant hypothesis, and, rare 
variants are poorly captured by GWA approach428. 
So far, published GWA studies for COPD and lung cancer have identified several 
risk loci, and some of them overlap (Table 2.3). One of the loci, which specifically 
modulates susceptibility to both diseases, is located on chromosome 15q25 and maps 
to the CHRNA3 and CHRNA5 (cholinergic receptor, nicotinic, subunits α3 and α5) genes 
which encode neuronal nicotinic acetylcholine receptors (nAChR)429-431.  
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Table 2.3: Chromosomal loci and candidate/nearest genes associated with COPD and lung cancer 
identified by genome-wide association studies.  
region candidate or nearest gene region candidate or nearest gene 
COPD lung cancer 
1q23  RPL31P11432 3q28  TP63433-435 
1q41  TGFB2436 3q29 XXYLT1437 
4q22 FAM13A
438
 5p15  TERT433,434,439,440, CLPTM1L439 
4q31 HHIP436,441 6p21  BAT3440, HLA class II region434, FOXP4-
AS1442 
7p15 NUPL2443 6q22 ROS1434 
11q14 DLG2443 9p21 CDKN2B-AS1442,444 
11q22 MMP12436 10q25 VTI1A434 
14q32 RIN3436 12q23 SLC17A8445 
15q25 CHRNA3/5436,441 13q12 MIPEP433 
19q13 RAB4B, EGLN2, MIA and 
CYP2A6446 
13q13 BRCA2435 
  13q31 GPC5447 
  15q25  CHRNA 3/5430,431,440, PSMA4431, HYKK430 
  18p11 PIEZO2448 
  22q12  HORMAD2433, MTMR3433, CHEK2435 
Bold indicates potential overlapped gene implicated in both COPD and lung cancer.  
BAT3: HLA-B associated transcript 3; BRCA2: breast cancer 2, early onset; CDKN2B-AS1: CDKN2B 
antisense RNA 1; CHEK2: checkpoint kinase 2; CHRNA3/5: cholinergic receptor, nicotinic, 
subunits α3 and α5; DLG2: discs, large homolog 2 (Drosophila); FAM13A: family with sequence 
familiarity 13 member A; FOXP4-AS1: FOXP4 antisense RNA 1; GPC5: glypican 5; HHIP: Hedgehog 
interacting protein; HORMAD2: HORMA domain containing 2; HYKK: hydroxylysine kinase; 
MIPEP: mitochondrial intermediate peptidase; MMP12: matrix metallopeptidase 12; MTMR3: 
myotubularin related protein 3; NUPL2: nucleoporin like 2; PIEZO2: piezo type mechanosensitive 
ion channel component 2; PSMA4: proteasome subunit α4; RIN3: Ras and Rab interactor 3; 
RPL31P11: ribosomal protein L31 pseudogene 11; SLC17A8: solute carrier family 17 member 8; 
TERT: telomerase reverse transcriptase; TP63: tumor protein p63; TGFB2: transforming growth 
factor β2; VTI1A: vesicle transport through interaction with t-SNAREs 1A; XXYLT1: xyloside 
xylosyltransferase 1. 
Specifically, in GWA analysis, the rs8034191 SNP was significantly associated with 
lung cancer, with an increased risk for both heterozygous (OR, 1.21; 95%CI, 1.11-1.31) 
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and homozygous variants (OR, 1.77; 95%CI, 1.58-2.00)431. In addition, the minor allele 
of the same SNP was estimated to have a population attributable risk for COPD of 
12.2%441. Furthermore, the allelic OR of the CHRNA3 rs12914385 SNP was 1.29 for the 
risk of lung cancer (p-value for trend, 4.79×10-16)440 and 1.39 for the risk of COPD (p-
value for trend, 2.70×10-16)436. 
 
Figure 2.5: Genome-wide association study. 
It is also well known that CHRNA3 and CHRNA5 are associated with cigarette 
smoking, and SNP in these genes (e.g., rs16969968 leading to a non-synonymous 
amino acid change in the α5 subunit) can regulate nicotine dependence449. Hence, 
concerns have been raised about whether this locus has a direct effect on lung cancer 
and COPD vulnerability, or whether this increased genetic risk of lung cancer and COPD 
can be explained solely through the genetic influence on nicotine addiction and 
smoking behaviour450. Smoking may serve as the greatest modifiable risk factor in this 
genetic association. Thorgeirsson and colleagues reported that most of the effect of 
SNPs in this region might be related to nicotine addition, with only a small direct effect 
on lung cancer risk451. On the contrary, there is also evidence supporting the potential 
existence of a direct genetic influence of this region on lung cancer and COPD. Several 
recent GWA studies showed that the genetic association of nicotine receptor SNPs 
 67 
with lung cancer and COPD remained, after controlling for smoking intensity436,440. 
These observations suggest that lung cancer and COPD may not be discrete diseases, 
but rather develop through overlapping pathogenetic pathways in individuals who are 
susceptible to both diseases. 
 
2.2.2 Candidate gene approach as to linking COPD and lung 
cancer 
A candidate gene study focuses on specifically selected genes in which variation is 
hypothesized to influence the risk of a disease452. This is in contrast to GWA studies, 
which scan the entire genome for common genetic variation influencing disease risk. 
Normally, candidate genes are selected based on a priori knowledge of the gene's 
biological function453. In fact, most genetic associations between COPD and lung 
cancer have been identified through a candidate gene approach, and a number of 
candidate genes recognized to relate to both COPD and lung cancer are engaged in 
pathways involved in the development of both diseases, including inflammation, 
oxidative stress, and extracellular matrix proteolysis428. Hereinafter, emphasis is placed 
on studies evaluating lung cancer and COPD jointly.  
 
2.2.2.1 nAChR 
As mentioned above, the SNPs in nAChR genes relating to risk of lung cancer and 
COPD have also been replicated in a number of candidate gene studies454-456. Kaur-
Knudsen and colleagues examined the associations between the nAChR polymorphism 
rs1051730, smoking behavior, and tobacco-related diseases in 10,330 participants 
with 18 years follow-up454. Smoking was found to be associated with the development 
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of lung cancer and COPD, but the smoking behavior-adjusted HRs for homozygotes (TT) 
versus non-carriers (CC) at rs1051730 were still 1.6 (95% CI, 1.1-2.2) for lung cancer 
and 1.3 (95% CI, 1.1-1.6) for COPD454. Similarly, a recent meta-analysis by Saccone and 
colleagues456 reported a significant association of the nonsynonymous CHRNA5 SNP 
rs16969968 with lung cancer (OR, 1.31; 95%CI, 1.24-1.38, p=1.99×10-21) and a 
relatively weak association with COPD (OR, 1.11; 95%CI, 1.02-1.23, p=0.01), after 
adjusting for number of cigarettes smoked per day. In a Chinese population, Yang and 
colleagues455 further analyzed the functional polymorphism of CHRNA3 in three strata 
of smoking status (ever smoker, passive smoker, smoking avoider), and observed a 
significant interaction between ever smoking and rs6495309C genotypes for risk of 
both diseases (p=0.003 for lung cancer; p=0.048 for COPD). In addition, Wang and 
Young pointed out that smoking behaviour and COPD had mediating effects on the 
association between CHRNA5-A3 region genetic variant and the risk of lung 
cancer457,458. Therefore, in parallel with the GWA studies, the results from candidate 
gene studies further support a genetic convergence of smoking quantity, lung cancer 
and COPD susceptibility.  
 
2.2.2.2 HHIP 
Another locus conferring increased risk of both COPD and lung cancer based on 
candidate gene studies is 4q31, where the hedgehog-interacting protein (HHIP) is 
located415. HHIP is a transmembrane protein which regulates the Hh signaling pathway 
and manipulates EMT421. Thus far, HHIP has been demonstrated to correlate with 
COPD436,441 and pulmonary function459,460, and show a week In addition, HHIP showed 
a week association with lung cancer431. In the joint analysis of the effect of HHIP 
polymorphisms461, the GG genotype of the rs1389759 HHIP SNP was observed to 
confer a protective effect on COPD (OR, 0.59; p=0.006) and lung cancer (OR, 0.70; 
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p=0.05). Moreover, stratification of lung cancer cases into those with and without 
COPD produced similar results, which could reliably exclude an interactive or 
confounding effect from coexisting COPD461,462. This evidence suggests that not only is 
COPD a common comorbidity that has possible common origins with lung cancer, but 
that gene conferring a propensity to COPD may also be significant for lung cancer 
susceptibility. 
 
2.2.2.3 TERT-CLPTM1L 
Candidate gene association studies also replicated the variants in the 
chromosome 5p15 locus in susceptibility to both COPD and lung cancer, which 
encompasses two potential genes: TERT and CLPTM1L462,463. In contrast to nAChR, the 
TERT-CLPTM1L locus was identified to be directly associated with lung cancer, entirely 
independent of smoking behaviour439, and this association has been replicated in 
never smokers464. The TERT gene encodes human telomerase reverse transcriptase, 
which is important in the maintenance of telomere length465, and the CLPTM1L (cleft 
lip and palate transmembrane protein 1-like protein) gene encodes a protein linked to 
apoptosis in lung cells425. Wauters and colleagues463 studied the rs31489 variant on 
5p15 and observed that homozygous carriers of the C-allele exhibited increased 
susceptibility to bronchial obstruction (OR, 1.82; 95%CI, 1.24-2.69), emphysema (OR, 
2.04; 95%CI, 1.41-2.94), and lung cancer (OR, 1.90; 95%CI, 1.21-2.99). Furthermore, 
when stratifying lung cancer patients into two categories, based on the presence or 
absence of COPD, rs31489 CC-carriers were almost twice as frequent in patients with 
COPD as in those without COPD, suggesting the at-risk C-allele is more strongly 
associated with development of both lung cancer and COPD rather than lung cancer 
alone463. However, this result was not confirmed by Young and colleagues, who 
reported that TERT-CLPTM1L locus predisposed to lung cancer in the absence of 
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COPD462. 
 
2.2.2.4 FAM13A 
Genetic variants in FAM13A gene, located at the 4q22 locus, have been associated 
in a number of GWA studies with lung function429,466 and a reduced risk of COPD438, 
although the biological function of the FAM13A gene is poorly understood. Sequence 
analysis has indicated that the Rho GTPase activating protein domain is encoded by 
exons 3-5. This domain has anti-inflammatory activity and tumor suppressor 
function467. Young and colleagues subsequently examined the rs7671167 SNP in 
FAM13A in relation to the risk of both COPD and lung cancer468. Their results confirmed 
the protective effect of the FAM13A variant on COPD (allelic OR, 0.79; 95%CI, 0.66-
0.96), and showed for the first time that this variant was also associated with lung 
cancer (allelic OR, 0.64; 95%CI, 0.47-0.87), even in those without COPD (allelic OR, 0.58; 
95%CI, 0.38-0.87)468. Ziolkowska-Suchanek and colleagues further performed a 
cumulative genetic risk score analysis based on the three SNPs (rs13180, rs7671167 
and rs2568494) in the FAM13A gene469, and revealed that the risk of COPD increased 
with increasing number of FAM13A risk alleles, with an OR of ≥5 risk alleles of 2.998 
(95%CI, 1.809-4.968). However, none of the SNPs displayed significant associations 
with lung cancer in their study469.   
To sum up, GWA studies and candidate gene studies have identified several of the 
same genetic variants associated with the risk of COPD and lung cancer (Figure 2.6). 
The SNPs showing strongest association, however, are not necessarily the causal loci; 
they may just be in linkage disequilibrium with a nearby causal variant. Therefore, 
further comparisons at the gene expression level within individuals of different 
genotypes are needed to provide biological evidence for the candidate genes 
underlying the specific disease.  
 71 
 
Figure 2.6: Chromosomal loci and associated genes related to COPD and lung cancer from GWA 
studies. COPD: chronic obstructive pulmonary disease; GWA: genome-wide association.  
 
2.2.3 Clinical implications and future work 
 There are a number of important implications stemming from the strong link 
between COPD and lung cancer at the genetic level39. First of all, it is obvious that the 
identification of genetic variants may help define individuals who are at high risk of 
disease in the preclinical setting. Incorporation of genetic markers into disease risk 
models has shown promise in raising predictive performance462,470. Young and 
colleagues attempted to create a gene-based risk model combining 12 SNPs with 
patient demographics (age, family history of lung cancer, and COPD) for lung cancer 
susceptibility, and their results showed that the area under the curve (AUC) reached 
0.75, with the SNP panel contributing most to the total predictive utility (the AUC of 
SNPs, 0.68)471. Along with the improvement of predictability, knowledge of individual 
genetic predisposition to a certain illness may also have an advantage in management 
to mitigate the risk exposure. Smokers who were informed of their gene-based health 
hazard were more likely to modify their smoking behaviour421,472. Preliminary results 
indicated that genetic testing can motivate up to 30% of smokers to quit473.  
 In addition, disease screening strategies can be improved with respect to the 
 72 
identification of target population and surveillance when genetic information is 
included within existing programmes. Current recommendations for CT screening for 
lung cancer are largely based on age, smoking status, family history, and history of lung 
diseases474,475. These criteria preclude young people, who represent 1-3% of all lung 
cancers476, from the benefits of screening. For these individuals, gene-based risk 
testing can identify younger smokers at high risk, promoting them for an earlier 
referral by the physician for CT imaging477. Meanwhile, screening eligible candidates 
who are considered to be in a higher-risk category based on gene testing might also 
benefit from closer follow-up478.  
 Although much progress in genetic knowledge has been made during the past 
decade, our ability to process and interpret the results still lag behind the technical 
capacity to produce tremendous amounts of genomic data39. Additionally, ever-
increasing genetic variants identified by association studies lead to a plethora of 
putative biomarkers that lack validation. The mechanisms of action of SNPs also 
remain to be elucidated479. Of more importance is how to translate these research 
findings into clinical practice in a reasonable and ethical manner, with the ultimate 
goal to improve the health of the public. 
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Chronic obstructive pulmonary disease (COPD) and lung cancer are both smoking-
related diseases and pose a huge combined burden on healthcare system 
worldwide294,480. Many studies have documented a close interaction between these 
two diseases with respect to pathogenetic pathways and clinical 
manifestations344,414,481. COPD is associated with greater risk for lung 
cancer246,296,303,409,417,481, and several studies indicate that the strength of this 
association is dependent on the timing of COPD diagnosis70,299,305. 
Since the implementation of low-dose computed tomography (CT) to screen for 
lung cancer, more lung cancers are diagnosed at their earlier and curable stages331. It 
has been reported that 40%-66% of early-stage non-small cell lung cancer (NSCLC) 
patients have concomitant COPD402,405,408; however, a significant number of patients 
were unaware of this comorbid condition482,483. The diagnosis of COPD is incidentally 
made during the clinical assessment of lung cancer in this patient population483.  
The role of COPD in lung cancer prognosis have been widely 
investigated128,364,402,405,408,484. Two recent meta-analyses showed that COPD had a 
negative impact on survival of lung cancer 406,407; however, the results suffered from a 
high level of heterogeneity, mostly subject to lung cancer stage and treatment 
modality406,407. Little is known about the prognostic factors stemming from COPD, and 
their potential influence, particularly for self-unrecognized COPD, on health-related 
quality of life (QOL) remains unclear.  
Since the timing of COPD diagnosis matters in relation to lung cancer risk, and 
COPD is generally under-diagnosed in patients with early-stage lung cancer, we set 
forth to investigate the impact of timing of diagnosis, particularly for incidentally 
diagnosed COPD, and severity of COPD in the prognosis of stage I NSCLC, and to 
explore independent risk factors for incidentally diagnosed COPD in this patient 
population. 
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3.1 Methods 
3.1.1 Patients and data collection 
The study protocol was reviewed and approved by the Mayo Clinic Institutional 
Review Board. Detailed procedures of patient enrollment, data collection, and follow-
up are described in the Appendix. Between January 2000 and December 2014, a total 
of 1,986 patients with stage I pathologically-confirmed NSCLC who underwent 
complete resection were included in this study. All patients had written informed 
consent.  
The diagnosis of COPD was determined by patient’s medical records and/or 
documented airflow limitation (the ratio of post-bronchodilator forced expiratory 
volume in 1 second [FEV1] and forced vital capacity [FVC] of less than 0.7134). In this 
study, patients with COPD were divided into two groups according to the timing of 
diagnosis: those with ‘previous COPD’ and those with ‘incidental COPD’. Those that 
have a history that was recorded at least 6 months preceding lung cancer diagnosis are 
categorized as ‘previous COPD’, and those without a history of COPD, having been 
incidentally diagnosed within 6 months of lung cancer, are categorized as ‘incidental 
COPD’. Airflow limitation was graded based on the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD)134: mild (FEV1 ≥80% predicted), moderate (50%≤ FEV1 
<80% predicted), and severe COPD (FEV1 <50% predicted). 
Postoperative complications were defined as those occurring during 
hospitalization or within 30 days of operation485. A composite variable termed “any 
postoperative complications” consisting of any complications recorded for each 
individual patient was also analyzed. Postoperative QOL was evaluated by the Lung 
Cancer Symptom Scale (LCSS)486 within two years after surgery (Table 3.1), and each 
item was assessed as scales varying from 0 (worst) to 10 (best)106.  
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Table 3.1: The Lung Cancer Symptom Scale (patient scale) 
1. How is your appetite (appetite)? 
2. How much fatigue do you have (fatigue)? 
3. How much coughing do you have (cough)? 
4. How much shortness of breath do you have (dyspnea)? 
5. How much blood do you see in your sputum (hemoptysis)? 
6. How much pain do you have (pain)? 
7. How bad are your symptoms from lung cancer (lung cancer symptom distress)? 
8. How much has your illness affected your ability to carry out normal activities (illness affecting 
normal activities)? 
9. How would you rate your quality of life today (overall QOL)? 
 
3.1.2 Statistical analysis  
Data was compared across groups using the chi-square (x2) test for categorical 
variables, and the unpaired t-test for continuous variables. Survival curves were 
generated by the Kaplan-Meier method and differences were assessed by the log-rank 
test. Cox Proportional Hazard modeling was used to control for confounding variables. 
The difference of postoperative QOL between groups was assessed using the x2 test 
and a clinically important difference was defined as a greater than 1 point. A 
multivariate logistic regression analysis was performed using backward selection to 
identify risk factors (i.e., patient’s demographics, presenting symptoms, and comorbid 
disease) for incidental COPD in lung cancer patients. A p-value less than 0.05 was 
considered statistically significant. All statistical analyses were performed by SAS, 
version 9.3 (SAS Institute). 
 
3.2 Results 
The mean age was 68.4±9.9 years and 938 (47.2%) patients were male in this 
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entire cohort. The diagnosis of COPD was identified in 823 (41.4%) patients, including 
549 (66.8%) patients with incidental COPD and 274 (33.2%) with previous COPD (Table 
3.2). Both incidental COPD and previous COPD were observed more frequently in older 
age, male gender, and active smokers compared to non-COPD (all p<0.01). Among 
individuals who had COPD, patients with incidental COPD were younger and had a 
higher prevalence of current smokers compared to those with previous COPD (both 
p<0.01). Squamous cell carcinoma was more commonly seen in the setting of COPD, 
regardless of the timing of COPD diagnosis (both p<0.01). Patients with incidental 
COPD had a relatively better pulmonary function than those with previous COPD, with 
statistically significant differences in FEV1, FEV1% and FEV1/FVC (all p<0.05). 
Table 3.2: Patient demographics and clinical characteristics (N=1986) 
 
non-COPD 
COPD 
p¶ 
all incidental p# previous p# 
No. of patients 1163 (58.6) 823 (41.4) 549 (27.6)  274 (13.8)   
Age (years) 66.8±10.5 70.7±8.6 70.1±8.9 <0.01 72.0±7.9 <0.01 <0.01 
Sex    <0.01  <0.01 0.64 
    male 494 (42.5) 444 (53.9) 293 (53.4)  151 (55.1)   
    female 669 (57.5) 379 (46.1) 256 (46.6)  123 (44.9)   
BMI 27.6±5.6 27.3±5.5 27.0±5.5 0.05 27.7±5.3 0.40 0.03 
Smoking status    <0.01  <0.01 <0.01 
    never 303 (26.1) 38 (4.6) 27 (4.9)  11 (4.0)   
    former 577 (49.6) 497 (60.4) 305 (55.6)  192 (70.1)   
    current 283 (24.3) 288 (35.0) 217 (39.5)  71 (25.9)   
Pack years  42.3±28.3 56.1±31.4 55.4±30.8 <0.01 57.3±32.5 <0.01 0.54 
Cell type    <0.01  <0.01 0.08 
    ADC 888 (76.4) 494 (60.0) 343 (62.5)  151 (55.1)   
    squamous 180 (15.5) 278 (33.8) 171 (31.1)  107 (39.1)   
    other NSCLC 95 (8.2) 51 (6.2) 35 (6.4)  16 (5.8)   
Tumor grade    <0.01  <0.01 0.18 
    well 487 (41.9) 220 (26.7) 153 (27.9)  67 (24.5)   
    moderate 455 (39.1) 437 (53.1) 279 (50.8)  158 (57.7)   
    poorly 221 (19.0) 166 (20.2) 117 (21.3)  49 (17.9)   
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Table 3.2: Patient demographics and clinical characteristics (N=1986) 
 
non-COPD 
COPD 
p¶ 
all incidental p# previous p# 
Stage     0.08  0.84 0.31 
  IA 801 (68.9) 542 (65.9) 355 (64.7)  187 (68.2)   
  IB 362 (31.1) 281 (34.1) 194 (35.3)  87 (31.8)   
FEV1 (L) 2.6±0.7 1.9±0.6 1.9±0.6 <0.01 1.8±0.6 <0.01 0.02 
FEV1% predicted 94.5±15.7 67.9±17.4 69.5±16.9 <0.01 64.5±18.1 <0.01 <0.01 
FEV1/FVC 77.6±4.8 58.4±9.8 59.1±9.0 <0.01 57.0±11.1 <0.01 0.01 
DLCO 19.4±5.5 16.1±5.2 16.2±5.2 <0.01 15.7±5.3 <0.01 0.21 
DLCO% predicted 84.6±17.3 69.4±19.2 70.0±18.6 <0.01 68.2±20.1 <0.01 0.24 
Values are mean ± standard deviation or number (%). #compared with non-COPD; ¶comparison 
between incidental COPD and previous COPD. COPD: Chronic obstructive pulmonary disease; 
BMI: body mass index; ADC: adenocarcinoma; FEV1: forced expiratory volume in one second; 
FVC: forced vital capacity; DLCO: diffusion capacity of lung for carbon monoxide; NSCLC: non-
small cell lung cancer. Bold values indicate P values with statistically significant difference. 
 
3.2.1 Presenting symptoms and comorbid diseases 
The presenting symptoms at lung cancer diagnosis differed significantly between 
incidental COPD and non-COPD in terms of cough, dyspnea and hemoptysis (all p<0.01; 
Table 3.3). To note, a history of lung infection was also more common in patients with 
incidental COPD compared to those without COPD (p=0.03).  
Table 3.3: Presenting symptoms and comorbid diseases 
 non-COPD 
n (%) 
incidental COPD 
 
previous COPD 
p¶ 
n (%) p# n (%) p# 
Symptoms        
cough 184 (15.8) 124 (22.6) <0.01  60 (21.9) 0.02 0.82 
dyspnea 103 (8.9) 82 (14.9) <0.01  38 (13.9) 0.01 0.68 
sputum 58 (5.0) 36 (6.6) 0.18  13 (8.4) 0.03 0.33 
chest pain 47 (4.0) 16 (2.9) 0.25  8 (2.9) 0.38 0.99 
fatigue 46 (4.0) 21 (3.8) 0.89  12 (4.4) 0.75 0.70 
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Table 3.3: Presenting symptoms and comorbid diseases 
 non-COPD 
n (%) 
incidental COPD 
 
previous COPD 
p¶ 
n (%) p# n (%) p# 
back pain 20 (1.7) 3 (0.5) 0.05  1 (0.4) 0.09 0.72 
hemoptysis 16 (1.4) 20 (3.6) <0.01  9 (3.3) 0.03 0.79 
Comorbidities        
other cancer history 268 (23.0) 114 (20.8) 0.29  70 (25.5) 0.38 0.12 
previous lung infection 126 (10.8) 79 (14.4) 0.03  63 (23.0) <0.01 <0.01 
diabetes 92 (7.9) 43 (7.8) 0.95  29 (10.6) 0.15 0.19 
heart disease 183 (15.7) 92 (16.8) 0.59  61 (22.3) <0.01 0.06 
hypertension 288 (24.8) 137 (25.0) 0.93  86 (31.4) 0.02 0.05 
#compared with non-COPD; ¶comparison between incidental COPD and previous COPD.  
COPD: Chronic obstructive pulmonary disease;  
Bold values indicate P values with statistically significant difference. 
Among patients with COPD, the symptoms and comorbid conditions were similar 
between patients with incidental COPD and those with previous COPD; however, 
previous lung infection was more frequently noted in previous COPD (Table 3.3).  
 
3.2.2 Perioperative outcomes 
The distribution of type of surgical procedure differed significantly between 
groups (Table 3.4). Segmentectomy and wedge resection were performed more often 
in COPD groups than non-COPD group. Furthermore, patients with previous COPD 
were more likely to receive sublobar resections as compared to those with incidental 
COPD (p<0.01). The rate of any postoperative complications was significantly higher in 
COPD groups (incidental COPD: 28.1%, previous COPD: 27.0%) than in non-COPD 
group (16.5%). Specifically, incidental COPD was associated with higher incidence of 
atrial fibrillation (12.9% vs. 8.5%, p<0.01), postoperative pneumonia (3.8% vs. 1.8%, 
p=0.01), and prolonged air leak (12.9% vs. 6.0%, p<0.01) as compared to non-COPD. 
Previous COPD was also associated with prolonged air leak (13.1%, p<0.01). There was 
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no significant difference in postoperative complications between incidental COPD and 
previous COPD (Table 3.4). The perioperative mortality rate was 1.3% in incidental 
COPD patients and 0.7% in previous COPD patients, whereas it was 0.5% in non-COPD 
patients (no significant difference). 
Table 3.4: Type of surgical procedure and postoperative complications 
 non-COPD 
n (%) 
incidental COPD 
 
previous COPD 
p¶ 
n (%) p# n (%) p# 
Surgical type   <0.01   <0.01 <0.01 
  wedge resection 220 (18.9) 137 (25.0)   88 (32.1)   
  segmentectomy 58 (5.0) 57 (10.4)   47 (17.2)   
  lobectomy 885 (76.1) 355 (64.6)   139 (50.7)   
Any postoperative 
complications 
192 (16.5) 154 (28.1) <0.01  74 (27.0) <0.01  
atrial fibrillation 99 (8.5) 71 (12.9) <0.01  32 (11.7) 0.10 0.61 
pneumonia 21 (1.8) 21 (3.8) 0.01  10 (3.6) 0.06 0.90 
prolonged air leak 70 (6.0) 71 (12.9) <0.01  36 (13.1) <0.01 0.93 
empyema 2 (0.2) 0 (0.0) 0.33  1 (0.4) 0.53 0.16 
chylothorax 16 (1.4) 5 (0.9) 0.41  3 (1.1) 0.71 0.80 
DVT/PE 5 (0.4) 1 (0.2) 0.42  1 (0.4) 0.88 0.62 
Perioperative mortality 6 (0.5) 7 (1.3) 0.09  2 (0.7) 0.67 0.48 
#compared with non-COPD; ¶comparison between incidental COPD and previous COPD.  
DVT/PE: deep vein thrombosis/pulmonary embolism; COPD: Chronic obstructive pulmonary 
disease. “Any postoperative complications” consisted of any complications recorded for each 
individual patient. Bold values indicate P values with statistically significant difference. 
 
3.2.3 Health-related quality of life 
Analysis of health-related QOL found no remarkable difference in overall QOL 
score between non-COPD and incidental COPD (8.2±1.8 vs. 7.9±1.9). Among specific 
symptom subscales, dyspnea symptoms were worse in patients with incidental COPD 
than in those without COPD (6.5±2.4 vs. 8.0±2.4). Similar results were noticed 
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between non-COPD and previous COPD (Figure 3.1). 
 
Figure 3.1: Comparison of postoperative quality of life among non-COPD, incidental COPD and 
previous COPD. (Outer circle representing a higher score and better quality of life; #comparison 
with non-COPD: p<0.05 and difference ≥1 point) 
 
3.2.4 Long-term overall survival 
In regard to the severity of COPD, 218 (26.5%) patients had mild, 478 (58.1%) 
moderate, and 127 (15.4%) severe airflow limitation. Kaplan-Meier curves show that 
patients with COPD have worse overall survival than those without (p<0.01), and the 
survival difference is independent of the timing of COPD diagnosis. Additionally, there 
was a more apparent decrease in survival as severity of airflow limitation increased 
(p<0.01, Figure 3.2).  
In the multivariate Cox proportional hazard model adjusting for patient 
demographics and tumor characteristics (Table 3.5), COPD was significantly associated 
with decreased overall survival (hazard ratio [HR], 1.22; 95% confidence interval [CI], 
1.06-1.42), which was mainly owing to incidental COPD (HR, 1.23; 95%CI, 1.05-1.45). 
The impact of previous COPD was on the borderline of statistical significance (HR, 1.20; 
95%CI, 0.98-1.46). When COPD cases were stratified based on airflow limitation, the 
HR was statically significant for moderate (HR, 1.22; 95%CI, 1.04-1.44) and severe 
COPD (HR, 1.75; 95%CI, 1.38-2.23), but not for mild COPD (HR, 0.99; 95%CI, 0.79-1.23). 
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Figure 3.2: Kaplan-Meier curves for overall survival. a) comparison between COPD and non-
COPD; b) comparison among non-COPD, incidental COPD and previous COPD; c) comparison 
between non-COPD and the severity of COPD regardless of timing of diagnosis. 
 
3.2.5 Risk factors for lung cancer with incidental COPD 
To further characterize lung cancer cases with an incidental COPD, multivariate 
logistic regression analysis revealed that older age (odds ratio [OR], 1.04), male gender 
(OR, 1.30), lower body mass index ([BMI]; OR, 0.97), former and current smokers (OR 
for former smoker, 4.86; OR for current smoker, 9.02), presenting cough (OR, 1.44), 
dyspnea (OR, 1.68) and hemoptysis (OR, 2.63) were significant risk factors for having 
an incidental diagnosis of COPD in newly-diagnosed lung cancer patients (Table 3.6). 
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Table 3.5: Multivariate Cox proportional hazard model for overall survival 
 COPD status Timing of diagnosis Severity 
HR (95%CI) p HR (95%CI) p HR (95%CI) p 
All COPD* 1.22 (1.06, 1.42) 0.01 --  --  
Timing*       
  incidental --  1.23 (1.05, 1.45) 0.01 --  
  previous --  1.20 (0.98, 1.46) 0.07 --  
severity*       
  mild --  --  0.99 (0.79, 1.23) 0.91 
  moderate --  --  1.22 (1.04, 1.44) 0.02 
  severe --  --  1.75 (1.38, 2.23) <0.01 
Age 1.05 (1.04, 1.06) <0.01 1.05 (1.04, 1.06) <0.01 1.05 (1.04, 1.06) <0.01 
Sex       
    male reference  reference  reference  
    female 0.75 (0.65, 0.87) <0.01 0.75 (0.65, 0.87) <0.01 0.76 (0.66, 0.87) <0.01 
BMI 0.98 (0.97, 1.00) 0.03 0.98 (0.97, 1.00) 0.03 0.98 (0.96, 1.00) 0.04 
Smoking        
    never reference  reference  reference  
    former 1.34 (1.05, 1.70) 0.02 1.34 (1.05, 1.70) 0.02 1.33 (1.04, 1.69) 0.02 
    current 1.84 (1.42, 2.38) <0.01 1.83 (1.42, 2.37) <0.01 1.81 (1.40, 2.34) <0.01 
Cell type       
    ADC reference  reference  reference  
    squamous  1.03 (0.87, 1.22) 0.73 1.03 (0.87, 1.22) 0.72 1.02 (0.86, 1.21) 0.82 
    other NSCLC 1.50 (1.16, 1.93) <0.01 1.49 (1.16, 1.93) <0.01 1.49 (1.15, 1.92) <0.01 
Tumor grade       
    well reference  reference  reference  
    moderate 1.46 (1.22, 1.74) <0.01 1.46 (1.22, 1.74) <0.01 1.44 (1.21, 1.72) <0.01 
    poorly 1.65 (1.32, 2.05) <0.01 1.65 (1.32, 2.05) <0.01 1.67 (1.34, 2.08) <0.01 
Stage        
  IA reference  reference  reference  
  IB 1.32 (1.15, 1.52) <0.01 1.32 (1.15, 1.52) <0.01 1.32 (1.15, 1.52) <0.01 
*Patients without COPD were used as reference group. COPD: Chronic obstructive pulmonary 
disease; BMI: body mass index. ADC: adenocarcinoma. HR: hazard ratio; CI: confidence interval. 
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3.3 Discussion 
Our investigation revealed a high prevalence of incidentally-diagnosed COPD 
among patients with stage I NSCLC. Similar to previous COPD, the presence of 
incidental COPD was associated with postoperative complications and poor health-
related QOL. Moreover, COPD significantly decreased overall survival, likely 
attributable to incidental COPD. Older age, male sex, lower BMI, being former and 
current smokers, and presenting cough, dyspnea, and hemoptysis were independent 
predictors for incidental COPD in patients with stage I NSCLC.  
In the clinical setting, COPD is often concomitant with primary lung cancer but 
remains substantially underdiagnosed402,405. Our survey revealed that incidental COPD 
(within 6 months at lung cancer diagnosis) was present in two-thirds of spirometry-
defined COPD in lung cancer patients, which was a bit lower to the reported rates of 
undiagnosed COPD in the surveys of general population (approximately 71.2%-
81.4%).155,156 It is possibly due to the different study design that we only included 
surgical patients who were more likely to have good lung function. 
Table 3.6: Logistic regression analysis to predict incidental COPD in lung cancer patients 
 OR 95% CI p-value 
Age 1.04 (1.03, 1.05) <0.01 
Sex (male) 1.30 (1.04, 1.64) 0.02 
Body mass index 0.97 (0.95, 0.99) 0.02 
Smoking status    
never reference   
former 4.86 (3.16, 7.49) <0.01 
current/ever 9.02 (5.75, 14.15) <0.01 
Cough 1.44 (1.06, 1.94) 0.02 
Dyspnea 1.68 (1.16, 2.43) <0.01 
Hemoptysis 2.63 (1.24, 5.57) 0.01 
OR: odds ratio; CI: confidence interval. 
Previous case-control studies have shown that the association between COPD and 
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lung cancer development was more significant when a diagnosis of COPD was 
chronologically close to the diagnosis of lung cancer70,305. However, to the best of our 
knowledge, its prognostic effect has not been studied before. We therefore targeted 
patients with surgically resected stage I NSCLC, for the purpose of eliminating the 
potential survival bias caused by lung cancer stage and treatment407. The results 
showed that COPD was significantly associated with worse overall survival, mainly 
owing to incidental COPD. 
The exact mechanisms by which incidental COPD worsen lung cancer survival have 
not been clearly elucidated thus far. Several hypotheses have been proposed, such as 
uncontrolled inflammation and tendency to continued smoking in these patients. 
COPD is characterized by chronic neutrophilic inflammation134,487 that could stimulate 
angiogenesis and promote tumor metastasis488,489, which has been demonstrated to 
be inversely correlated with early-stage lung cancer outcomes104,490,491. 
Pharmacological treatment for COPD, represented by inhaled bronchodilators and 
corticosteroids492, can attenuate airway inflammation and reduce the level of some 
markers of systemic inflammation317,493. Zhang and colleagues found that lung cancer 
patients with documented diagnosis of COPD were more likely to receive medications 
for COPD while those with incidental COPD were mostly under-treated483. Therefore, 
patients with stage I NSCLC who have an incidental diagnosis of COPD may suffer from 
the persistent uncontrolled inflammation, contributing to poorer lung cancer survival. 
In addition, early COPD diagnosis may motivate smoking cessation494, which is the 
most effective measure to improve future prospects for the patients480,495. As shown 
in our study, current smokers were more commonly seen in lung cancer patients with 
incidental COPD compared to both non-COPD and previous COPD, which could pose 
an additional risk of death from lung cancer496,497. Therefore, in view of the high 
prevalence of incidental COPD and its negative impact on lung cancer survival, the 
timely identification and subsequent effective treatment for COPD are critically 
important to newly-diagnosed lung cancer patients. 
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Interestingly, the impact of previous COPD was borderline significant in the 
multivariate model. This could be due in part to the small group size. On the other 
hand, Powell and colleagues pointed out that COPD which was diagnosed long before 
(at least 6 months interval) the diagnosis of lung cancer was not necessarily directly 
associated with lung cancer; rather the association was possibly due to a patient’s 
smoking habit305. Furthermore, COPD diagnosed within short time windows may 
reflect the COPD status in a more accurate way. This association will need to be 
confirmed by larger studies. 
When COPD was stratified by severity of airflow limitation, survival was similar in 
patients with mild COPD and patients without COPD, whereas moderate-to-severe 
COPD was significantly associated with worse outcome. This result is concordant with 
Qiang and colleagues484, who reported an apparent decrease in recurrence-free 
survival in NSCLC patients with moderate/severe COPD but not in those with mild 
COPD.  
Postoperative QOL was also associated with incidental COPD, mainly in dyspnea 
subscale. This result is in contrast to the study from Pompili and colleagues411, who 
reported no difference with regard to COPD status; however, disparities in the study 
design, targeted population and type of survey make comparison uncertain. Our study 
only included stage I NSCLC and showed that patients with incidental COPD tended to 
be older and active smokers. Ferguson and colleagues found that lung cancer patients 
aged ≥70 years experienced worse dyspnea than those <70 years after major lung 
resection498. In addition, a recent systematic review demonstrated that cigarette 
smoking was often associated with an increase in symptom burden499. These factors 
could predispose COPD patients to poorer QOL. Accordingly, lung cancer patients with 
incidental COPD should also be given rigorous interventions (e.g., pulmonary 
rehabilitation) to promote disease recovery and improve their long-term QOL, as is 
generally suggested in those with previously recognized COPD481.  
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COPD is considered as an independent risk factor for postoperative 
complications500. Our study demonstrated that patients with incidental COPD had a 
higher incidences of overall postoperative complication than those without, with 
significant differences noted in atrial fibrillation, pneumonia, and prolonged air leak. 
These findings highlighted the importance of identification of “insidious” COPD for an 
accurate surgical risk assessment. 
Although concurrent diseases should be detected in patients with lung cancer, no 
consensus exists on how and when to systemically screen for comorbidities. In addition, 
given patients with COPD are at higher risk for developing lung cancer, early detection 
of COPD would be important for lung cancer surveillance296,417. However, our data 
shows that approximately two-thirds of subjects with COPD were incidentally 
diagnosed due to the clinical assessment for lung cancer. As such, recommendation for 
lung cancer screening in previously-diagnosed subjects with COPD would only benefit 
a limited population, leaving vast majority of cases underestimated. Hence, we further 
determine the risk factors for incidental COPD; patient smoking history and respiratory 
symptoms (cough, dyspnea, and hemoptysis) were the most important risk 
determinants, which is consistent with previous studies155,337,501. Since the US 
Preventive Services Task Force (USPSTF) recommends against screening for COPD in 
asymptomatic adults502,503, our study characterized those who may have undiagnosed 
COPD, which in turn could improve risk stratification in lung cancer screening in 
individuals who are already at an increased risk of developing but remain unrecognized. 
This might have both cost and prognostic implications. 
The major strength of our study is to record the timing of diagnosis and severity 
of airflow limitation in all COPD patients. This will allow us to determine the prevalence 
and impact of incidental COPD in the context of early-stage lung cancer, address the 
gap in the implementation of active lung cancer screening in COPD patients, and to 
refine the prognostication in lung cancer cases with varying COPD grades. However, a 
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number of limitations should be acknowledged. First, although our patient cohort was 
prospectively followed, this study was retrospective and observational in nature; thus, 
the potential bias could not be completely eliminated. Second, the ‘incidental COPD’ 
was defined arbitrarily by an interval of 6 months between COPD and lung cancer 
diagnosis. Nevertheless, the prevalence rate of ‘incidental COPD’ in our study is similar 
to the reported rates in previous studies155,482 , justifying this method of grouping to 
some extent. Third, the treatment for COPD and the cause of death are not available, 
which limits the ability of the study to assess the effects of treatment-related factors 
on lung cancer- and COPD-specific mortality. Lastly, the insignificant association for 
previous COPD and lung cancer survival could be possibly due to lower statistical 
power as this group is smaller than incidental COPD (274 vs. 549). Therefore, further 
validation from larger-scale cohorts is warranted to address these issues. 
 
3.4 Chapter Summary 
In summary, our study uncovered a substantially high prevalence of incidentally-
diagnosed COPD among patients with stage I NSCLC, and demonstrated that timing of 
diagnosis and severity of COPD mattered with respect to lung cancer prognosis. COPD 
significantly decreased overall survival, mainly owing to incidental COPD. Moderate 
and severe COPD negatively affected survival outcome while mild COPD did not. 
Therefore, the clear identification of COPD status at lung cancer diagnosis is important.
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Chronic obstructive pulmonary disease (COPD) and lung cancer are leading causes 
of death worldwide295. Emphysema is the major component of COPD and has been 
demonstrated to confer a higher risk of lung cancer, independent of tobacco smoking 
and airflow obstruction302,304. It is reported that more than half of patients with newly 
diagnosed lung cancer have emphysema504,505, but the prognostic role of emphysema 
in lung cancer remains unclear and conflicting313,345,506,507. Our previous experience 
indicates that the local risk of lung cancer was related to severity of regional 
emphysema353; however, the prognostic significance of regional emphysema has not 
been well characterized. This chapter investigates the impact of the region 
emphysema scores (RES) on the long-term prognosis of patients with early-stage non-
small cell lung cancer (NSCLC) in terms of overall survival (OS), health-related quality 
of life (QOL), and postoperative recovery of pulmonary function. 
 
4.1 Methods 
4.1.1 Subject inclusion 
Detailed procedures of patient enrollment, data collection, and follow-up can be 
found in the Appendix. To ensure patients with at least five-year follow-up 
appointments, the cohort of patients whose disease was diagnosed between 1997 and 
2009 was considered; a total of 1,073 patients met our study inclusion criteria: 
pathologically-confirmed early-stage NSCLC (stage I-II), available standard-dose CT 
scan before treatment, and provision of written informed consent.  
 
4.1.2 Patient evaluation 
The diagnosis of COPD was determined by patient’s medical record and/or 
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documented irreversible airflow limitation (post-bronchodilator forced expiratory 
volume in 1 second [FEV1]/forced vital capacity [FVC] of less than 70%)134. 
Perioperative mortality was defined as death during hospitalization or within 30 days 
of operation485. Postoperative complications included conditions such as atrial 
fibrillation, pneumonia, prolonged air leak (more than 7 days), and tracheostomy that 
occurred during hospitalization or within 30 days following surgery. A composite 
variable “any postoperative complications” consisting of any complications recorded 
(including but not limited to the aforementioned) was generated for each individual 
patient. Pulmonary function tests (PFT) were performed within half a year before lung 
cancer treatment and repeated within two years after pulmonary resection. The values 
of FEV1/FVC, percentage of FEV1 (FEV1%), residual volume (RV), total lung capacity 
(TLC), and diffusion capacity of lung for carbon monoxide (DLCO) were evaluated and 
expressed as the changes from preoperative to postoperative evaluation. QOL was 
assessed using the Lung Cancer Symptom Scales486 within two years after treatment, 
and each item was scored on a scale of 0-worst to 10-best106.  
 
4.1.3 Computed tomography scan 
 CT scans were performed using helical CT scanner (General Electric Medical 
Systems, Milwaukee, WI, USA)309. CT examinations extended in a craniocaudal 
direction, without intravenous contrast material. The technical scan parameters 
included the following: tube voltage, 120 kV; tube current, 40 mA; 5 mm section width 
with 3.5-3.75 mm reconstruction interval; and high-speed mode309,508. The CT images 
of the entire lung region were obtained in a single breath hold at full inspiration. All 
images were viewed by an experienced thoracic radiologist, who was blinded to all 
clinical data, at standard lung (width, 1500HU; level, -600HU), soft tissue (width, 
400HU; level, 40HU), and bone (width, 1000 HU; level, 200HU) window settings508.  
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4.1.4 Emphysema evaluation 
Emphysema evaluation was based on a standard-dose CT before treatment. 
Patients with a low-dose CT only were excluded. The severity of emphysema was 
scored through direct interpretation under computer-aided quantitative standard 
images that were generated by using -950HU as the threshold for emphysema312,353. 
The extent of emphysema was given to each of six lung zones: right and left lung, upper, 
middle (or lingula), and bilateral lower lobes. Individual RESs were derived from the 
emphysematous region and classified as follows: mild (≤5%), moderate (6-24%) and 
severe (25-60%). Patients were then divided into three groups according to the tumor 
location and treatment modality (Figure 4.1): lung cancer in emphysematous (group 1, 
n=565) and non-emphysematous (group 2, n=435) regions with surgical resection and 
lung cancer with non-surgical treatment (group 3, n=73).  
 
Figure 4.1: Study population. 
The frequencies of mild, moderate and severe RES were 63.0%, 26.6%, and 10.4% 
in group 1 (surgically treated cancer in the emphysematous region), 71.7%, 19.8%, and 
8.5% in group 2 (surgically treated cancer in the non-emphysematous region). In group 
3 (non-surgically treated cancer), the frequency of RES was in a similar distribution 
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(50.7% mild, 37% moderate and 12.3% severe) but the small numbers (total of 73 
patients) meant that severe and moderate RES were combined for subsequent analysis.  
 
4.1.5 Statistical analysis  
Clinical data were compared using the chi-square (x2) test, or the Fisher exact text 
(as appropriate) for categorical variables, and the unpaired t-test for continuous 
variables. Survival curves were generated by the Kaplan-Meier method and differences 
were assessed by the log-rank test. Cox proportional hazards models were used to 
evaluate the association between RES and OS after adjusting for patient’s 
demographics, tumor stage and treatment, and COPD status. The difference in QOL 
between groups was assessed by using the x2 test and a clinically important difference 
was defined as a greater than 1 point. A p-value less than 0.05 was considered 
statistically significant. All statistical analyses were performed with SAS, v9.3 (SAS 
Institute). 
 
4.2 Results 
4.2.1 Baseline clinical features 
Patient demographic and clinical characteristics are listed in Table 4.1. In all groups, 
moderate and severe RESs were noted more frequently than mild RESs in patients who 
were former or current smokers and had smoked for more pack-years (p<0.05). 
Coexistence of COPD was significantly more frequent in patients with a higher RES 
(p<0.01).  
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Of the 1,000 patients receiving surgical resection (group 1 and group 2), 
lobectomy was performed in 782 (78.2%) patients, segmentectomy in 68 (6.8%), and 
wedge resection in 150 (15.0%). No significant difference was found in the distribution 
of type of surgical procedure between the two groups (p=0.73). In group 3, the 
patients with non-surgical treatment, 34 (46.6%) received radiation, 27 (37.0%) 
underwent chemotherapy/chemoradiotherapy, and the remaining 12 (16.4%) had 
other supportive treatment.  
In surgically-treated patients (group 1 and group 2), the preoperative PFT results 
are summarized in Table 4.2. As expected, with higher RESs, there was evidence of 
greater airflow obstruction, lower diffusion capacity and more marked hyperinflation.  
Table 4.2: Preoperative pulmonary function (group 1 and group 2) 
RES 
group 1 group 2 
mild moderate severe mild moderate severe 
FEV1 (L) 2.4±0.7 2.1±0.8 1.8±0.7** 2.3±0.7 2.2±0.7 1.6±0.7** 
FEV1%  84.0±19.4 69.6±21.9 60.0±19.6** 83.0±20.5 71.2±17.2 60.7±22.5** 
FEV1/FVC 71.5±9.6 58.6±12.5 51.5±11.2** 71.1±11.0 61.2±12.1 51.2±14.7** 
TLC (L) 6.1±1.2 7.1±1.4 7.1±1.3** 6.2±1.3 6.8±1.6 6.8±1.4* 
TLC% 104.0±14.2 114.9±15.9 118.3±13.7** 102.6±16.4 108.2±18.4 117.9±17.8** 
RV (L) 2.9±0.9 3.7±1.2 3.7±1.0** 2.9±9.5 3.2±1.0 3.8±1.1** 
DLCO  20.0±5.8 16.0±5.2 13.9±4.7** 19.8±5.4 16.3±4.5 10.8±3.5** 
DLCO% 85.2±19.4 65.6±17.8 57.2±14.1** 85.1±18.5 66.9±15.4 48.2±14.5** 
RES: regional emphysema score; FEV1: forced expiratory volume in 1 second; FVC: forced vital 
capacity; TLC: total lung capacity; RV: residual volume; DLCO: diffusion capacity of lung for 
carbon monoxide; Comparisons between different emphysema scores in group 1 and group 2: 
*p<0.05, **p<0.01 
Postoperative complications increased in both surgical groups as the RES 
increased (Table 4.3). Postoperative pneumonia occurred more commonly in patients 
with a severe RES than in those with a mild to moderate RES in both groups (both 
p<0.05). In group 1 (cancer in the emphysematous region), the incidence of prolonged 
air leak was twice as high in patients with a moderate RES and three times as high in 
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patients with a severe RES than in patients with a mild RES (p<0.01). Three patients 
died during the postoperative course, including 2 of pneumonia and 1 of acute renal 
failure; however, there was no significant association between the RES and 
postoperative mortality in either group.  
Table 4.3: Postoperative complications in surgically treated patients (group 1 and group 2) 
Regional emphysema 
score 
group 1 group 2 
mild moderate severe mild moderate severe 
atrial fibrillation 35 (9.8) 20 (13.3) 5 (8.5) 25 (8.0) 11 (12.8) 6 (16.2) 
pneumonia 6 (1.7) 7 (4.7) 5 (8.5)* 4 (1.3) 2 (2.3) 3 (8.1)* 
prolonged air leak (>7d) 21 (5.9) 16 (10.7) 11 (18.6)** 16 (5.1) 8 (9.3) 4 (10.8) 
tracheostomy 2 (0.6) 1 (0.7) 2 (3.4) 1 (0.3) 0 (0.0) 0 (0.0) 
any postoperative 
complications 
88 (24.7) 62 (41.3) 29 (49.2)** 74 (23.7) 27 (31.4) 15 (40.5)* 
perioperative mortality 0 (0.0) 1 (0.7) 1 (1.7) 1 (0.3) 0 (0.0) 0 (0.0) 
Comparisons between different emphysema scores in group 1 and group 2: *p<0.05; **p<0.01 
Operative mortality and complications defined as the event (death or complications) that 
occurred during hospitalization or within 30 days of the operation. “Any postoperative 
complications” defined as any complications recorded for each individual patient. 
 
4.2.2 Changes in pulmonary function 
After surgery, 152 (26.9%) patients in group 1 and 122 (28.0%) in group 2, had a 
follow-up PFT, at a mean of 13.4±5.9 months after surgery (range, 3.2 to 23.8 months). 
In general, some decline in lung function was noticed in both groups. In group 1 
(cancer in the emphysematous region) there was a significantly greater decline in lung 
function (as measured by FEV1% and DLCO%) in patients with a mild RES than in those 
with a moderate or severe RES; however, a significant improvement in FEV1/FVC was 
observed in patients with a moderate or severe RES (Figure 4.2). These associations 
were not evident in group 2 (cancer in the non-emphysematous region). 
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Figure 4.2: Postoperative pulmonary function changes within 2 years. Values were expressed as 
the changes from preoperative evaluation to postoperative evaluation. Group 1, tumor in 
emphysematous region; Group 2, tumor in non-emphysematous region.  
 
4.2.3 Post-treatment quality of life 
Within two years after treatment, 394 (69.7%) patients in group 1, 322 (74.0%) in 
group 2, and 54 (74.0%) in group 3 answered the QOL questionnaire. No striking 
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difference in overall QOL was observed between different RES in each group (Figure 
4.3). On the specific symptom subscales, dyspnea scores were worse in patients with 
a severe RES in all groups (all p<0.05 and difference >1 point). In group 3 (cancer with 
non-surgical treatment), fatigue was worse in patients with a moderate/severe RES 
than in those with a mild RES, which was independent of non-surgical treatment 
modalities (p=0.68).  
 
Figure 4.3: Quality of life within 2 years after treatment. (a) lung cancer in emphysematous 
region with surgical resection; (b) lung cancer in non-emphysematous region with surgical 
resection; (c) lung cancer with non-surgical treatment. (Outer circle representing a higher score 
and better quality of life; *p<0.05 and difference >1 point). 
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4.2.4 Overall survival 
The respective 5-year OS rates in patients with mild, moderate and severe RES 
were 79.6%, 67.8% and 63.8% in group 1; 74.1%, 55.8% and 50.0% in group 2; and 
24.3% and 22.2% in patients with mild and moderate/severe RESs in group 3. Kaplan-
Meier survival analysis showed significant differences in OS among those with mild, 
moderate and severe RES in the surgical groups (both p<0.01), but no significant 
difference between mild and moderate/severe RES in the non-surgical group (p=0.90, 
Figure 4.4).  
 
Figure 4.4: Kaplan-Meier curves for overall survival (OS) between different regional emphysema 
scores (RES) in three groups: (a) lung cancer in emphysematous region with surgical resection; 
(b) lung cancer in non-emphysematous region with surgical resection; (c) lung cancer with non-
surgical treatment. 
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In multivariate analysis, RES was significantly associated with reduced survival for 
moderate and severe RES compared with mild RES in group 1 (moderate: HR, 1.41[1.08, 
1.84]; severe: HR, 1.63[1.11, 2.38]) and group 2 (moderate: HR, 1.43[1.04, 1.96]; 
severe: HR, 2.04[1.33, 3.12]). RES was not a prognostic factor in group 3 (Table 4.4). 
Table 4.4: Multivariate analysis for overall survival in 3 comparative groups 
Variable 
group 1 group 2 group 3 
HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Age <0.0001 <0.0001 0.2341 
 1.06 (1.04,1.08) 1.04 (1.02,1.06) 1.02 (0.98,1.07) 
Gender 0.0064 0.0868 0.0762 
   Male reference  reference  reference  
   Female 0.71 (0.56,0.91) 0.79 (0.59,1.04) 0.58 (0.31,1.06) 
Body mass index  0.5921 0.5669 0.6854 
 0.99 (0.97,1.02) 0.99 (0.97,1.02) 1.01 (0.96,1.07) 
Smoking status 0.2917 0.0922 0.2348 
   Never reference reference 1.21 (0.36,4.09) 
   Former 0.85 (0.55,1.31) 1.61 (1.01,2.57) reference 
   Current/ever 1.05 (0.65,1.68) 1.39 (0.81,2.40) 1.84 (0.93,3.66) 
Histology  0.5812 0.6960 0.3155 
   adenocarcinoma reference reference reference 
   squamous 1.06 (0.80,1.40) 0.94 (0.68,1.31) 1.06 (0.43,2.58) 
   other NSCLC 0.84 (0.53,1.31) 1.16 (0.74,1.81) 0.56 (0.19,1.69) 
Grade  0.1025 0.4165 0.1073 
   well reference  reference  reference  
   moderate 1.36 (1.02,1.81) 1.08 (0.77,1.51) 0.54 (0.17,1.68) 
   poorly 1.33 (0.92,1.92) 0.83 (0.54,1.29) 1.22 (0.39,3.79) 
COPD 0.9123 0.5060 0.8330 
   no reference reference reference 
   yes 1.01 (0.78,1.32) 1.11 (0.82,1.50) 1.12 (0.38,3.29) 
Stage  0.8101 0.0052 0.4888 
   Ia reference  reference  reference  
   Ib 1.01 (0.77,1.32) 1.20 (0.88,1.64) 1.04 (0.43,2.52) 
   IIa 1.10 (0.73,1.65) 1.79 (1.24,2.59) 1.70 (0.57,5.10) 
   IIb 1.20 (0.81,1.77) 1.81 (1.19,2.77) 1.76 (0.77,4.01) 
 101 
Table 4.4: Multivariate analysis for overall survival in 3 comparative groups 
Variable 
group 1 group 2 group 3 
HR (95% CI) p HR (95% CI) p HR (95% CI) p 
Surgical treatment 0.0983 0.0216  -- 
surgery only reference reference --  
surgery+chemotherapy 0.78 (0.46,1.33) 1.49 (0.97,2.30) --  
surgery+radiation 1.27 (0.67,2.42) 1.69 (0.79,3.61) --  
surgery+chemoradiation 2.13 (1.12,4.06) 3.58 (1.49,8.63) --  
Non-surgical treatment  --  -- 0.0018 
radiation only --  --  reference  
 chemotherapy only --  --  0.56 (0.16,1.93) 
 chemoradiotherapy --  --  0.43 (0.18,1.02) 
 other treatment --  --  3.04 (1.17,7.94) 
COPD 0.9123 0.5060 0.8330 
   no reference  reference  reference  
   yes 1.01 (0.78,1.32) 1.11 (0.82,1.50) 1.12 (0.38,3.29) 
RES 0.0095 0.0027 0.9712 
   mild reference  reference  reference  
   moderate 1.41 (1.08,1.84) 1.43 (1.04,1.96) 0.99 (0.55,1.78)* 
   severe 1.63 (1.11,2.38) 2.04 (1.33,3.12)   
*including patients with moderate and severe regional emphysema score. 
Group was divided by tumor location and treatment modality: group 1, tumor in the 
emphysematous region with surgical resection; group 2, tumor in the non-emphysematous region 
with surgical resection; group 3, tumor with non-surgical treatment. 
NSCLC, non-small cell lung cancer; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; 
CI, confidence interval; RES: regional emphysema score. 
 
4.3 Discussion 
Emphysema is a frequent coexisting disease in patients with lung cancer and 
increases postoperative pulmonary morbidities after lung resection506,509. Our findings 
demonstrated that the RES was an independent predictor of OS in early-stage NSCLC 
after surgery regardless of tumor location, and it was also associated with post-
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treatment dyspnea in those with a severe RES versus a mild or moderate RES. Lung 
function declined postoperatively in both surgical groups, with a significant increase in 
FEV1/FVC noted in those with a moderate or severe RES in group 1 (cancer in the 
emphysematous region). 
To date, much attention has been focused on the difference in prognosis between 
lung cancer arising in emphysematous and non-emphysematous lungs345. Several 
studies313,507,510 reported an association between the presence of emphysema and 
lung cancer mortality but others studies482,506,511did not support such association after 
controlling for patient age, gender, smoking history, and cancer stage. In these 
previous studies, quantification of emphysema was based on whole lung evaluation, 
without accounting for the regional distribution of emphysema. However, recent 
studies353,504 suggest that primary lung cancers arise more frequently in regional areas 
of worse emphysematous change. We therefore hypothesized that RES may have 
prognostic value in lung cancer. 
The multivariate analysis demonstrated that higher RES was significantly 
associated with worse OS in surgically-treated lung cancer, regardless of the tumor 
location and independent of smoking and COPD status. This finding was in line with 
previous studies where emphysema was quantified according to whole lung 
evaluation313,504,507. Zulueta and colleagues revealed that patients with mild, moderate, 
and marked emphysema had a respective HR of death from lung cancer of 1.4, 1.8 and 
3.2 as compared with those patients who were free of emphysema507. Oelsner and 
colleagues demonstrated the association between quantitatively assessed 
emphysema and lung cancer mortality in which patients with worse emphysema had 
poorer outcomes313. These results indicated that RES had an impact on OS similar to 
that of generalized emphysema, and that a systemic effect of RES might underlie the 
prognostic association in this study cohort. Possible systemic mechanisms for the 
effect of regional emphysematous change on lung cancer survival could include the 
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tumor-promoting effect of neutrophilic inflammation104,488,490, enhanced angiogenesis 
secondary to chronic inflammation512, and up-regulation of matrix metalloproteinase 
(MMP) in emphysematous lungs345,356. Typically, emphysema was characterized by 
lung parenchymal destruction through the influx of neutrophils513. The neutrophilic 
inflammation in the context of lung cancer could inhibit cytotoxic lymphocytes to 
downregulate the immune response against cancers104,490, and facilitate 
transendothelial migration of tumor cell to stimulate progression and metastasis488. 
There is evidence that the neutrophil count, or neutrophil to lymphocyte ratio, in the 
intratumoral microenvironment is inversely correlated with lung cancer outcomes514. 
In addition, chronic inflammation can activate angiogenesis and increase vascular 
permeability to provide support for the malignant cells, by which tumors are likely to 
behave as “wounds that do not heal”512,515. Up-regulation of MMP has been associated 
with lymphovascular tumor invasion and postoperative recurrence356 and could 
potentially contribute to poorer outcomes with more severe RES. 
Health-related QOL has been increasingly emphasized in lung cancer106. Previous 
studies found patient comorbidities, such as COPD, did not affect QOL for lung cancer 
patients411,516; however, the influence of emphysema is still uncertain. Our study 
showed that the overall QOL score did not differ significantly between RES whereas 
dyspnea scores were worse in patients with a severe RES in all groups. Dyspnea has 
been reported to constitute a major component of symptom burden in patients with 
lung cancer499. Balduyck and colleagues found a significant correlation between 
comorbidity index and postoperative dyspnea517. Our study further demonstrated that 
dyspnea symptoms were worse in patients with severe RES, regardless of tumor 
location and treatment modalities, indicating a need for proactive intervention to 
symptom of dyspnea when managing lung cancer patients with severe emphysema. 
Fatigue is a common symptom of inoperable lung cancer518. Our study found that 
fatigue was associated with RES in non-surgical group. In comparison to patients with 
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mild RES, those with moderate/severe RES had a higher proportion of concomitant 
COPD and more severe airflow obstruction, which are negative predictors of QOL498,519. 
In addition, these patients tended to be current smokers, a known association with 
poor QOL520. Therefore, it is possible that the addition of targeted emphysema therapy 
and smoking cessation may improve patient’s health-related outcome. 
Lung function is the main limiting factor when planning surgery for early-stage 
lung cancer. It has been recognized that lobectomy may lead to an improvement in 
postoperative ventilation capacity in patients with moderate to severe pulmonary 
emphysema392,521. Our findings highlighted the predictive value of RES in postoperative 
recovery of pulmonary function. When tumor resection was performed in 
emphysematous region (group 1), patients with a higher RES had less marked decline 
in FEV1% but greater reductions in RV, contributing to “volume reduction effect” on 
FEV1/FVC (and subsequent increase in FEV1/FVC). This finding concurred with those of 
Ueda and colleagues391, who reported an association between emphysematous lung 
tissue in resected lung and volume reduction effect on postoperative FEV1/FVC. In 
contrast, when lung cancer occurred away from emphysematous region (group 2), no 
obvious volume reduction effect was noted after surgical resection. Therefore, the 
grading of regional emphysema by quantitative CT can help determine the optimal 
treatment of patients with early-stage NSCLC who have compromised lung function. 
RES was significantly associated with postoperative pneumonia in both surgical 
groups. Prolonged air leak occurred more frequently in those patients with a severe 
RES, and a statistically significant difference was noted in group 1 (cancer in the 
emphysema region) for a severe RES compared with a mild or moderate RES. Possible 
mechanisms include poorer postoperative healing owing to more fragile, 
emphysematous tissue after522. 
The current study has several limitations. First, although our patient cohort was 
prospectively followed in the past decade, this study was retrospective and 
 105 
observational in nature; thus, the potential bias could not be completely eliminated 
even with rigorous statistical analysis. Second, follow-up by lung function was not 
conducted routinely in the postoperative course; rather, the PFT data were passively 
collected upon availability in medical records; only one-fourth of patients had follow-
up of lung function. Third, preoperative QOL was unavailable, which limits the ability 
of the study to assess the effects of therapy (and RES) on post-treatment change. Lastly, 
the relatively small number of early-stage patients who received non-surgical 
treatment in the present study limits interpretation of results for this group. Therefore, 
a larger-scale study is needed to confirm our results.  
 
4.4 Chapter Summary 
This study explored the prognostic significance of regional emphysema severity in 
a retrospective analysis and found that RES was an independent predictor of OS in 
early-stage NSCLC after surgery regardless of tumor location, and was associated with 
post-treatment QOL related to dyspnea and postoperative recovery of pulmonary 
function.  
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CHAPTER 5. IMPACT OF COMORBID COPD ON 
OVERALL SURVIVAL IN LUNG CANCER PATIENTS 
CHAPTER FIVE 
IMPACT OF COMORBID COPD ON 
OVERALL SURVIVAL IN LUNG 
CANCER PATIENTS 
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Chronic obstructive pulmonary disease (COPD) and lung cancer are two leading 
causes of death in the world, which are projected to rank fourth and sixth by 2030, 
respectively295. Both are caused by cigarette smoking and there is an increasing 
evidence linking the two diseases through epidemiologic and genetic studies246,420. In 
clinical practice, the prevalence of COPD is estimated at 50% to 70% among patients 
diagnosed with lung cancer296.  
Recently, Durham and Adcock performed a review on the relationship between 
COPD and lung cancer, aiming to expand the understanding on mechanistic possibility 
of these two linked diseases344. Despite many studies from large national databases 
reporting the survival for primary lung cancer or COPD111,134,523,524, the outcome of 
lung cancer coexisting with COPD, namely the prognostic significance of COPD in lung 
cancer is poorly understood. Lee and colleagues405 reported that COPD did not worsen 
the prognosis for lung cancer after adjustment for baseline characteristics while 
Tammemagi and colleagues525 found that the presence of COPD was an independent 
factor of a poor prognosis regardless of cancer stages. A recent meta-analysis 
discussed the impact of COPD and emphysema on lung cancer and indicated these as 
predictors of poor survival406, but the study population included patients with 
emphysema without evidence of airway obstruction128 and congestive heart failure526, 
resulting in a high heterogeneity, thus some conclusions may be biased.  
Since COPD is very prevalent in lung cancer patients and the conclusions from 
previous studies remain conflicting regarding the prognostic significance of COPD 
preceding lung cancer diagnosis, we aimed to systematically review the current 
available literature to verify and quantify the impact of COPD on survival of lung cancer 
patients. 
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5.1 Methods 
5.1.1 Literature search strategy 
A systematic search was performed using the PubMed database to identify articles 
mentioning the impact of COPD on overall survival (OS) in patients with lung cancer. 
Inclusion criteria were: (1) peer-reviewed and published original articles, (2) study 
populations involving 20 or more cases in each group (COPD group and non-COPD 
group), and (3) a hazard ratio (HR) and 95% confidence interval (CI) were stated, or 
could be calculated in the article. Publications were excluded if the study (i) was 
published in a book or in non-English, (ii) lacked accessibility of HR and 95%CI, or (iii) 
only described the severity of COPD and its relationship to lung cancer prognosis. If 
the enrolled patients came from the same institution and in the same period, the most 
proper study would be chosen according to the needs of stratified analysis.  
A search strategy using the keywords “(chronic obstructive pulmonary disease) 
AND (lung cancer) AND survival” with the limitation of English language, human 
research and publication date through October 31, 2015 identified 672 articles (Figure 
5.1). Of these, 629 were excluded on the basis of title or abstract and the full-text of 
43 articles was reviewed. Three articles366,527,528 were published from a single 
institution with the same study periods, so one study527 was excluded and the other 
two articles366,528 were divided into different analyses (i.e., stratified analyses by 
different cancer stages and treatment modalities) to avoid double counting the 
patients cohorts. Three additional studies482,525,529 were identified from the reference 
in obtained articles. One published study from Mayo Clinic (Rochester, MN) was also 
added523. Finally, 16 studies were included in the meta-analysis. 
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5.1.2 Data extraction 
The extracted data included (1) year of publication, (2) study design, (3) ethnic 
population, (4) number of patients, (5) diagnostic method of COPD, (6) histopathology 
and stage of lung cancer, (7) treatment for lung cancer, (8) OS in each group, and (9) 
HR and 95%CI in each study. 
 
Figure 5.1: Literature selection procedures to identify relevant studies reporting the impact of 
COPD on overall survival in patients with lung cancer. 
 
5.1.3 Statistical analysis  
For each study, the log (HR) and its standard error were used as the outcome 
variables for data combination530. For the studies in which HR could not be achieved 
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directly, the Kaplan-Meier survival curves from original papers would be read by 
Engauge Digitize version 4.1 to extract data and to calculate the HR according to the 
methods introduced by Tierney and colleagues530. As shown in Figure 5.2, the HRs in 
3 studies were calculated by data reading from Kaplan-Meier survival curves366,403,531.  
 
Figure 5.2: Data extraction from Kaplan-Meier survival curve using Engauge Digitize. 
It is noted that there are obvious typographical errors in two papers which give 
the HR and 95%CI as 1.15[0.04, 2.23] and 0.74[0.83, 2.23], respectively367,510. 
Therefore, these HRs were regenerated as 1.15[0.93, 1.42] and 1.36[0.83, 2.23] by 
RevMan Calculator (Figure 5.3).  
 
Figure 5.3: Correction of Hazard ratios in two studies using RevMan Calculator. 
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Meta-analysis was performed with RevMan version 5.1 using a random-effects 
model or a fixed-effect model according to the results of heterogeneity test. The 
heterogeneity among studies was assessed with the Cochrane Q test and I2 statistics. 
The publication bias was detected by funnel plot visually, and analyzed by Egger’s test 
quantitatively through Stata 12.0. 
 
5.2 Results 
The characteristics of the included studies are summarized in Table 5.1. Most 
studies were based on the retrospective analysis except for two (by Lopez-
Encuentra531 and Xie523), in which patients were enrolled prospectively. The data in 
four studies came from population-based studies or multicenter trials403,529,531,532. The 
size of the cohorts varied from 114 to 19,337, with a total number of 38,966 patients. 
COPD was mainly diagnosed by spirometry. 
Table 5.1: General characteristics of included studies 
Author, year of 
publication, study 
design 
Ethnicity Diagnosis 
for COPD 
Pathol
ogy of 
LC 
Stage 
of LC 
Treatment 
for LC 
Total 
Xie523 2015, 
prospective 
Caucasian not 
mentioned 
SCLC extensive 
limited 
all 
all 
555 
383 
Iachina529 2015, 
retrospective, 
population-based 
Caucasian not 
mentioned 
NSCLC mixed all 10378 
Kuo533 2014, 
retrospective  
Asian spirometry NSCLC I surgery 181 
Zhai402 2014, 
retrospective 
Caucasian physician-
diagnosed & 
self-report  
NSCLC IA-IIB surgery 902 
Izquierdo404 2014, 
retrospective 
Caucasian spirometry NSCLC
+SCLC 
IIIB/IV chemothe
rapy or TKI 
324 
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Table 5.1: General characteristics of included studies 
Author, year of 
publication, study 
design 
Ethnicity Diagnosis 
for COPD 
Pathol
ogy of 
LC 
Stage 
of LC 
Treatment 
for LC 
Total 
Lee 2014405, 
retrospective 
Asian spirometry NSCLC mixed  all 221 
Sekine366 2013, 
retrospective 
Asian spirometry NSCLC mixed  surgery 1461 
Mina482 2012, 
retrospective 
Caucasian spirometry NSCLC
+SCLC 
mixed  all 114 
Gullon510 2011, 
retrospective 
Caucasian spirometry NSLCL mixed  all 353 
Kondo534 2011, 
retrospective 
Asian spirometry NSCLC
+SCLC 
mixed  surgery 531 
Kiri403 2010, 
retrospective, 
population-based 
Caucasian physician-
diagnosed 
NA. NA. NA. 19337 
Birim532 2006, 
retrospective, 
multicenter 
Caucasian spirometry NSCLC mixed  all 776 
Lopez-Encuentra531 
2005, prospective, 
multicenter 
Caucasian spirometry NSCLC IA/IB surgery 2051 
Tammemagi525 2003, 
retrospective 
Caucasian not 
mentioned 
NSCLC
+SCLC 
mixed  
I/II 
III//IV 
all 1155 
304 
851 
Sekine367 2002, 
retrospective 
Caucasian spirometry NSCLC mixed  surgery 244 
Sekine528 2007, 
retrospective*  
Asian spirometry NSCLC IA surgery 442 
* only used in stage-specific subgroup analysis;   
COPD: chronic obstructive pulmonary disease;  LC: lung cancer;  NSCLC: non-small cell lung 
cancer;  SCLC: small cell lung cancer;  OS: overall survival;  TKI: tyrosine kinase inhibitors;  
NA: not available. 
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5.2.1 General Impact in all patients 
A meta-analysis for all 15 publications reporting the impact of COPD on OS of lung 
cancer was shown in Figure 5.4a. The statistical heterogeneity was non-significant 
(p=0.11, I2=32%), and thus a fixed-effect model was used. The result suggested that 
COPD was an adverse prognostic factor in lung cancer (HR, 1.22; 95%CI, 1.18-1.27). 
The funnel plot displays a symmetric distribution (Figure 5.9a), and no sign of 
publication bias was proved by Egger’s test (p=0.760). 
 
Figure 5.4: Forest plots of HR for the impact of COPD on survival of lung cancer: a) HRs gained 
from univariate analysis, b) adjusted HRs gained from multivariate analysis in original studies.  
 
After adjustment for important covariates such as age, gender, smoking status, 
performance status and stage of lung cancer, the result (Figure 5.4b), on the basis of 
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adjusted HRs in 4 available studies402,404,405,525, suggested that COPD was an 
independent deleterious factor (HR, 1.29; 95%CI, 1.15-1.45). No significant 
heterogeneity was found (p=0.48, I2=0%). The funnel plot (Figure 5.9b) shows 
symmetry indicating no obvious publication bias, as confirmed by Egger’s test 
(p=0.062).  
 
5.2.2 Stratified analysis based on ethnic populations 
When stratified by different ethnicities, the association remained significant in 
both Asians (HR, 1.33; 95%CI, 1.18-1.51) and Caucasians (HR, 1.21; 95%CI, 1.16-1.26), 
respectively (Figure 5.5). There was no significant heterogeneity detected in any 
subgroups; with respective Cochran test and I2 statistics for Asian and Caucasian 
population being p=0.41, I2=0% and p=0.11, I2=35%.  
 
Figure 5.5: Forest plots of HR for the impact of COPD on survival of lung cancer in different ethnic 
groups. 
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5.2.3 Stratified analysis according to cancer types 
Histopathologic types of lung cancer were non-small cell lung cancer (NSCLC) in 
nine studies, small cell lung cancer (SCLC) in one study, and mixed types (NSCLC+SCLC) 
in four studies (Figure 5.6). A stratified analysis showed that the difference in OS 
between patients with and without COPD was significant in NSCLC (HR, 1.23; 95%CI, 
1.16-1.30), less significant in mixed types (HR, 1.16; 95%CI, 1.03-1.30), but not 
significant in SCLC (HR, 1.01; 95%CI, 0.87-1.17). No obvious heterogeneity in each 
group (p=0.17, I2=31%; p=0.94, I2=0%; p=0.28, I2=14%) or publication bias (p=0.462) 
was detected. 
 
Figure 5.6: Forest plots of HR for the impact of COPD on survival of lung cancer in different 
histopathologic types. 
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5.2.4 Stratified analysis according to cancer stages 
 Seven studies reported the impact of COPD in stage-specific lung cancer including 
six publications studying early stage (stage I-II or limited stage) and three publications 
studying late stage (stage III-IV or extensive stage) (Figure 5.7). A stratified analysis 
showed that COPD had a significantly negative impact on early stage lung cancer (HR, 
1.35; 95%CI, 1.12-1.63) but not on late stage lung cancer (HR, 1.08; 95%CI, 0.92-1.27). 
Because the statistical heterogeneity was moderate in the early stage subgroup 
(p=0.03, I2=62%), a random-effects model was used. No significant publication bias 
was found by either funnel plot (Figure 5.9c) or Egger’s test (p=0.058).  
 
Figure 5.7: Forest plots of HR for the impact of COPD on survival of lung cancer in different 
cancer stages. 
 
5.2.5 Stratified analysis according to treatment modalities 
Only one study404 focused on patients receiving non-surgical treatment 
(chemotherapy and/or tyrosine kinase inhibitors) and the result suggested that COPD 
has no impact on the mortality in this population (HR, 1.12; 95%CI, 0.85-1.47). In 
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patients receiving surgical treatment (Figure 5.8), six studies were included and a 
pooled analysis showed a significant association between the presence of COPD and 
worse OS (HR, 1.31; 95%CI, 1.13-1.51). The statistical heterogeneity was mild (p=0.07, 
I2=52%), so that a random-effects model was used. The funnel plot shows symmetry 
(Figure 5.9d) and no publication bias was detected (p=0.316). 
 
Figure 5.8: Forest plots of HR for the impact of COPD on survival of lung cancer in surgically 
treated lung cancer. 
 
5.3 Discussion 
This meta-analysis based on 16 studies which examined the association between 
the presence of COPD and the prognosis of lung cancer has verified that COPD had a 
significant deleterious impact on lung cancer survival regardless of the ethnic groups 
studied. In addition, the impact of COPD appeared to be more pronounced in NSCLC, 
early stage, and surgically-treated patients.  
Recently, many studies were keen on the relationship between COPD and the risk 
of lung cancer246,296,347; however, the prognostic impact of COPD on lung cancer is not 
clearly defined. To our knowledge, this is the first meta-analysis to quantify its impact 
based on a strict screening for patients with COPD. In previous studies, COPD was 
shown to correlate with higher rates of tumor recurrence and metastasis528,533, with 
underlying mechanism by which COPD affects the prognosis of lung cancer remaining 
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elusive. Some studies indicated that a host environment with chronic inflammation 
could contribute to the poor prognosis535,536. Besides, genetic and epigenetic pathway 
in, for example, SPARC, p16 and smoking-related CXCL14 gene may also modulate the 
prognosis363,537. 
 
Figure 5.9: Funnel plots of meta-analysis. (a) impact of COPD on OS in lung cancer patients; (b) 
impact of COPD on OS on the basis of adjusted HRs; (c) impact of COPD on OS in stage-specific 
lung cancer patients; (d) impact of COPD on OS in surgically treated lung cancer patients. 
COPD is characterized by two components: airflow obstruction (bronchitis) and 
peripheral airspace disease (emphysema), and chronic inflammation is involved in 
both of their pathogenesis134,167. One common feature of this chronic inflammation is 
the influx of neutrophils490 while the neutrophilic inflammation in the context of lung 
cancer may act as a dual-edged sword538. On one hand, it can suppress tumor 
progression by means of direct tumor cytotoxicity539. On the other hand, it may 
possess a tumor-promoting effect not only to survive cancer cells by suppressing the 
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action of cytotoxic lymphocytes490 , but also to promote tumor metastasis by 
facilitating tumor cell transendothelial migration488. As a result, many studies indicated 
that the neutrophil count or neutrophil to lymphocyte ratio in the tumor and/or in the 
peripheral blood inversely correlated with the outcome in various types of solid 
cancers, including SCLC523 and NSCLC490,514. 
Another mechanistic explanation proposed by Dvorak and colleagues is that 
chronic inflammation can activate angiogenesis and increase vascular permeability515, 
which provides support for the malignant cells, by which tumors are likely to behave 
as “wounds that do not heal”.512 Additionally, in some cases, inflammation could 
diminish the beneficial effects of therapy540. Clinically, Berry and colleagues has 
disclosed an apparent decrement in survival for patients with lower pulmonary 
function541. Therefore, considering the results documented previously and presented 
in our study, COPD did negatively impact the long-term outcome in lung cancer, and 
this disadvantage was also observed after the adjustment for important prognostic 
factors (e.g., smoking status, performance status, and stage of disease). Further 
studies including genomic and epigenetic analysis to explore and verify this prognostic 
link are still warranted, which could serve as a novel biologic target for both prevention 
and treatment of lung cancer with COPD.  
In this meta-analysis, examinations for pooled HR were performed among all 
ethnic, pathological, and staging subgroups. The presence of COPD had a negative 
influence in both examined ethnicities (Asian and Caucasian). Histopathologically, the 
association of COPD with NSCLC survival seemed more pronounced than that with 
SCLC, because the pooled HR was significant in NSCLC but not significant in SCLC. We 
hypothesize that this subgroup-specific association can be partly explained by a highly 
aggressive nature and a rapid disease progression of SCLC, which could minimize or 
overwhelm any potential influence of patient’s comorbidities like COPD on survival542. 
Although there likely be an interaction between stage of disease and choice of 
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treatment for lung cancer, we are unable to conduct a multivariate model for the meta-
analysis because of the inconsistent data provided in the published studies. When 
analyzing stage-specific subgroup separately, the pooled HR was significant in early 
stage but not significant in late stage lung cancer. Although only three studies were 
eligible for analysis in the late stage subgroup, the HR in each study was merely 
marginally significant or even not significant. 
With regard to treatment modalities, one study by Izquierdo and colleagues 
demonstrated no influence of COPD on OS of lung cancer in patients receiving non-
surgical treatment404 whereas our meta-analysis revealed a worse survival in 
surgically-treated patients with COPD. Owing to the fact that surgical treatment is 
commonly associated with diseases in the early stage, it is reasonable to infer that the 
influence of COPD is more evident in patients at an early stage and/or receiving 
surgical treatment. However, this result did not mean that patients with COPD were 
unfit for surgery, because lung resection for tumor sometimes had volume reduction 
benefit, contributing to improved quality of life381. The findings of this investigation 
highlight the association of COPD and lung cancer prognosis, disclosing the 
inhomogeneous magnitude of COPD in different phases of lung cancer, thus aiding the 
decision-making process when clinicians are selecting best possible strategies for the 
management and long-term monitoring in this particular population, especially in the 
field of multidisciplinary care for inflammation control and pulmonary rehabilitation 
because both may be beneficial to lung cancer outcome.  
There were several limitations in the current study. First, the majority of the 
enrolled studies were retrospective and the numbers of studies in the subgroups were 
relatively small, which might be subject to some biases, such as selection bias. Second, 
due to the lack of accessible data, we were unable to perform a stratified analysis by 
severity of COPD since the result by Sekine and colleagues suggested that the severity 
of COPD was related to lung cancer prognosis366. Third, two HRs in this meta-analysis 
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were obtained from the data in 2-year and 3-year follow-ups403,482, which may be not 
as accurate as the HRs calculated from 5-year follow-up information. Future studies 
should supplement the impact of COPD on survival of SCLC and in patients with other 
non-surgical treatment, and investigate the mechanisms underlying the association of 
COPD with lung cancer prognosis.  
 
5.4 Chapter Summary 
our meta-analysis not only has confirmed that COPD is an independent prognostic 
factor of lung cancer survival, but also demonstrated that the deleterious impact tends 
to be more pronounced in patients with non-small cell lung cancer, at an early-stage, 
and on those who received surgical treatment. Further mechanistic investigations for 
this relationship and potential clinical interventions are warranted. 
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Lung cancer is a rapidly fatal disease with poor long-term prognosis; the average 
5-year overall survival rate is estimated to be below 20% across all stages543. Non-small 
cell lung cancer (NSCLC) constitutes more than 80% of all lung cancers17. Despite 
recent progress in lung cancer treatment, such as targeted therapy and 
immunotherapy544-546, lung cancer remains the leading cause of cancer specific 
morality for both men and women in the world32. Thus, considerable efforts are 
dedicated to risk stratification and optimal management of lung cancer. 
It is increasingly clear that inherited genetic factors play a central role in the clinical 
outcomes of lung cancer patients. Several genome-wide association (GWA) studies 
and candidate gene studies have identified a variety of putative polymorphic 
biomarkers related to lung cancer prognosis547-551. Hence, independent replication of 
these findings is needed to aid better understanding and provide irrefutable and 
accurately quantified evidence of these identified genetic associations. 
Chronic obstructive pulmonary disease (COPD), characterized by persistent 
airflow limitation, is the third leading cause of death worldwide130,134. Approximately 
40-60% patients with lung cancer have concomitant COPD402,404, and lung cancer 
arising in COPD has a unique profile of disease manifestation and clinical outcomes481. 
Nevertheless, in many of the previous studies examining associations between genetic 
variants and lung cancer survival, COPD status has not been taken fully into account. 
Young and colleagues argued that some genetic loci implicated in COPD might be 
mistakenly attributed to lung cancer, due to the failure to identify the coexisting 
COPD421. In addition, there is accumulating evidence suggesting the genetic 
associations overlap to some degree between lung cancer and COPD (see Chapter 2). 
Hence, integrated research is required in the association analyses including genetic 
variations, COPD, and lung cancer survival552,553. 
Therefore, this study aimed to identify specific genetic markers associated with 
lung cancer survival, and to examine whether the associations were influenced by 
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COPD status. 
 
6.1 Methods 
6.1.1 Patient cohort 
The study protocol was reviewed and approved by the Mayo Clinic Institutional 
Review Board. Detailed procedures of patient enrollment, data collection, and follow-
up can be found in the Appendix. Patients with pathologically confirmed NSCLC 
between 1997 and 2013 were included in this study. Informed consent was obtained 
from all participants. 
The diagnosis of COPD was determined by examination of the patient’s medical 
record and/or documented irreversible airflow limitation, i.e., post-bronchodilator 
forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) of less than 
70%134. In the current study, tumor grade was classified into well-, moderately-, and 
poorly-differentiated100. Treatment modalities included surgery alone, surgery plus 
adjuvant therapy (chemotherapy and/or radiation), chemoradiation (concurrent or 
sequential), and chemotherapy or radiotherapy only or other supportive care. 
 
6.1.2 SNP selection and genotyping 
We selected 384 SNPs from 332 genes following a review of the lung cancer 
literature and based on out previous unpublished GWA studies (Appendix Table 
1)447,554,555. Genomic DNA was extracted from peripheral blood using the QIAmp DNA 
extraction kit (Qiagen) and genotyped in the Mayo Clinic Genomics Shared Resource 
using a custom-designed Illumina GoldenGate panel. 
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Quality control was implemented in multiple steps, as described previously554. In 
brief, SNPs were removed from subsequent analysis if they had call rates less than 95%, 
or Hardy-Weinberg equilibrium (HWE) p values less than 10-4, or minor allele 
frequencies (MAF) less than 0.01 in this study population. In addition, samples with 
call rates of less than 95% were excluded at the same time. As such, 1 SNP failed 
genotyping, 16 SNPs had missing call rates more than 5%, 4 SNPs had MAF less than 
1%, and 14 SNPs deviated from HWE, resulting in 349 SNPs being included in the 
further analyses (Appendix Table 2).  
 
6.1.3 Statistical analysis  
Data was compared across groups using the chi-square (x2) test for categorical 
variables, and the unpaired t-test for continuous variables. According to the COPD 
status, patients were categorized into 2 groups: lung cancer with COPD (LC+COPD), 
and lung cancer without COPD (LC only). In each group, Cox proportional hazards 
models were performed using backward selection to identify potential confounders: 
patient’s age, sex, race, smoking status, histological type, tumor grade, pathological 
stage, and treatment modality. The significant variables (p<0.05) were retained as 
covariates in the subsequent genetic association tests.  
For each SNP that passed quality control thresholds, a Cox regression model was 
used to assess the associations between SNP genotypes and overall survival while 
adjusting for covariates. Hazard ratio (HR) and 95% confidence interval (CI) were 
estimated for the rare homozygous and heterozygous genotypes versus the common 
homozygote genotype. The best genetic model was determined by comparing the 
hazard ratios of three models: dominant (major allele homozygotes versus minor allele 
carrying genotypes), recessive (major allele carrying genotypes versus rare 
homozygotes), and additive (P for trend). If the rare homozygous genotype was 
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observed at a frequency <5% of total, only the dominant model was considered. To 
correct for multiple comparisons, q values (a false discovery rate-adjusted p value) 
were computed for each SNP, and a false discovery rate (FDR) of 20% was accepted556.  
Survival curves were generated by the Kaplan-Meier method to assess the 
differences in survival time by genotype from each individual SNP. Linkage 
disequilibrium measures (D’) were used to detect association between identified SNPs. 
The likelihood ratio test was used to compare the difference in HR and 95%CI of each 
SNP between LC+COPD model and the LC only model by comparing the model with 
and without the COPD*SNP interaction term. All analyses were performed in SAS, 
version 9.3 (SAS Institute) or R software (version 3.3.1) 
 
6.2 Results 
6.2.1 Patient clinical features 
A total of 1,694 patients were identified in this study (Table 6.1). The mean age of 
all patients was 65.5±10.9 years, with slightly more women (51.9%) than men (48.1%). 
The diagnosis of COPD was identified in 767 (45.3%) patients. Compared to those 
without COPD, COPD was noted more frequently in male patients (53.1% vs. 43.9%, 
p=1.7×10-4) and smokers (78.4% vs. 45.1%, p=7.7×10-43). Squamous cell carcinoma 
represented 19.0% of the patient population, with a significantly higher rate in the 
LC+COPD group (26.5% vs. 12.8%, p=6.4×10-12). Due to a higher proportion of early 
stage NSCLC (stage I and II) in cases with COPD, treatment with surgery alone was also 
noted more frequently in the LC+COPD group than that in the LC only group. 
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Table 6.1: Patient demographic and clinical characteristics 
 
LC+COPD 
n=767 (45.3%) 
LC only  
n=927 (54.7%) 
total 
n=1,694 
p 
age (years) 67.8±9.6 63.7±11.5 65.5±10.9 5.5E-15 
sex    1.7E-04 
    male 407 (53.1%) 407 (43.9%) 814 (48.1%)  
    female 360 (46.9%) 520 (56.1%) 880 (51.9%)  
race    1.4E-01 
    white 714 (93.1%) 845 (91.2%) 1559 (92.0%)  
    non-white 53 (6.9%) 82 (8.8%) 135 (8.0%)  
smoking status    7.7E-43 
    never 166 (21.6%) 509 (54.9%) 675 (39.8%)  
    former 381 (49.7%) 270 (29.1%) 651 (38.5%)  
    current 220 (28.7%) 148 (15.9%) 368 (21.7%)  
cell type    6.4E-12 
    adenocarcinoma 454 (59.2%) 667 (72.0%) 1121 (66.2%)  
    squamous cell 203 (26.5%) 119 (12.8%) 322 (19.0%)  
    other NSCLC 110 (14.3%) 141 (15.2%) 251 (14.8%)  
tumor grade    2.1E-03 
    well differentiated  187 (24.4%) 232 (25.0%) 419 (24.7%)  
    moderately differentiated 361 (47.1%) 365 (39.4%) 726 (42.9%)  
    poorly differentiated 219 (28.6%) 330 (35.6%) 549 (32.4%)  
pathological stage    9.2E-23 
    I 370 (48.2%) 300 (32.4%) 670 (39.6%)  
    II 118 (15.4%) 90 (9.7%) 208 (12.3%)  
    III 165 (21.5%) 209 (22.5%) 374 (22.1%)  
    IV 114 (14.9%) 328 (35.3%) 442 (26.1%)  
therapy    6.7E-21 
    surgery alone 458 (59.7%) 347 (37.4%) 805 (47.6%)  
    surgery + adjuvant therapy 111 (14.5%) 150 (16.2%) 261 (15.4%)  
    chemo-/radio-/other only 116 (15.1%) 292 (31.5%) 408 (24.1%)  
    chemoradiation 82 (10.7%) 138 (14.9%) 220 (13.0%)  
Bold values indicate P values with statistically significant difference (p<0.05). 
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6.2.2 Baseline survival model 
The overall median survival and 5-year survival rate for the entire cohort were 4.5 
years and 47.3%, respectively. In the analysis of patient characteristics, 6 variables 
were simultaneously associated with overall survival: age, sex, race, tumor grade, 
pathological stage, and treatment modality (Appendix Table 3.1).  
In the LC+COPD cohort, the median survival and 5-year survival rate were 5.6 years 
and 53.0%, respectively. The Cox proportional hazards model indicated age, sex, tumor 
grade, pathological stage, and treatment modality were significantly associated with 
overall survival (Appendix Table 3.2). In the LC only cohort, the average 5-year survival 
rate was lower at 42.5%, with a median survival time of 3.7 years, most likely due to 
the proportion of patients whose lung cancers were diagnosed at an advanced stage. 
Age, tumor grade, pathological stage, and treatment modality were shown to be 
related to survival in this group (Appendix Table 3.3). Therefore, these identified 
variables were considered to be potential confounders and were adjusted in the 
subsequent SNP analyses. 
 
6.2.3 Associations of individual SNPs with survival 
The analysis of SNPs and survival in the whole cohort identified 28 SNPs with 
p<0.05 in the multivariate Cox model (Appendix Table 4.1), of which only 1 SNP 
(rs10218481) passed the FDR<20% assessment (p=4.46×10-4, q=0.16). Each additional 
variant allele contributed to a 14% reduction in risk of death (HR, 0.86; 95%CI, 0.89-
0.94). 
In the stratified analysis of the LC+COPD cohort, 24 SNPs were associated with 
lung cancer survival (p<0.05, Appendix Table 4.2), with one SNP (rs74798757) with q 
value less than 0.20 (p=1.56×10-4, q=0.05). Patients carrying the rare allele had a 
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significantly poorer overall survival (HR, 1.68; 95%CI, 1.29-2.20).  
In the LC only cohort, there were 32 SNPs related to lung cancer survival (Appendix 
Table 4.3), and 5 SNPs remained significant after FDR correction (Table 2). Consistent 
with the total cohort, the rs10218481 polymorphism showed a similar protective 
effect on overall survival (HR, 0.81; 95%CI, 0.73-0.91; p=4.19×10-4, q=0.12). In the 
dominant model, improved survival was observed in patients with the minor allele of 
rs17090907 (HR, 0.71; 95%CI, 0.58-0.87; p=9.18×10-4, q=0.12). In addition, the variant 
alleles of the two GPC5 SNPs, rs1409600 (HR, 0.73; 95%CI; 0.61-0.89, p=1.38×10-3, 
q=0.12) and rs163933 (HR, 0.73; 95%CI; 0.60-0.89, p=1.59×10-3, q=0.12) were 
associated with decreased death risk. In contrast, the variant allele of rs8192627 
displayed an association with worse survival (HR, 1.41; 95%CI, 1.14-1.74; p=1.79×10-3, 
q=0.12). The Survival curves for the 6 identified SNPs are shown in Appendix Figure 1.  
Table 6.2: SNPs associated with lung cancer survival 
SNP gene chr best model 
total 
HR (95%CI) p q 
rs10218481 NR5A2* 1 Additive 0.86 (0.79, 0.94) 4.46E-04 0.16 
rs74798757 HAAO* 2 Dominant 1.28 (1.04, 1.57) 2.06E-02 0.46 
rs17090907 CASP7 10 Dominant 0.85 (0.74, 0.99) 3.21E-02 0.48 
rs1409600 GPC5 13 Dominant 0.86 (0.75, 0.98) 2.81E-02 0.46 
rs163933 GPC5 13 Dominant 0.86 (0.75, 0.99) 3.86E-02 0.50 
rs8192627 TAAR8 6 Dominant 1.22 (1.04, 1.42) 1.38E-02 0.46 
SNP 
LC+COPD LC only 
HR (95%CI) p q HR (95%CI) p q 
rs10218481 0.92 (0.82, 1.05) 2.09E-01 0.85  0.81 (0.73, 0.91) 4.19E-04 0.12  
rs74798757 1.68 (1.29, 2.20) 1.56E-04 0.05  0.98 (0.70, 1.36) 8.99E-01 0.97  
rs17090907 1.10 (0.89, 1.35) 3.71E-01 0.88  0.71 (0.58, 0.87) 9.18E-04 0.12  
rs1409600 1.02 (0.83, 1.24) 8.71E-01 0.98  0.73 (0.61, 0.89) 1.38E-03 0.12  
rs163933 1.03 (0.84, 1.27) 7.56E-01 0.96  0.73 (0.60, 0.89) 1.59E-03 0.12  
rs8192627 1.07 (0.84, 1.35) 5.94E-01 0.96  1.41 (1.14, 1.74) 1.79E-03 0.12  
*nearest gene; underlined numbers denote significant association at q<0.20;  
HR: hazard ratio; CI: confidence interval. 
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Likelihood ratio tests revealed that rs74798757 (p=9.60×10-3), rs17090907 
(p=2.17×10-3), rs1409600 (p=2.51×10-2), and rs163933 (p=2.36×10-2) had significant 
interactions with COPD status, indicating that the effects of these SNPs on survival 
differ between lung cancer with COPD and lung cancer without COPD.  
 
6.2.4 Cumulative risk assessment  
Pairwise linkage disequilibrium measurements indicated that rs1409600 was in 
strong linkage disequilibrium with rs163933 (D’=0.92), representing a potential single 
association signal in the GPC5 gene. Therefore, the more significant SNP, rs1409600, 
was selected in subsequent joint analysis. In the LC only cohort, when the 4 significant 
SNPs (rs10218481, rs17090907, rs1409600, and rs8192627) were included in a single 
multivariate Cox model, the significance remained for all of the 4 SNPs (Table 6.3). 
Table 6.3: Multivariate Cox analysis of significant SNPs in LC only cohort 
 best model HR (95%CI)* p 
rs10218481 additive 0.83 (0.74, 0.93) 1.07E-03 
rs17090907 dominant 0.72 (0.59, 0.88) 1.40E-03 
rs1409600 dominant 0.74 (0.61, 0.89) 1.69E-03 
rs8192627 dominant 1.37 (1.11, 1.70) 3.80E-03 
*adjusted for age, tumor grade, pathological stage, and therapy. HR: hazard ratio; CI: confidence 
interval. 
In the analysis of cumulative effect, each of the SNPs were assigned point scores 
corresponding to the direction of their HR estimates in the multivariate Cox model 
(Table 6.3). An unfavorable genotype was given 1 point. For SNP rs10218481 the effect 
was consistent with an additive model, and the risk score was the number of risk alleles 
carried by each patient. Thus, the total score was the sum of component scores from 
each of the SNPs. Due to the small number of patients with a total score of 0 (n=8), 
these were combined with those having a total score of 1, to constitute the reference 
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group. Patients with a higher score had a worse survival (Table 6.4); each increment of 
1 unit in risk score indicated a 29% greater risk of death. When the total risk score was 
further divided into low-risk category (scores between 0 and 2 points) and high-risk 
category (scores between 3 and 5 points), the latter conferred a 1.73-fold increased 
risk of death (95%CI, 1.46-2.06) in comparison to the low-risk category.  
Table 6.4: Genotypes score-based prediction model for survival in LC only cohort 
genotype 
risk score 
No. of patients 
N=927 
dead 
N=641 
multivariate HR (95%CI)* p 
0-1 67 (7.2%) 38 (56.7%) reference  
2 235 (25.4%) 150 (63.8%) 1.31 (0.92, 1.88) 1.35E-01 
3 361 (38.9%) 251 (69.5%) 2.04 (1.45, 2.88) 4.81E-05 
4 228 (24.6%) 173 (75.9%) 2.24 (1.57, 3.20) 8.35E-06 
5 36 (3.9%) 29 (80.5%) 2.53 (1.56, 4.12) 1.79E-04 
per score (trend test)  1.29 (1.19, 1.39) 2.98E-10 
*adjusted for age, tumor grade, pathological stage, and therapy. HR: hazard ratio; CI: confidence 
interval. 
The significance of the scoring system was also confirmed in Kaplan-Meier analysis 
(p=5.25×10-5, Figure 6.1). However, no correlation was found between the risk score 
system and survival in the LC+COPD cohort (p=0.94). 
 
Figure 6.1: Kaplan-Meier estimates of overall survival grouped by the genetic risk score in the 
lung cancer only cohort. 
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6.3 Discussion 
In this study, we have examined previously reported lung cancer risk SNPs in 
relation to survival, and investigated the role of COPD status in the association 
between genetic variants and lung cancer prognosis. Our results demonstrated that 
SNP rs74798757 was significantly associated with survival from lung cancer when 
COPD was also present, whereas SNP rs10218481, CASP7:rs17090907, 
GPC5:rs1409600, GPC5:rs163933, and TAAR8:rs8192627 showed predictive effects on 
overall survival in lung cancer patients who were free of COPD. To the best of our 
knowledge, this is the first evidence suggesting a difference in prognostic genetic 
effects between lung cancer arising in COPD and non-COPD.  
 Lung cancer is often concomitant with COPD, and they are closely linked above 
and beyond their associations with smoking415. Numerous studies have demonstrated 
that the presence of COPD is an important risk factor for both lung cancer 
development and its ultimate prognosis296,306,407,481. Additionally, lung cancer 
developing on a background of COPD has a distinct genetic profile from that without 
COPD421,557. Therefore, it is necessary to study the genetic factors influencing lung 
cancer survival in the presence or absence of COPD separately. 
For individual SNP analysis in the LC only cohort, rs1409600 and rs163933, located 
in the GPC5 gene, showed strong associations with survival. GPC5 is a member of 
glypican gene family, and spans a large genomic region of 1.47 Mb at 13q31.3558. 
Evidence to date suggests that GPC5 is involved in the signaling pathways of Wnt, 
hedgehog (Hh), and fibroblast growth factors (FGF)559,560. It has been reported that 
GPC5 polymorphisms are associated with lung cancer susceptibility in never 
smokers447,561, with downregulation of GPC5 levels being detected in lung 
adenocarcinoma tissue447,562. Consistent with this finding, overexpression of GPC5 has 
been shown to suppress proliferation, migration and invasion activities of lung cancer 
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cells in vitro562,563. Previous studies have found that level of GPC5 expression might 
have an impact on lung cancer prognosis, although the results are still conflicting563,564. 
Our study demonstrated that polymorphisms in GPC5 (rs1409600 and rs163933) were 
significantly associated with lung cancer survival; patients carrying the variant allele of 
the SNPs had a 27% reduced risk of death compared to those of the wildtype 
homozygous genotype. These two SNPs are in close linkage disequilibrium (D’=0.92), 
and both are intronic and not in any obvious functional elements. Therefore, they are 
most likely linked with other functional loci that regulate the expression of GPC5. 
Nevertheless, it is of note that neither of the two SNPs was implicated in lung cancer 
survival with concomitant COPD (rs1409600: HR=1.02; p=0.87; rs163933: HR=1.03; 
p=0.76), suggesting a prognostic role for GPC5 in lung cancer only. The functional basis 
for the association of this gene with lung cancer survival dependent upon COPD status 
requires further study. 
An intronic variant (rs17090907) located it the CASP7 gene was also found to 
relate to lung cancer survival. Caspases (CASPs), members of the cysteine-aspartic acid 
protease family, serve as the central components of the apoptotic response, and 
CASP7 plays a crucial part in the execution of the final cell death program565. Many 
studies have shown that polymorphisms in CASP7 gene are associated with the risk of 
lung cancer566,567. It has also been reported that the CASP7 rs2227310 polymorphism 
can be a potentially prognostic marker for early-stage NSLCL after surgical resection568, 
and genetic variants at rs4353229 and rs12415607 may affect survival in lung cancer 
treated with platinum-based chemotherapy569. We used LDlink to compute the LD 
coefficients between rs17090907 and the other 3 reported SNPs570. The results of the 
LDlink analysis showed that the r2 ranged from 0.034 to 0.039, suggesting that these 
SNPs are not in linkage disequilibrium (Appendix Figure 2). Nevertheless, through eQTL 
analysis on the GETx Portal (https://gtexportal.org/home/), the rs17090907 genotypes 
were significantly correlated with the expression level of the CASP7 gene in normal 
lung tissue (p=1.2×10-9, Figure 6.2). Hence, the CASP7 rs17090907 can be a promising 
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prognostic factor of survival in lung cancer; future biological studies should elucidate 
this relationship in more detail. 
 
Figure 6.2: Expression quantitative trait loci (eQTLs) analysis for association of the rs17090907 
genotypes with expression level of CASP7 gene in normal lung tissue. The plot was generated by 
the GETx Portal (https://gtexportal.org/home/). 
Another SNP that was significantly associated with survival in the LC only group 
was rs8192627, which is a nonsynonymous SNP located in the coding region of TAAR8 
(trace amine associated receptor 8). The rs8192627A>C produces a D-to-A or D-to-V 
change at amino acid position 328. TAAR8 is a member of the TAAR gene family that 
belongs primarily to the G protein-coupled receptors (GCPR) family571. TAARs are 
ubiquitously expressed in human tissues, with the main expression in various brain 
areas572. Although some members of this receptor family (such as TARR1 and TARR4) 
have been implicated in neuropsychiatric disorders, understanding of the functional 
role of TAAR8 is still in its infancy573. Therefore, further functional characterization is 
needed to elucidate the biological basis for this association with lung cancer survival. 
The most plausible candidate was rs10218481, which was significantly associated 
with a decreased risk of death in both the LC only cohort (HR, 0.86; 95%CI, 0.79-0.94) 
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and the total cohort (HR, 0.81; 95%CI, 0.73-0.91). In the LC+COPD cohort, it showed a 
consistent direction of effect (HR, 0.92; 95%CI, 0.82-1.05), albeit nonsignificantly. This 
SNP is located within a gene desert region on chromosome 1q32.1. The NR5A2 
(nuclear receptor subfamily 5 group A member 2), approximately 7.5kb upstream of 
rs10218481, is the closest gene. Genetic variants in the NR5A2 gene have been 
identified in genome-wide association studies to confer a risk of pancreatic 
cancer574,575, and NR5A2 gene polymorphisms were reportedly associated with the 
clinical outcomes in various cancer types, such as pancreatic cancer and gastric 
cancer576,577. However, the role of NR5A2 gene has not been previously studied with 
respect to lung cancer. Biological experiment are necessary to determine whether this 
significant SNP influences the regulation of NR5A2 gene or is linked to other functional 
SNPs that affect lung cancer outcome. 
In the stratified analysis of the LC+COPD cohort, only one SNP, rs74798757, 
showed a significant association with overall survival. This SNP is located in a gene 
desert region on the 2p21 locus, where the nearest gene is HAAO (3-
hydroxyanthranilate 3,4-dioxygenase), about 98kb upstream of rs74798757. 
Epigenetic modulations of HAAO gene have been reported in various types of 
gynecologic cancer, in which hypermethylation of HAAO was implicated in 
susceptibility to ovarian cancer and endometrial cancer578,579. Nevertheless, no 
reports are currently available on the association of rs74798757 with lung cancer 
survival. Moreover, none of the known lung cancer SNPs were identified in close 
linkage disequilibrium (r2≥0.8) with this variant by use of HaploReg software580. Thus, 
further deep sequencing would be warranted to identify the potential causal locus 
responsible for this finding. 
It is noteworthy that no overlap was identified between significant SNPs in the 
LC+COPD cohort and in the LC only cohort, and the genotype scoring system generated 
based on the LC only cohort, which showed a cumulative effect on survival, was no 
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longer significant in the LC+COPD cohort. These results indicate the need for 
subphenotyping lung cancer by COPD status in genetic association analysis.  
 To our knowledge, the present study represents the first effort to characterize the 
association of genetic variations with survival in lung cancer with or without COPD. 
However, several limitations should be acknowledged. First, although we adopted an 
FDR correction approach for multiple testing, and carefully chose clinical variables to 
account for the potential confounding effects, false positive associations cannot be 
completely eliminated. Second, despite a very large and well-characterized study 
population (n=1,694), the relatively small group size in the LC+COPD cohort (767 vs. 
927) may compromise the statistic power to detect significant associations. Third, no 
biological explanation for the differential SNP effects on lung cancer survival by COPD 
status is currently available. Nevertheless, our results will hopefully send out an 
important message that COPD plays a significant role in the association between 
genetic variations and lung cancer survival, and therefore, COPD status should be fully 
taken into account in future studies. 
 
6.4 Chapter Summary 
 In summary, COPD status could influence the association of genetic variants with 
lung cancer survival. Specifically, SNP rs74798757 was significantly associated with 
lung cancer survival only when COPD coexisted. SNP rs10218481, CASP7 rs17090907, 
GPC5 rs1409600 and rs163933, and TAAR8 rs8192627 had significant effects on 
survival in lung cancer patients who were COPD-free. Further validation of these SNP 
associations and functional characterization of their roles in lung cancer outcomes are 
warranted.
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CHAPTER 7. CONCLUSIONS AND FUTURE WORK 
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7.1 Summary of main findings 
COPD and lung cancer are common respiratory diseases, and both pose a huge 
mortality burden on healthcare systems worldwide295,480. The results in present thesis 
suggest that not only COPD is an important comorbid disease in lung cancer, affecting 
near 40% to 60% of lung cancer patients, but these two diseases are closely related in 
the clinical setting and at the genetic level.  
COPD is an independent predisposing factor for lung cancer development 
(Chapter 2), and both spirometric airflow limitation and radiographic emphysema have 
been reported to correlate with lung cancer risk304,307. Therefore, lung cancer 
prevention and screening are suggested in COPD patient population. Effective 
preventive measures include smoking cessation, control for secondhand tobacco 
smoke exposure, and several promising, albeit not well established, chemopreventive 
agents such as inhaled corticosteroids and statins. Although previous studies have 
identified a marked benefit of cancer screening in the COPD population315,334, a 
number of clinical changes remain, including the common underdiagnosis and 
misdiagnosis of COPD, and competing causes of mortality and morbidity inherent to 
COPD. In addition, lung cancer in COPD appeared to be more aggressive and less likely 
to harbor EGFR mutations and ALK rearrangements361. Treatment for lung cancer 
coexisting with COPD is challenging as COPD may increase postoperative morbidities; 
therefore, precise surgical risk assessment, optimal preoperative management, and 
integrated multidisciplinary treatment are critically important in the perioperative 
setting. 
There is genetic evidence linking lung cancer and COPD (Chapter 2). Previous 
genome-wide association studies implicate several common genetic loci that 
predispose individuals to both COPD and lung cancer, of which 15q25, containing 
nicotinic acetylcholine receptor subunit genes CHRNA3 and CHRNA5, are the most well 
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studied430,441. Candidate gene studies jointly measuring genetic variation in lung 
cancer and COPD have also identified a number of overlapping susceptibility genes, 
including HHIP, TERT-CLPTMA1, and FAM13A461,463,468. Identification of the genetic 
links between COPD and lung cancer offers great potential for disease prevention and 
surveillance. 
COPD is often concomitant with lung cancer but most is unrecognized483. Study on 
COPD status at lung cancer diagnosis revealed that COPD was substantially under-
diagnosed in patients with early stage lung cancer, with an underdiagnosed rate of 
66.8% (Chapter 3). Timing of COPD diagnosis and severity of airflow limitation were 
associated with overall survival and quality of life in lung cancer patients after surgery. 
Incidental COPD was a major factor (compared to previously recognized COPD) that 
increased the risk of postoperative complications and negatively impact long-term 
survival; thus, highlighting the importance of identification of COPD in newly 
diagnosed lung cancer patients. Predictors for incidental COPD were older age, male 
sex, lower BMI, being former and current smokers, and presenting cough, dyspnea, 
and hemoptysis. Patients with moderate and severe COPD had decreased lung cancer 
survival; however, similar survival was found between patients with mild COPD and 
with normal lung function, which was concordant with previous studies408,484. These 
findings suggest that pulmonary rehabilitation in moderate-to-severe COPD patients 
may improve their lung cancer outcomes.  
Pulmonary emphysema is a crucial constituent of COPD. Previous studies revealed 
a strong association between lung cancer location and emphysema severity352,353, but 
the prognostic value of emphysema in tumor progression remains unclear. The 
quantitative assessment of radiological emphysema showed that the severity of 
regional emphysema was associated with survival, which was independent of tumor 
location (Chapter 4). Regional emphysema was also predictive of quality of life related 
to dyspnea scale after treatment for lung cancer, with higher severity indicating worse 
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dyspnea. Thus, there may be a need for prophylactic management of dyspnea 
symptom in lung cancer patients with emphysema, in order to reduce long-term 
symptom burden. In addition, when tumor resection was performed in the 
emphysematous region, the severity of emphysema was correlated with postoperative 
lung function recovery; patients with moderate-to-severe emphysema might have an 
improvement of postoperative pulmonary ventilation capacity (i.e., lung volume 
reduction effect), which was in line with the previous report391. These findings are of 
prime importance to determine the indications for surgery in patients with lung cancer 
who have compromised lung function. 
 The pooled analysis of 16 previous studies, by a systematic research of PubMed 
database (Chapter 5), found that the presence of COPD was associated with worse 
survival of lung cancer across the ethnic groups studied (Asian and Caucasian). 
Subsequent stratified analyses demonstrated that the deleterious impact of COPD 
appeared to be more pronounced in patients with NSCLC, at an early-stage, and who 
received surgical treatment. Nevertheless, the prognostic significance of COPD in 
advanced stage lung cancer and SCLC needs further exploration due to the small 
numbers of studies in the subgroups.  
 Genetic associations between COPD and lung cancer risk have been well studied; 
however, little is known about the impact of COPD on the association of genetic 
variants with lung cancer survival. In the study of the 384 SNPs (Chapter 6), SNP 
rs74798757 was associated with overall survival in patients with lung cancer with 
COPD, while SNP rs10218481, CASP7 rs17090907, GPC5 rs1409600 and rs163933, and 
TAAR8 rs8192627 had significant effects on survival in lung cancer patients who were 
free of COPD. The difference in genetic markers between lung cancer with and without 
COPD indicates that COPD status should be taken into account when attempting to 
identify prognostic SNP for lung cancer. Further research is necessary to validate and 
characterize the functional basis for the associations. 
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7.2 Suggestions for future work 
Although results in recently published studies are intriguing and of importance to 
clinical practice, almost all the findings were based on a number of single-center 
retrospective analyses, which warrants validations based on future multi-institutional 
prospective studies. In addition, the actual impact of COPD in late stage lung cancer 
with chemotherapy remains unclear. Furthermore, there is no convincing evidence to 
demonstrate the efficacy of chemoprevention and screening for lung cancer in COPD 
patients, and the association between COPD and lung cancer mutation profile (e.g., 
EGFR, Kras, and ALK) is not well defined. Therefore, further research is needed to 
advance our understanding in these aspects of COPD-lung cancer relationship, which 
will ultimately improve the outcomes of this patient population. 
At the genetic level, the associations between COPD, lung cancer, and survival 
SNPs needs further validation from independent cohorts, and the functional basis for 
the association of identified loci with clinical outcome in lung cancer with and without 
COPD requires investigations. In the era of the precision medicine, a better 
understanding of the clinical association and genetic basis for COPD and lung cancer 
may provide a unique opportunity to:  
(i) optimize screening benefit from an individualized program tailored to their risks,  
(ii) assist in selection of optimal treatment modalities according to the response 
to therapy,  
(iii) refine prognostication by integration of validated genetic markers to the 
current predictive models, and thus to 
(iv) allow allocation of limited clinical resources by means of effective surveillance 
for disease progression and cancer recurrence. 
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In addition, there is the potential to identify novel chemopreventive measures and 
therapeutic targets for both diseases to promote the health of the public.
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Appendix A: Patient enrollment, data collection, and 
follow-up strategies 
Since 1997, all of the new patients who had lung cancer diagnosed or confirmed 
at Mayo Clinic (Rochester, MN) were collected from the electronic pathology reporting 
system581. Each newly identified patient with primary lung cancer was evaluated for 
study eligibility and actively followed if they agree to participate in future research and 
give their informed consent581.  
Information abstracted from medical records for each patient included 
demographics (age, gender, race, education, occupation, history of tobacco exposure, 
and alcoholic use); history of previous diseases; lung cancer histopathology, staging, 
anatomical site, and treatment modalities; and family history of cancer and other 
medical conditions. Smoking history data were found in the patients’ medical record 
and was confirmed with a follow-up questionnaire or an interview, encompassing age 
of regular smoking initiation, duration, average amount of cigarettes smoked per day, 
and the number of years since the patient quit smoking582,583. Never smokers were 
defined by self-report as having smoked fewer than 100 cigarettes during their lifetime. 
Former smokers were defined as reporting at least six months of smoking abstinence 
at the time of lung cancer diagnosis. Current smokers were daily cigarette smokers or 
those with less than six months of smoking abstinence at the time of diagnosis582. 
Histologic classification was made according to the World Health Organization’s 
International Histological Classification of Tumors584. Histologic grade was evaluated 
as follows: well, moderately, poorly differentiated, and undifferentiated100. TNM stage 
was assigned as proposed by Mountain in 1997 (sixth edition staging system)585 or by 
Detterbeck and colleagues in 2009 (seventh edition staging system)586, dependent 
upon the time of lung cancer diagnosis. 
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All patients have been actively followed beginning at six months after diagnosis 
with subsequent annual follow-up by mailed questionnaires583. Timely verification of 
each patient’s vital status was accomplished through the Mayo Clinic’s electronic 
clinical notes and registration database, death certificates, next-of-kin reports, 
obituary documents, as well as through the Mayo Clinic Tumor Registry and Social 
Security Death Index website100,581-583. For living patients, the most up-to-date 
information was obtained from the last Mayo Clinic visit report or the last follow-up 
questionnaire, whichever was most recent. For deceased patients, the follow-up 
packet was sent to the next-of-kin to obtain proxy information regarding new diseases 
occurring after the initial diagnosis and cause of death, changes in smoking status, 
body weight, appetite, dietary supplements, and updated family history of lung cancer 
or other cancers581,583. 
All studies included in the thesis have utilized existing resources of Mayo Clinic 
Epidemiology and Genetic of Lung Cancer (EGLC)587,588, which enrolled and followed 
all primary lung patients from 1997 to 2016. 
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Appendix B: Selected single nucleotide polymorphisms 
and survival models
Appendix Table 1: SNP selection 
Chromo-
some 
Candidate Gene No. of 
SNPs 
chr 1 ALG6 2 
 ATP1A4 1 
 C1orf140 1 
 DNM3 1 
 EPB41 1 
 FDPSP1 1 
 IL10 1 
 KLF17 1 
 LOC100506985 1 
 LOC100967224 1 
 PTGER3 1 
 PTGS2 1 
 TP73 1 
chr 2 ALK 1 
 B3GALT1 3 
 COL4A3 1 
 CTNNA2 1 
 GPR155 1 
 LINC00570 1 
 LINC01105 4 
 LOC105373608 1 
 LOC105374567 1 
 LOC107985958 1 
 MGAT5 1 
 NFE2L2 1 
 NRXN1 8 
 THUMPD2 1 
chr 3 CHL1 1 
 FOXP1 2 
 LINC00971 1 
 LOC105374147 1 
 SLC7A14 1 
chr 4 IRF2 1 
 KCNIP4 1 
Appendix Table 1: SNP selection 
Chromo-
some 
Candidate Gene No. of 
SNPs 
 LOC105374505 2 
 TERT 1 
chr 5 ADCY2 3 
 CCNH 1 
 CD74 2 
 CLPTM1L 1 
 LOC389273 1 
 MSH3 4 
 SLC6A3 1 
chr 6 GCLC 4 
 GLP1R 1 
 LINC00472 1 
 LYRM4 1 
 MAP3K4 2 
 PARK2 5 
 PDE7B 1 
 SASH1 1 
 SERAC1 1 
 SLC17A3 2 
 TAAR8 1 
chr 7 CNTNAP2 1 
 CTTNBP2 1 
 EGFR 1 
 FAM3C 1 
 GATS 1 
 MAGI2 4 
 MCM7 1 
chr 8 CER1 1 
 CHD7 1 
 CSMD1 4 
 FBXO25 1 
 SCARA3 1 
 SGCZ 2 
 TNFRSF10B 4 
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Appendix Table 1: SNP selection 
Chromo-
some 
Candidate Gene No. of 
SNPs 
 TOX 1 
chr 9 ASTN2 1 
 CKS2 1 
 DEC1 1 
 SLC24A2 2 
 VPS13A 1 
 XPA 1 
chr 10 ABCC2 2 
 CASP7 1 
 LOC101929727 1 
 PRKG1 1 
 TRUB1 1 
chr 11 CCND1 1 
 CNTN5 2 
 DRD4 1 
 FZD4 1 
 GSTP1 1 
 KCNQ1 3 
 LOC105376605 2 
 LUZP2 1 
 MTMR2 1 
 RRM1 2 
chr 12 CACNA1C 1 
 FBXO21 2 
 WIF1 1 
chr 13 ABCC4 2 
 BRCA2 1 
 GPC5 129 
 LOC105370220 1 
 PARP4 1 
 STARD13 1 
chr 14 DHRS4L1 1 
 LOC105370582 1 
 PPP2R5E 1 
 RGS6 10 
chr 15 ATP8B4 2 
 FSD2 1 
 HOMER2 1 
 LOC105370964 1 
Appendix Table 1: SNP selection 
Chromo-
some 
Candidate Gene No. of 
SNPs 
 MCTP2 3 
 RYR3 1 
 SYNM 1 
 THSD4 3 
chr 16 ABCC1 2 
 WWOX 1 
chr 17 ABCC3 1 
chr 18 CTIF 1 
 DCC 1 
 DLGAP1 1 
 GAREM1 1 
 LOC284241 1 
 PIEZO2 1 
chr 19 ARHGEF18 1 
 C19orf54 1 
 ERCC2 1 
 KXD1 2 
 LEUTX 1 
 PPP2R1A 1 
 PRSS57 2 
chr 20 CRLS1 1 
 GSS 1 
 LRRN4 1 
 MACROD2 1 
 PTPRA 1 
chr 21 APP 1 
 DSCAM 3 
chr 22 SGSM1 1 
 UPB1 1 
Subtotal  332 
 unknown 52 
Total  384 
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Appendix Table 2: Quality control assessment 
Chr Total SNP 
failed call rate <0.95 MAF<0.01 HWE<10-4 remaining 
N % N % N % N % N % 
1 17 0 0.0 2 11.8 0 0.0 0 0.0 15 88.2 
2 40 0 0.0 2 5.0 0 0.0 3 7.5 35 87.5 
3 10 0 0.0 0 0.0 0 0.0 1 10.0 10 90.0 
4 6 0 0.0 0 0.0 0 0.0 0 0.0 6 100.0 
5 17 0 0.00 1 5.9 1 5.9 1 5.9 14 82.4 
6 23 0 0.0 1 4.3 1 4.3 3 13.0 18 78.3 
7 12 0 0.00 1 8.3 0 0.0 1 8.3 10 83.3 
8 17 0 0.0 0 0.0 0 0.0 2 11.8 15 88.2 
9 9 0 0.0 1 11.1 0 0.00 0 0.0 8 88.9 
10 7 0 0.0 0 0.0 0 0.0 0 0.0 7 100.0 
11 16 0 0.0 0 0.0 0 0.0 2 12.5 14 87.5 
12 8 0 0.0 0 0.0 0 0.0 0 0.0 8 100.0 
13 137 0 0.00 7 5.1 2 1.5 0 0.0 128 93.4 
14 15 0 0.0 0 0.0 0 0.0 0 0.0 15 100.0 
15 14 0 0.0 0 0.0 0 0.0 0 0.0 14 100.0 
16 4 0 0.0 0 0.0 0 0.0 0 0.0 4 100.0 
17 2 0 0.0 0 0.0 0 0.0 0 0.0 2 100.0 
18 7 0 0.0 1 14.3 0 0.0 0 0.0 6 85.7 
19 10 1 10.0 0 0.0 0 0.0 1 10.0 8 80.0 
20 6 0 0.0 0 0.0 0 0.0 0 0.0 6 100.0 
21 5 0 0.0 0 0.0 0 0.0 0 0.0 5 100.0 
22 2 0 0.0 0 0.0 0 0.0 0 0.0 2 100.0 
overall 384 1 0.3 16 4.1 4 1.0 14 3.6 349 90.8 
MAF: minor allele frequency; HWE: Hardy-Weinberg equilibrium 
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Appendix Table 3.1: Baseline survival model for the whole cohort 
 alive/death MST HR (95%CI) p 
age (years) 501/1193 4.4 1.02 (1.01, 1.03) 4.2E-12 
sex      
  male 200/614 3.8 reference  
  female 301/579 5.2 0.80 (0.72, 0.90) 1.5E-04 
race     
  white 480/1079 4.8 reference  
  non-white 21/114 2.7 1.27 (1.04, 1.54) 1.7E-02 
tumor grade     
  well 196/223 10.1 reference  
moderately/poorly 305/970 3.4 1.35 (1.15, 1.58) 1.9E-04 
pathological stage     
I 330/340 10.2 reference  
  II 64/144 5.9 1.47 (1.21, 1.80) 1.3E-04 
  III 71/303 2.6 1.93 (1.60, 2.33) 7.0E-12 
  IV 36/406 1.6 2.81 (2.27, 3.48) 1.5E-21 
therapy     
surgical treatment 447/619 8.4 reference  
  non-surgical treatment 54/574 1.6 2.55 (2.15, 3.02) 5.1E-27 
MST: median survival time by year; HR: hazard ratio; CI: confidence interval. 
Surgical treatment including surgery alone and surgery plus adjuvant therapy; non-surgical 
treatment including chemotherapy, radiotherapy, chemoradiation, and other therapy.  
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Appendix Table 3.2: Baseline survival model for the LC+COPD cohort 
 alive/death MST HR (95%CI) p 
age (years) 215/552 5.6 1.02 (1.01, 1.03) 2.2E-06 
sex      
  male 90/317 4.8 reference  
  female 125/235 6.7 0.72 (0.60, 0.85) 1.8E-04 
tumor grade     
  well 79/108 9.1 reference  
moderately/poorly 136/444 4.3 1.31 (1.05, 1.64) 1.7E-02 
pathological stage     
I 155/215 9.6 reference  
  II 30/88 4.7 1.48 (1.15, 1.91) 2.2E-03 
  III 23/142 2.6 1.93 (1.50, 2.48) 3.3E-07 
  IV 7/107 1.4 2.85 (2.06, 3.94) 2.3E-10 
therapy     
surgical treatment 201/368 8.2 reference  
  non-surgical treatment 14/184 1.4 2.47 (1.91, 3.20) 6.6E-12 
MST: median survival time by year; HR: hazard ratio; CI: confidence interval. 
Surgical treatment including surgery alone and surgery plus adjuvant therapy; non-surgical 
treatment including chemotherapy, radiotherapy, chemoradiation, and other therapy.  
 
  
 194 
 
Appendix Table 3.3: Baseline survival model for the LC only cohort 
 alive/death MST HR (95%CI) p 
age (years) 286/641 3.6 1.02 (1.01, 1.03) 2.9E-06 
tumor grade     
  well 117/115 10.8 reference  
moderately/poorly 169/526 2.85 1.38 (1.10, 1.74) 5.8E-03 
pathological stage     
I 175/125 10.9 reference  
  II 34/56 6.5 1.47 (1.06, 2.03) 2.1E-02 
  III 48/161 2.6 2.00 (1.50, 2.66) 2.5E-06 
  IV 29/299 1.6 2.89 (2.14, 3.91) 6.0E-12 
therapy     
surgical treatment 246/251 8.8 reference  
  non-surgical treatment 40/390 1.6 2.65 (2.10, 3.330 1.7E-16 
MST: median survival time by year; HR: hazard ratio; CI: confidence interval. 
Surgical treatment including surgery alone and surgery plus adjuvant therapy; non-surgical 
treatment including chemotherapy, radiotherapy, chemoradiation, and other therapy.  
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Appendix Table 4.1: Individual SNPs associated with survival in the whole cohort (p<0.05) 
SNP gene chr best model HR (95%CI) p q 
rs10218481  1 Additive 0.86 (0.79, 0.94) 4.46E-04 0.16  
rs1979100 B3GALT1 2 Additive 1.14 (1.04, 1.24) 5.20E-03 0.46  
rs3211683 CKS2 9 Dominant 0.81 (0.69, 0.94) 5.70E-03 0.46  
rs11659007  17 Recessive 1.34 (1.09, 1.66) 6.63E-03 0.46  
rs4072556  16 Additive 0.90 (0.83, 0.97) 8.13E-03 0.46  
rs215100 ABCC1 16 Additive 1.12 (1.03, 1.22) 1.08E-02 0.46  
rs1356888 NRXN1 2 Dominant 0.85 (0.76, 0.96) 1.12E-02 0.46  
rs8192627 TAAR8 6 Dominant 1.22 (1.04, 1.42) 1.38E-02 0.46  
rs7432792  3 Additive 0.90 (0.83, 0.98) 1.43E-02 0.46  
rs4885110  13 Additive 1.11 (1.02, 1.21) 1.55E-02 0.46  
rs17469423 SCARA3 8 Dominant 0.84 (0.73, 0.97) 1.82E-02 0.46  
rs883429 TNFRSF10B 8 Additive 0.89 (0.82, 0.98) 1.87E-02 0.46  
rs5752019 SGSM1 22 Dominant 0.87 (0.78, 0.98) 1.95E-02 0.46  
rs12482863 DSCAM 21 Dominant 0.84 (0.72, 0.97) 1.99E-02 0.46  
rs74798757  2 Dominant 1.28 (1.04, 1.57) 2.06E-02 0.46  
rs12609586 PRSS57 19 Recessive 0.81 (0.68, 0.97) 2.21E-02 0.46  
rs7132154 CACNA1C 12 Additive 1.12 (1.02, 1.23) 2.22E-02 0.46  
rs1180898 GPC5 13 Additive 1.10 (1.01, 1.19) 2.39E-02 0.46  
rs746892 ARHGEF18 19 Recessive 1.19 (1.02, 1.38) 2.62E-02 0.46  
rs1409600 GPC5 13 Dominant 0.86 (0.75, 0.98) 2.81E-02 0.46  
rs2830001 APP 21 Dominant 0.80 (0.65, 0.98) 2.85E-02 0.46  
rs3024498 IL10 1 Dominant 0.88 (0.78, 0.99) 2.90E-02 0.46  
rs17090907 CASP7 10 Dominant 0.85 (0.74, 0.99) 3.21E-02 0.48  
rs7359916 PRSS57 19 Recessive 0.81 (0.67, 0.98) 3.33E-02 0.48  
rs11791132 ASTN2 9 Dominant 1.19 (1.01, 1.39) 3.65E-02 0.50  
rs16946431 GPC5 13 Dominant 0.85 (0.72, 0.99) 3.82E-02 0.50  
rs163933 GPC5 13 Dominant 0.86 (0.75, 0.99) 3.86E-02 0.50  
rs1047275 TNFRSF10B 8 Dominant 0.88 (0.78, 1.00) 4.40E-02 0.55  
Underlined numbers denote significant association at q<0.20; HR: hazard ratio; CI: confidence 
interval. 
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Appendix Table 4.2: Individual SNPs associated with survival in the LC+COPD cohort (p<0.05) 
SNP gene chr best model HR (95%CI) p q 
rs74798757  2 Dominant 1.68 (1.29, 2.20) 1.56E-04 0.05  
rs11659007  17 Recessive 1.66 (1.22, 2.26) 1.26E-03 0.22  
rs9556107 GPC5 13 Recessive 1.43 (1.13, 1.81) 3.30E-03 0.38  
rs2209828 GPC5 13 Additive 1.18 (1.05, 1.32) 7.07E-03 0.53  
rs3211683 CKS2 9 Dominant 0.75 (0.60, 0.93) 1.08E-02 0.53  
rs4885110  13 Additive 1.17 (1.04, 1.33) 1.18E-02 0.53  
rs62563275 SLC24A2 9 Dominant 1.40 (1.07, 1.84) 1.39E-02 0.53  
rs12482863 DSCAM 21 Dominant 0.76 (0.61, 0.95) 1.50E-02 0.53  
rs725040 GPC5 13 Recessive 1.30 (1.05, 1.62) 1.70E-02 0.53  
rs1979100 B3GALT1 2 Additive 1.17 (1.03, 1.34) 1.78E-02 0.53  
rs10092265 CSMD1 8 Additive 0.85 (0.75, 0.98) 2.02E-02 0.53  
rs1180898 GPC5 13 Additive 1.16 (1.02, 1.31) 2.02E-02 0.53  
rs9589446 GPC5 13 Recessive 1.26 (1.03, 1.54) 2.16E-02 0.53  
rs9523597 GPC5 13 Recessive 0.68 (0.49, 0.95) 2.26E-02 0.53  
rs11489584 GATS 7 Dominant 0.81 (0.68, 0.97) 2.27E-02 0.53  
rs4072556  16 Additive 0.87 (0.77, 0.98) 2.74E-02 0.57  
rs7132154 CACNA1C 12 Additive 1.16 (1.02, 1.33) 2.76E-02 0.57  
rs746892 ARHGEF18 19 Recessive 1.28 (1.02, 1.61) 3.25E-02 0.61  
rs17469423 SCARA3 8 Dominant 0.80 (0.66, 0.98) 3.34E-02 0.61  
rs8075406 ABCC3 17 Dominant 0.83 (0.70, 0.99) 3.48E-02 0.61  
rs13268772 CSMD1 8 Recessive 0.74 (0.56, 0.98) 3.71E-02 0.62  
rs17404274  1 Dominant 1.22 (1.01, 1.48) 4.07E-02 0.64  
rs847260 RGS6 14 Dominant 1.26 (1.01, 1.58) 4.23E-02 0.64  
rs11675550 NRXN1 2 Dominant 1.26 (1.00, 1.58) 4.73E-02 0.69  
Underlined numbers denote significant association at q<0.20; HR: hazard ratio; CI: confidence 
interval. 
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Appendix Table 4.3: Individual SNPs associated with survival in the LC only cohort (p<0.05) 
SNP gene chr best model HR (95%CI) p q 
rs10218481  1 Additive 0.81 (0.73, 0.91) 4.19E-04 0.12  
rs17090907 CASP7 10 Dominant 0.71 (0.58, 0.87) 9.18E-04 0.12  
rs1409600 GPC5 13 Dominant 0.73 (0.61, 0.89) 1.38E-03 0.12  
rs163933 GPC5 13 Dominant 0.73 (0.60, 0.89) 1.59E-03 0.12  
rs8192627 TAAR8 6 Dominant 1.41 (1.14, 1.74) 1.79E-03 0.12  
rs9283847  6 Dominant 1.30 (1.09, 1.55) 3.86E-03 0.21  
rs215100 ABCC1 16 Additive 1.18 (1.05, 1.33) 5.36E-03 0.21  
rs6448050 KCNIP4 4 Dominant 0.80 (0.68, 0.94) 5.51E-03 0.21  
rs16946431 GPC5 13 Dominant 0.73 (0.59, 0.91) 5.54E-03 0.21  
rs192422272 LINC00570 2 Dominant 1.93 (1.19, 3.14) 8.21E-03 0.29  
rs16946366 GPC5 13 Dominant 0.79 (0.65, 0.95) 1.32E-02 0.40  
rs868678 LOC284241 18 Dominant 0.82 (0.70, 0.96) 1.36E-02 0.40  
rs9938424 WWOX 16 Dominant 1.27 (1.05, 1.53) 1.58E-02 0.41  
rs950725 GPC5 13 Additive 1.15 (1.02, 1.28) 1.73E-02 0.41  
rs17655393 FOXP1 3 Dominant 1.21 (1.03, 1.41) 1.85E-02 0.41  
rs883429 TNFRSF10B 8 Additive 0.86 (0.76, 0.98) 1.97E-02 0.41  
rs457099  5 Additive 1.14 (1.02, 1.27) 2.30E-02 0.41  
rs31490 CLPTM1L 5 Additive 1.14 (1.02, 1.27) 2.35E-02 0.41  
rs140335 UPB1 22 Additive 1.14 (1.02, 1.27) 2.39E-02 0.41  
rs12609586 PRSS57 19 Recessive 0.75 (0.58, 0.96) 2.40E-02 0.41  
rs4460370 TNFRSF10B 8 Recessive 0.74 (0.57, 0.97) 2.69E-02 0.41  
rs3024498 IL10 1 Dominant 0.84 (0.72, 0.98) 2.77E-02 0.41  
rs7986332 GPC5 13 Dominant 0.76 (0.59, 0.97) 2.81E-02 0.41  
rs13417432  2 Dominant 1.22 (1.02, 1.47) 2.82E-02 0.41  
rs7432792  3 Additive 0.88 (0.79, 0.99) 2.96E-02 0.41  
rs16958772  15 Dominant 1.20 (1.02, 1.42) 3.09E-02 0.41  
rs12897719 RGS6 14 Dominant 1.19 (1.01, 1.39) 3.31E-02 0.43  
rs4754610 CNTN5 11 Additive 0.87 (0.76, 0.99) 3.76E-02 0.47  
rs553717 GPC5 13 Dominant 0.81 (0.66, 0.99) 4.13E-02 0.49  
rs7999520 GPC5 13 Recessive 0.73 (0.54, 0.99) 4.28E-02 0.49  
rs16949076 MCTP2 15 Dominant 1.20 (1.01, 1.43) 4.33E-02 0.49  
rs16949077 MCTP2 15 Dominant 1.20 (1.00, 1.43) 4.81E-02 0.52  
Underlined numbers denote significant association at q<0.20; HR: hazard ratio; CI: confidence 
interval. 
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Appendix Figure 1: Kaplan-Meier survival curves 
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Appendix Figure 2: Analysis of linkage disequilibrium 
 
 
 
